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ABSTRACT
The incidence of oesophageal cancer has increased in the United Kingdom over the
past 30 years and is the fifth most common cause of cancer death. However, prognosis
prediction and treatment decision for individual patients currently still rely only on the
determination of the Tumour Node Metastasis (TNM) classification.
This thesis aimed to identify markers which can predict prognosis in OeC patients who
were treated either by chemotherapy and surgery or surgery alone. It examined the
prognostic value of the circumferential resection margin status, tumour cell density and
the intratumoural immune cell infiltration. Data from Leeds and Manchester patients as
well as from the international OE02 trial were used.
The results suggest that the presence of tumour cells either within 1mm or at the
circumferential resection margin (CRM) is related to a significantly worse prognosis in
univariate analyses. However, the CRM status was not an independent prognostic
marker for cancer specific survival after neoadjuvant chemotherapy and surgery.
Tumour cell density (TCD) was measured using well established morphometric
methods at the luminal surface of the resected tumour in the OE02 cohort. A significant
difference was seen in TCD between the two treatment groups. A three tiered TCD
classification was found to be related to prognosis in the chemotherapy and surgery
treatment group. However TCD was not an independent predictor of patient survival
when established clinicopathological variables were included in the multivariate
analysis.
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Differences were found in the proportion of tumour infiltrating immune cells between
the two treatment arms of the OE02 patients. The level of T cell infiltration was shown
to have prognostic value in the chemotherapy followed by surgery treatment arm,
although this was not an independent prognostic marker. When using a ratio score of T
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1. INTRODUCTION
This thesis will assess potential new prognostic markers for aiding in the management
of oesophageal cancer patients and compare their relationship with markers currently
used in the United Kingdom (UK). Oesophageal cancer incidence is increasing
worldwide and most rapidly in the UK. Currently, the only established prognostic
marker for OeC patients is the tumour node metastasis (TNM) classification.
This thesis aims to investigate whether the use of morphometrically measured tumour
cell density of the primary tumour or immunohistochemical staining for intratumoural
immune cells can be used to better stratified patients into treatment relevant prognostic
groups improving and individualising post-operative patient management. This thesis
will also examine the value of the post-operative circumferential resection margin
clearance and compare the prognostic value of the presence of tumour cells at the
CRM versus within a distance of one millimetre (mm).
1.1 Anatomy of the oesophagus
The oesophagus is a tubular muscular structure which connects the oral cavity with the
stomach (Figure 1). The oesophagus begins at the pharynx at the level of the cricoid
cartilage (around vertebral level C6) where the upper oesophageal sphincter is located.
The oesophagus then extends caudally behind the trachea and thyroid gland, being
located in front of the cervical vertebrae of the neck. As it enters the thorax it descends
caudally between the two lungs and posteriorly of the left atrium of the heart in the
mediastinum. It exits the thorax through its own oesophageal opening in the diaphragm
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at the vertebral level T10. Once in the abdomen, the oesophagus is located directly
posterior of the left lobe of the liver before turning sharply left connecting to the
stomach through the cardiac orifice. The lower oesophageal sphincter is located at the
entrance to the stomach. This sphincter plays an important role in preventing reflux of
stomach contents and/or bile into the lower oesophagus (1).
Figure 1: The upper gastrointestinal tract anatomy.
The diagram above illustrates the anatomy of the oesophagus and its relation to both, the oral
and gastric cavity. Picture from www.webMD.co.uk (2).
The average length of the human oesophagus is 23-25cm with an average diameter of
1.5-2cm. It has a wall which consists of four layers (Figure 2);
a.) Mucosa: the inner most luminal layer consisting of epithelial cells and lamina
propria which line the entire oesophagus. Most of the oesophagus is lined by
non-keratinizing stratified squamous epithelium, only the intra-abdominal part is
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lined by columnar epithelium. The location of the change in the epithelial
phenotype is an important landmark in the oesophagus and is described as the
Z-line. This line can be seen on endoscopic examination of the oesophagus.
b.) Submucosa: separated from the mucosa by the muscularis mucosae, the
submucosa layer contains the oesophageal glands. These glands produce
mucus to aid lubrication of food boluses on their passage towards the stomach.
c.) Muscularis propria: the muscularis propria consists of an inner circular and an
outer longitudinal muscle layer. In the upper third, the outer layer consists of
striated muscle and in the lower two thirds consists of smooth muscle
responsible for peristalsis to move contents downwards toward the gastro-
oesophageal sphincter.
d.) Adventitia: The outer most layer of the oesophagus consists of a thin layer of
loose fibrofatty tissue which is mostly not covered by serosa with the exception
of focal coverage by the pleura.
~ 20 ~
Figure 2: Haematoxylin & Eosin stained slide illustrating the layers of the oesophageal
wall.
The diagram shows a microscopic view of the layers of the oesophagus. A= mucosa (squamous
epithelium), B= submucosa containing glandular tissue, C1= circular muscle of muscular layer,
C2=longitudinal muscle of the muscular layer and D= adventitia. T= malignant tumour
1.2 Histological subtypes
There are two main histological subtypes of oesophageal cancer (OeC): squamous cell
carcinoma and adenocarcinoma. Squamous cell carcinomas originate from the non-
keratinizing stratified squamous cells lining the oesophagus therefore are usually
localised in the upper two thirds of the oesophagus. Adenocarcinomas are thought to
originate from columnar (glandular) cells and typically occur in the lower third of the
oesophagus. As well as histological and location differences, there is evidence to
suggest that the pathogenesis of these two histological types of OeC is different (3).
Squamous cell cancers usually develop in a stepwise process from mild to severe
dysplasia and subsequently into an invasive squamous cell carcinoma (4).
Adenocarcinoma of the oesophagus is thought to develop as a result of a sequence of
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genetic and phenotype alterations known as the ‘metaplasia-dysplasia-neoplasia
sequence’ (3, 5). This sequence begins with the normal lower oesophageal epithelial
being persistently injured resulting in replacement of normal stratified squamous
epithelium cells by abnormal columnar epithelial cells, also known as Barrett’s mucosa
(6). It is thought that in the presence of continuous stimulation, this premalignant
mucosa is prone to malignant transformation.
Other histological types of OeC are much less common and are therefore not featured
in detail in this thesis.
1.3 Epidemiology of oesophageal cancer
1.3.1 Worldwide
Oesophageal cancer (OeC) is the eighth most common cancer in the world with
456,000 new cases diagnosed worldwide in 2012 accounting for 3.2% of all cancers
diagnosed worldwide (7). OeC has been shown to cause 400,000 deaths worldwide in
2012 (7). There is a 2-4 times higher incidence in men than women and the highest
incidence occurs in the 50-70 year old age group (8). The 2012 global cancer report
indicated there were 281,000 OeC deaths in males compared to 119,000 in females
(9). The overall incidence of OeC in Europe between 2000-2004 was 5.39 per 100,000
population in males and 1.13 per 100,000 for females, taken from the recent European
cancer registry (EUROCARE) publication (10). The incidence of OeC shows
substantial geographical variation globally. 80% of all reported cases are from areas
found in the developing world (11, 12). The incidence rates worldwide range from 28.2
(Malawi) to 0.3 (Nigeria) age standardised rates per 100,000 in males and 20.8
(Malawi) to 0.3 (Nigeria) age standardised rates per 100,000 in females (7). The
cumulative risk of developing OeC can vary 60 fold between countries worldwide and
also between countries in the similar geographically areas (12). For example, there is a
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twofold difference in developing oesophageal adenocarcinoma in Scotland as
compared to the Republic of Ireland (0.60% risk vs. 0.29%, p<0.001) (12). Similarly,
the overall incidence of OeC varies substantially between Southern African and West
African regions. The age-standardised incidence rates (ASR) for men from Southern
African areas is 22.3 cases per 100,000 population and 11.7 cases per 100,000 in
women, compare this to the equivalent incidence for men in Western Africa where
there is 1.4 cases per 100,000 population with 1 case per 100,000 in women (13). This
dramatic variation in incidence has been of great interest to researchers over the past
20 years, leading to studies into genetic, environmental and culture differences
between regions with contrasting incidences throughout the world (14-17).
1.3.2 United Kingdom
Oesophageal cancer (OeC) overall was diagnosed in 8,332 people in the United
Kingdom (UK) in 2011 (18). Overall ASR of OeC in the UK is 6.4 per 100,000
populations, which is the highest in Europe (13, 19). It is the seventh most common
cancer in males (ASR of 14.1 per 100,000) and in females, it is the fourteenth most
common cancer in the UK (ASR of 5.3 per 100,000) (19). There has been an overall
rise in incidence of OeC in the UK over the past 30 years, particular in males. The ASR
of OeC has nearly doubled for males in the UK from 8.8 per 100,000 populations in
1975 (19). This rise is less apparent in females suggesting that the overall trend of
rising OeC incidence cannot be explained by improved classification or diagnostic
techniques (20, 21). However, a recent study suggests that the incidence of OeC in the
UK has started to stabilise since 2002 (19).
1.3.3 Epidemiological differences between two main histological
subtypes of oesophageal cancer
The frequency of the histological subtypes of OeC shows vast geographically variation
across countries in the same continent, as well as regions of the same country (13, 22).
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Global statistics show that squamous cell carcinoma makes up 87% of all oesophageal
cancers diagnosed worldwide (398,000 cases), with a predominance in males (2:1
male: female ratio) (7). Adenocarcinomas accounted for 52,000 new OeC cases
worldwide in 2012 with a male to female ratio of 4:1 (7). The incidence of squamous
cell carcinoma by far exceeds that of adenocarcinoma in 90% of countries worldwide;
however in some countries such as the UK and The Netherlands, adenocarcinomas
are the predominant histological subtype of OeC (13, 19). Other countries showing this
opposite trend compared to global figures are the United States of America (USA),
Canada, New Zealand, Australia, Iceland, Sweden, Norway, Ireland, Malta and Cyprus
(13, 23).
The highest risk areas for squamous cell carcinomas are found in the ‘Asian
oesophageal cancer belt’ which includes Turkey, Iran, Mongolia and China among
others. China itself, is responsible for more than half of the global squamous cell
cancer cases, and squamous cell cancer of the oesophagus accounts for 23% of all
cancer mortality in China (24). In Linxian, a rural community in the Henan province of
northern China, there are more than 100 squamous cell carcinoma cases per 100,000
population per year, which is the highest reported prevalence of OeC in the China (11).
However, outside this so called “cancer belt” zone, there are isolated areas worldwide
which also report high incidences of squamous cell carcinoma of the oesophagus.
South Africa has a significantly higher incidence of squamous cell cancer compared to
the rest of Africa with incidence rates exceeding 100 cases per 100,000 population
(17). Likewise there is also an isolated high incidence rate of squamous cell carcinoma
(26 cases per 100,000 population) in northwest France in the Burgundy and Normandy
regions (25). This high incidence is in contrast to the rest of northern Europe where the
incidence rate is less than 4 cases per 100,000 populations. These findings suggest
that there are likely environmental factors involved in squamous cell carcinoma
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development. One study linked these isolated high incidences found in northern France
to a regional culture of drinking hot alcoholic beverages (26).
There are also ethnic variations within countries such as in the USA where black Afro-
American’s have a 5-fold increased risk of developing squamous cell cancer compared
to Caucasian Americans (27). Despite these high incidences in specific regions
worldwide, the overall incidence of squamous cell carcinoma seems to have decreased
or at least stabilised throughout the developed world in the past 30 years (24, 28, 29).
In the mid 1970’s, adenocarcinomas of the oesophagus accounted for only around 5%
of all cases of OeC worldwide (21). However, in contrast to squamous cell cancer, the
incidence of adenocarcinoma of the oesophagus has increased over the past 30 years
(30). Population-based studies in the USA and Europe indicate that the incidence of
oesophageal adenocarcinoma has doubled between the 1970s and the late 1980s (31,
32). From there the incidence continued to increase by 5% every year (31, 32). Another
study showed that the annual rise in the incidence of adenocarcinoma of the
oesophagus in males was greater than that of any other cancer in the USA during the
1980s (33). This trend has also the been seen in the UK over the past 40 years where
the adenocarcinoma incidence has risen sharply and to the point where
adenocarcinoma of the oesophagus is now more prevalent than squamous cell
carcinoma (19). In the UK, the 2012 overall age-standardised incidence of
oesophageal adenocarcinoma was 7.2 per 100,000 in men and 2.5 per 100,000 in
women which is the highest incidence of adenocarcinoma of the oesophagus in the
world (7, 19, 21, 34).
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1.4 Risk factors for the development of oesophageal carcinoma
1.4.1 Alcohol and tobacco
Tobacco (either smoked or chewed) and alcohol indigestion have been suggested to
be the two main risk factors for OeC development (13). For squamous cell carcinoma
in low risk, developed regions such as the USA and northern Europe, tobacco
exposure and alcohol consumption are thought to account for up to 90% of cases (35).
For both risk factors, there is some evidence that the quantity and duration of exposure
are related to the risk of developing either subtype of OeC (36-40). There is however
some evidence suggesting that smoking of tobacco (or ingestion) alone is an important
risk factor for developing either subtype of OeC (38, 41-47). However, the exact
mechanisms are still uncertain. Although both tobacco smoking and alcohol
consumption appear to be independent risk factors, it has been suggested that in
combination they may have a synergistic affect placing heavy smokers and excessive
alcohol drinkers at the highest risk of developing OeC (27, 38, 48, 49).
1.4.2 Barrett’s oesophagus and gastro-oesophageal reflux disease
(GORD)
Barrett’s mucosa results from the replacement of the normal stratified squamous cell
epithelium by metaplastic columnar epithelium and was named after a surgeon called
Norman Barrett who described this abnormal cell findings in 1950 (50). The mucosal
change can be seen endoscopically and is usually confirmed by histological evaluation
of tissue biopsies. Barrett’s mucosa is associated with the development of
adenocarcinoma of the oesophagus and is thought to be the most important precursor
lesion (51-55). Barrett’s mucosa results from recurrent cell irritation secondary to
gastro-oesophageal reflux (GORD) where an incompetent lower oesophageal sphincter
leads to acidic contents refluxing into the oesophagus (56). Therefore GORD has also
been well described as a significant risk factor for adenocarcinoma of the oesophagus
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through its role in the development of Barrett’s mucosa (57-59). Recurrent acid
exposure and related cellular irritation due to GORD is thought to trigger the
metaplastic change from normal squamous epithelial cells to metaplastic columnar
cells. However, only 5-8% of patients with GORD will develop Barrett’s (60).
Continuing stimulus (i.e. acid reflux) can induce dysplastic epithelial changes in some
patients and eventually lead to invasive cancer (52, 55). Studies have shown that the
length of the Barrett’s mucosa is related to the severity of acid exposure (61, 62).
However, there is still an ongoing debate as to whether the length of the Barrett’s
segments is associated with an increased risk of developing adenocarcinoma (62-64).
The estimated risk of developing adenocarcinoma from Barrett’s mucosa varies across
the published literature. A recent review of European available literature showed a
range of 0.43 to 4.0% risk of progression from Barrett’s mucosa to adenocarcinoma per
year (65). The lowest risk (0.43%) was reported in a recent Dutch prospective study
which was the largest carried out in Europe to date (n=42207) (66). However, other
studies have shown the relative risk of developing adenocarcinoma in patients with
Barrett’s oesophagus is in the order of 50 to 100 times higher than someone without
Barrett’s mucosa (3, 60, 67).
1.4.3 Nutritional status/obesity
A person’s nutritional status has been associated with a risk of oesophageal cancer (3).
Malnourishment in the developing world or in low socioeconomic populations has been
associated with low fruit intake and vitamin deficiencies, both of which have been
shown to increase risk of developing oesophageal cancer (27, 68, 69). On the other
hand, obesity has also been linked to a significant increased risk for developing
adenocarcinoma of the oesophagus most likely as obesity is a major risk factor for
GORD (30, 70, 71). The latter association may explain the rise in adenocarcinoma
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incidence in countries such as the UK and the USA where there has also been a rise in
the average body mass index (72-74).
1.4.4 Human papilloma virus (HPV)
Human Papilloma Virus (HPV) was first found to be associated with squamous cell
carcinoma of the oesophagus more than 30 years ago when a study found that 40%
(24/60) of OeC patients in the study had underlying HPV infection (75). In high risk
areas for OeC such as China, eastern Asia, India and South Africa, HPV infection is
known to be highly prevalent (76-78). Similarly, countries in Europe with regionally high
rates of squamous cell OeC, such as France, also seems to have a high prevalence of
HPV infection (79). However, despite this geographical relationship, causality between
HPV infection and oesophageal squamous cell carcinoma pathogenesis has not been
demonstrated so far.
1.4.5 Nitrosamines
Another associated risk factor for OeC is exposure to nitrosamines which are found in
high levels in preserved fish and salted or pickled vegetables, all of which are popular
in high prevalence areas such as Linxian in northern China. Furthermore, recent
evidence suggests that chewing betel nuts (popular in China and other high prevalence
regions), which is high in nitrosamines precursors, increases the risk of developing
squamous cell OeC by up to 13 fold (16, 80, 81). This risk is further increased in
patients who also smoke or drink alcohol as well as chewing betel nuts, with a recent
large study finding a 9-20 fold increased risk if two of the risk factors where present and
a 41 fold increased risk if a patient used all three substances (38).
1.5 Oesophageal cancer treatment options
The majority of UK patients present with advanced disease which is often not locally
resectable or with distant metastatic disease (82). In this situation, patients are
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managed with palliative intent which can involve chemotherapy, radiotherapy or
endoscopic measures. Overall 5 year relative survival in these patients can be as low
as 3.1% (83). However this thesis will focus on OeC when patients present with
potentially resectable disease.
1.5.1 Surgical treatment options
Surgical resection of OeC remains the only curative option despite advances in medical
chemotherapy, radiotherapy and endoscopic interventions. Potential curative surgery is
considered for OeC patients presenting with locally advanced disease i.e. Tumour
Node Metastasis (TNM) classed stage II or III disease (84, 85). In the UK, only around
35% of patients present with potentially curable disease (82).
Surgery involves the resection of the oesophagus including the tumour mass,
surrounding lymph nodes, lymphatics and any resectable surrounding structures that
are thought to have been infiltrated by the cancer. Surgical approaches commonly
used are the transhiatal or transthoracic approach. In the UK, a transthoracic approach
is commonly used such as an Ivor Lewis oesophagectomy (abdominal and right
thoracic approach) or the three-incision modified McKeown oesophagectomy that
involves laparotomy, right thoracotomy, and neck anastomosis (86-88). The choice of
surgical approach depends on the location of the tumour and the preference of the
surgeon (89). Over the past 10 years minimal invasive oesophagectomy has become
more commonly used in the UK which involves the use of laparoscopy to perform part
or sometimes all of the same procedure. Initial studies identified reduced median stays
in intensive care, with initial decreased morbidity and mortality following minimally
invasive surgery (90-92). However there remains uncertainty with regards to whether
minimal invasive surgical techniques are superior to open surgery in terms of overall
outcomes and complication rates hence there is currently a large randomised control
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trial ongoing to address this debate (93).Currently following surgical management the 5
year survival in the UK has been reported as 23% (94).
Over the past 10 years the treatment of patients with locally advanced resectable OeC
has changed following large multi-centre trials showing that neoadjuvant
chemo(radio)therapy improves patient survival (95-97). This is despite the fact that in
around 50% of the patients, no radiological measurable local response was achieved
(98). The first trial to highlight the possible benefit of neoadjuvant chemotherapy in
OeC was the UK medical research council (MRC) OE02 trial (99) (see 3.1 Background-
OE02 MRC trial). Figure 3 shows a typical treatment algorithm used to differentiate
cases and guide management of individual oesophageal cancer patients (85). There
are two decision points in the patient pathway: (1) based on clinical staging
(determined from imaging via Computerised Tomography scans (CT), Positron
Emission Tomography (PET) or endoscopic ultrasound scan (EUS) and direct
endoscopic examination) and (2) pathological tumour staging after surgical resection.
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Figure 3: UK oesophageal cancer patient treatment algorithm.
The flow chart above illustrates how disease stage influences the management of OeC patients
in the UK. The first treatment decision point is based on clinical staging where one needs to
differentiate between early, locally advanced and metastatic disease. The second treatment
decision point is in patients who have undergone surgery and is dependent on the pathological
stage based on the resected specimen.
1.5.2 The role of neoadjuvant chemotherapy in the management of
patients with oesophageal cancer
In the 1980s, 5 year survival of patients with OeC was <10% in the USA despite radical
resection (100, 101). This prompted studies looking at improving survival rates by using
pre-operative (neoadjuvant) chemotherapeutic agents, such as Vindesine (102-104)
and Bleomycin (105, 106) as well as Cisplatin (107, 108). A study by Kelsen et al
showed that the use of pre-operative chemotherapy in patients with squamous cell
carcinoma induced tumour regression and resulted in higher resection rates (102, 109-
111). Two large multi-centre randomised control trials were conducted in the early
1990’s (99, 112). The first one was conducted by the US Radiation Therapy Oncology
Group (RTOG) lead by Kelsen (112) involving 440 patients who were randomly
allocated to either surgery alone (n=227) or chemotherapy followed by surgery
(n=213). Patients in the chemotherapy followed by surgery group received three cycles
of Cisplatin and 5-Fluorouracil. The trial recruited patients with squamous cell
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carcinoma (46%) and adenocarcinoma (54%) with locally advanced, resectable
disease. Patients with distant metastasis (M1 disease) were excluded. Responders and
patients with an R0 (complete resection with no involved margins) also received two
further cycles of chemotherapy post operatively. Patients were recruited over 5 years
from 123 institutions across the USA (1990-1995). This study found no significant
difference in overall and disease free survival between the two groups (112). It was
speculated that earlier studies in smaller patient cohorts may have overestimated the
potential effect of neoadjuvant chemotherapy (112). Subsequent randomised controlled
trials (113, 114) in the USA using chemotherapy alongside radiotherapy preoperatively
were more successful and established pre-operative chemo(radio)therapy as the
standard of care in the US for patients with locally advanced potentially curable OeC
(115).
The other major randomised control trial was the OE02 trial carried out by the UK MRC
(99). The OE02 trial was a multi-centre randomised trial which compared patients
undergoing neoadjuvant 5-FU/cisplatin chemotherapy followed by surgery with patients
treated by surgery only. It included patients from the UK and The Netherlands. This trial
is discussed in more detail later (3.1 Background- OE02 MRC trial). In summary, the
results showed a significant improvement in overall and disease free survival in
patients who had neoadjuvant chemotherapy (p=0.04 and p=0.0014, respectively)
compared to those who underwent surgery alone changing the clinical practice in the
UK (99). In the UK following the OE02 trial neoadjuvant chemotherapy followed by
surgical resection has become the ‘gold-standard’ treatment option for locally advanced
(stage II or III) oesophageal cancer.
The most recent meta-analysis by Sjoquist et al (n=4188) looked at literature
comparing surgery alone with neoadjuvant chemotherapy or neoadjuvant
chemoradiotherapy followed by surgery in patients with resectable OeC (116).
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Although no significant difference in survival was seen between patients who had
neoadjuvant chemotherapy compared to those who had neoadjuvant
chemoradiotherapy followed by surgery, a clear difference in survival was seen
between patients who received some form of neoadjuvant treatment followed by
surgery to those who were treated by surgery alone (p=0.005; hazard ratio 0.87; 95%
confidence interval 0.79-0.96) with an overall 2 year survival benefit of 5.1% (p=0.005)
(116).
1.5.3 Challenges of neoadjuvant chemotherapy
The aim of neoadjuvant chemotherapy is to downstage the primary tumour to increase
the chance of a complete resection of the primary tumour and to prevent micro-
metastasis to lymph nodes or distant sites, therefore reducing tumour recurrence.
Managing a patient who receives or has received neoadjuvant chemotherapy can be
challenging as toxicity complications can lead to increased morbidity and mortality
(117). Chemotherapy may have side-effects ranging from hair loss and gastrointestinal
effects to acute chemotherapy toxicity which can lead to the patient being unable to
complete their regimen or can even be life threatening (118). Figures from the most
recent UK National Oesophagogastric Cancer Audit (NOGCA) suggest that nearly 3 in
10 patients are unable to complete their neoadjuvant chemotherapy course, mainly due
to the development of acute chemotherapy toxicity (82). Furthermore, chemotherapy
does not always lead to the intended preoperative disease control/tumour regression
and in fact disease progression may occur during this neoadjuvant treatment stage.
The NOGCA figures suggest that 4.5% of patient had disease progression during their
pre-operative chemotherapy (82). Lower rates were seen in the OE02 trial (1.4%) (99)
but higher rates in the RTOG randomised control trial (6.9%) (112). Unfortunately,
there is no clinically established biomarker to predict which patient might benefit from
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neoadjuvant chemotherapy and which patient might be at risk of severe chemotherapy
related side effects.
1.6 Oesophageal cancer patients and survival
Overall 5 year survival of all patients with OeC irrespective of disease stage is reported
between 9-15% (19, 119, 120). Figures from EUROCARE show an overall 1 year
survival rate of 35-37% and 5 year survival rates of 10-13% (10). In England, overall
survival rates are slightly lower than the European average, with 1 year survival at 31-
35% and 5 year survival 8-10%, respectively (10).
A recent study described a worldwide 5 year overall survival for patients with stage I
(early disease) oesophageal cancer disease of 60-80% (121). Worldwide figures for 5
year survival of patients who have locally advanced disease, and then undergo surgery
(typically stage II-III disease) ranges from 22-37% (83, 122-125). This relatively poor
prognosis is despite improvements in detection techniques, better surgical equipment,
advanced medical oncology treatment options and despite increasing public disease
awareness.
Recent studies suggest patients with squamous cell OeC have a worse prognosis
compare to those with adenocarcinoma OeC (126-130). This may be related to the fact
that patients with squamous cell OeC tend to have more significant co-morbidities,
older and have therefore have higher adjusted overall post-operative death risk (126,
131). Another potentially important factor is that 75% of squamous cell OeC are found
to be in contact with the trachea making surgery more difficult increasing post-operative
complications such as a tracheal fistula as well as increasing the risk of the tumours
being unresectable (126).
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1.7 Tumour node metastasis classification for oesophageal
cancer
The Tumour Node Metastasis (TNM) classification is currently the only established
prognosis prediction tool and is used for most malignant tumours worldwide. The TNM
classification was introduced in the 1940s by Pierre Denoix using different parameters
such as tumour size, depth of invasion of the primary tumour, lymphatic involvement,
and presence of metastases to classify cancer (132, 133). The initial work from Denoix
lead to the formation of the International Union Cancer Committee (UICC)(134) and the
American Joint Committee on Cancer (AJCC) leading to the introduction of a formal
cancer staging system (135, 136). Nowadays, the TNM classification is used
throughout the world to clinically predict patients’ prognosis as well as assist clinicians
to determine patient treatment (137).
In 1973 the first recognised staging system specifically aimed at classifying OeC was
introduced and was quickly followed by the second edition in 1977. Both these editions
only involved a clinical classification of T category by tumour length, position and the
presence of obstructive symptoms. In the 3rd edition of TNM both pathological and
clinical classification of the T category was introduced but as two separate categories
(T and pT staging). Following publications from Japan the 4th edition of the TNM
classification in 1985 focussed on depth of tumour to determine the T category (138).
Following on from similar subsequent editions of the TNM classification of OeC, there
have been significant changes in the most recent 7th edition most notably in the
classification of nodal status (N category), which now has 4 categories depending on
the actual number of positive lymph nodes (139). This is major change from 2
categories in previous editions based on whether there was at least one positive node
(140). Although these changes in staging are aimed to reflect changes in evidence of
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best clinical practice, there has often been controversy and debate. The most recent 7th
TNM edition (139) implemented changes for the staging of OeC (
Table 1) based on results from evidence taken from the worldwide oesophageal cancer
collaborative (WECC) (141).
Table 1: UICC TNM classification (7th ed.) of oesophageal cancer (139)
Primary tumour (T category)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis High grade dysplasia
T1a Tumour invades lamina propria or muscularis mucosae
T1b Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades adventitia
T4 Tumour invades surrounding structures
T4a Tumour invades pleura, pericardium or diaphragm
T4b Tumour invades other structures such as vertebrae or aorta
Regional lymph nodes (N category)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis involving 1-2 nodes
N2 Regional lymph node metastasis involving 3-6 nodes
N3 Regional lymph node metastasis involving 7 or more nodes
Distant metastasis (M category)
MX Distant metastasis cannot be assessed
M0 No evidence of distant metastasis
M1 Distant metastasis present
Only data from patients who had been treated by only surgery alone was used to
establish the revised TNM classifier (Table 1). Thus, the accuracy and validity of the
TNM classification for patients treated with neoadjuvant chemo(radio)therapy is
currently still uncertain (142-148). With the apparent change in clinical practice to treat
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oesophageal cancer patients with neoadjuvant or peri-operative chemo(radio)therapy,
there is a need to establish the prognostic value of the TNM classification in this setting
and investigate whether there are other prognostic factors.
1.8 Radiological prognostic markers in patients with
oesophageal cancer
Radiological imaging plays an important role in establishing the clinical stage of cancer
influencing patient management (Figure 3). Endoscopic ultrasound (EUS) allows
visualisation of the lesion and assessment of the depth of invasion (T category). The
use of EUS has been shown to be superior to Computed Tomography (CT) or Positron
Emission Tomography (PET) imaging in assessing locally advanced disease for the
determination of depth of invasion of the primary tumour and lymph node status (149-
151). However, EUS imaging is limited to a depth of 5cm and thus cannot be used to
assess distant disease so is usually used in conjunction with other imaging modalities
(150, 152). CT images are relevant for the clinical staging of OeC to localise the tumour
and assess any potential involvement of surrounding structures and/or lymph nodes.
CT scans also enable the identification of any distant metastases and are the imaging
of choice for the detection of local or distant recurrence during the post-operative follow
up. With respect to the best modality of staging OeC, the current literature is still
controversial (153-156).However a recent meta-analyses suggested that PET may
have a higher diagnostic performance in detecting distant metastasis (157, 158).
PET imaging is based on the principle that malignant cells can have an increased
uptake of glucose (159). Fluorine-18 fluorodeoxyglucose (FDG) is used to identify
higher uptake in malignant cells in comparison to the uptake of the normal tissues. The
use of PET imaging for staging OeC patients is relatively new and its value in
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identifying tumour regression after neoadjuvant therapy remains to be established
(160, 161).
PET scans may have a potential advantage over conventional CT scans in the
detection of lymph node metastases. Radiologists currently use size and shape criteria
to determine whether a lymph node maybe involved with cancerous cells or not when
assessing CT images (157). CT scanning has a poor sensitivity for correct lymph node
staging (162, 163). However, as PET scans detect metabolic changes in the lymph
node tissue which can be related to the infiltration of the lymph node by tumour, PET
has been shown to have a higher sensitivity to detect distant lymph node involvement
than conventional CT scans (164). A meta-analysis showed the sensitivity of detecting
distant lymph node involvement was 71% in PET imaging compared to 52% using CT
imaging (157). However, when involved lymph nodes are in close proximity to the
primary tumour, the FDG uptake by the primary tumour may be indistinguishable from
that of surrounding lymph nodes. It has been demonstrated that FDG PET had 33%
sensitivity to detect lymph node metastasis close to the primary tumour as opposed to
81% sensitivity of EUS imaging (165).
Recent studies have shown the overall accuracy in TNM staging improved from 83-
86% for PET imaging alone to 90-92% when PET imaging is done in conjunction with
CT (166, 167).
1.9 Tumour regression systems used to assess oesophageal
cancer
Patients with potentially curable OeC, who show response to neoadjuvant treatment
seem to have significantly improved survival than those who do not respond, especially
if they have a complete pathological response e.g. no viable tumour in the resection
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specimen (111, 168-173). Pathologic examination of the resection specimen after
neoadjuvant chemotherapy remains the “gold standard” for evaluation of tumour
response (98, 174). However, there I no consensus regarding which histopathological
tumour regression system should be used for oesophageal cancer resection
specimens (121, 175, 176).
A number of different tumour regression assessment systems have been suggested for
oesophageal cancer treated with neoadjuvant chemotherapy (175-180). The table
below (Table 2) summarises the details of some of the published scoring systems
which have all shown a relationship with OeC patient prognosis following neoadjuvant
therapy. There have also been recent attempts to incorporate regression grading of
tumour involved lymph nodes along with at the primary site to try to create a more
comprehensive scoring systems (181-183), however, grading of regression in lymph
node metastases will not be assessed in this thesis.
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Table 2: Published tumour regression scoring systems for oesophageal cancer
Authors Grading Pathological features
Mandard et al 1994 (177)
TRG1 Complete regression (i.e. fibrosis without
detectable residual cancer cells)
TRG2 Few residual cancer cells scattered through the
fibrosis
TRG3 Fibrosis and tumour cells with predominance of
fibrosis
TRG4 Residual cancer outgrowing fibrosis
TRG5 Absence of any regressive changes
Japanese Society of Esophageal Disease (184)
ypV0 Ineffective (i.e. no regression evidence)
ypV1 Slightly effective: Viable cell more than 1/3 of
tumour tissue, but with evidence of
degeneration
ypV2 Moderately effective: Viable cell less than 1/3 of
tumour tissue and severely degenerated or
necrotic
ypV3 Markedly effective: No viable cell
Schneider et al 2005 (185)
I >50% vital residual tumour cells
II 10%–50% vital residual tumour cells
III <10% vital residual tumour cells
IV no vital residual tumour cells
Chirieac et al 2005 (179)
1 No evidence of residual tumour
2 1-10% residual tumour
3 11-50% residual tumour
4 >50% residual tumour
*Becker et al 2003 (178)
Swisher et al 2005 (186)
Langer et al (175)
CRT no residual cell
P1 1%–50% of residual viable cell
P2 >50% residual viable cell in primary tumour
Brucher et al 2006 (176)
Barbour et al 2008 (187)
Responders <10% residual tumour cells
Non
responders
>10% residual tumour cells
Donington et al 2003 (188)
Complete
responders
No evidence of residual tumour
Residual
tumour
Any evidence of residual tumour
*Becker et al original paper developed the system originally for gastric cancer and later used the
same system for oesophageal cancer
1.9.1 Tumour regression grading according to Mandard et al – the
original system
A classification system to assess tumour regression in OeC after radiotherapy was first
suggested by Mandard et al (177). This initial study, evaluating specimens from 93
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OeC patients with squamous cell cancers led to the definition of 5 grades based on the
relative extent of fibrosis. Mandard et al suggested a significant difference (p<0.001) in
disease free survival between patients with TRG 1-3 compared to patients with TRG 4-
5 (Table 2). The Mandard TRG classification has been used in a number of OeC
studies since to assess tumour response to neoadjuvant therapy (189-192). The
Mandard TRG classification is currently used for the assessment of OeC resection
specimens by many pathologists in the UK. There have been concerns that the
determination of the TRG is very subjective and was particularly difficult to reproduce
reliably, especially when differentiation between TRG 2, 3 and 4 is required (181).
Studies have shown that observers often find it difficult to quantify fibrotic changes as
distinguishing between fibrosis (e.g. tumour regression) and desmoplastic stroma (a
normal component of the non-regressed tumour) is inherently difficult (174, 191-193).
1.9.2 Tumour regression grading according to Becker et al - the
European perspective
Becker et al agreed with Mandard’s findings that tumour regression leads to the
formation of fibrosis and fibro-inflammatory areas (178), however, they suggested an
alternative regression classification system which estimates the percentage of residual
viable tumour cells in the whole of the tumour bed. Becker et al proposed a 4 tier
classification system as opposed to Mandard’s 5 categories (see Table 2 ). The Becker
TRG classifier was initially tested in gastric cancer specimens and showed a
relationship with patient survival on univariate analysis (178). The same authors
summarised their original classification to a 3 or 2 tier system (175, 176).
1.9.3 Tumour regression grading according to Chirieac et al - the
American perspective
Chirieac et al proposed a regression grading classification with initially 4 groups and
later 3 groups (Figure 4). Their study showed a significant difference in disease free
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survival using the 4 tier classification system (194) and subsequently with a 3 tier
classification (186). Using the three tier classification, the percentage of residual
tumour cells found in a resection specimen was significantly related to patient survival
(3 year survival TRG1 (0% residual) =74% vs. TRG (1-50%) =54% vs. TRG3 (>50%) =
24%; p<0.001).
Figure 4: Chirieac et al 4 tier tumour regression grading system.
Illustration showing a cross-section picture of a primary oesophageal tumour after neoadjuvant
chemotherapy. (A) No evidence of residual tumour within the tumour bed (area of inflammatory
and fibrotic changes). (B) Between 1-10% of residual tumour cells, fibrosis and inflammatory
changes predominate. (C) Between 11-50% of residual tumour present at site of primary
tumour. (D) Greater than 50% residual tumour remaining. Diagram adapted from Chirieac et al
(179).
1.9.4 Japanese tumour regression grading for oesophageal cancer
Since 1974, Japan has used its own regression scoring system established by the
Japanese Society of Esophageal Disease (195). This current 4 tier system is based
upon identification of the site of the original tumour (‘tumour zone’) on haematoxylin
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and eosin stained slides. The percentage of tumour within the tumour zone is then
calculated by dividing the sum of areas with viable tumour by the overall tumour zone
and cases are classified as ypV0-ypV3 depending on the percentage (184). This
tumour regression classification was found to be an independent prognostic marker for
overall survival in patients with OeC treated by pre-operative chemoradiotherapy
(p<0.001).
1.9.5 Challenges of the current tumour regression grading systems
One of the difficulties in establishing which TRG classification is ‘best’ is that different
studies have used patient cohorts with different neoadjuvant treatment regimens
(chemotherapy alone vs chemoradiation), different histological subtypes and applied
different regression grading system. The majority of TRG studies to date have
examined tumour regression after neoadjuvant chemoradiotherapy in OeC (174, 176,
177, 179, 180, 186, 189). The Japanese society of esophageal disease and the
Mandard regression grading are being used the most worldwide and favour systems
with 5 or 4 grading categories. Recent European and American studies are favouring
classifications with fewer categories suggesting that such classifications will be easier
to implement with less inter-observer variability (174, 176, 179).
The main criticism for all the TRG classifications has been high intra-observer and
inter-observer variability with Kappa scores as low as 0.28 (174, 192, 196, 197). The
high intra- and inter-observer variability could potentially be reduced by using a more
objective quantitative method or an automated computer generated method. Recent
work in colorectal cancer used a quantitative morphometric method called ‘point
counting’ to establish a “tumour density score” per case (198, 199). The same
methodology could be used in post-chemotherapy resection specimens and might
improve the inter-observer agreement as predefined measurement points need to be
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assessed which will provide a quantitative measure of the relative amount of tumour
versus stroma/fibrosis.
Another challenge is that assessment of using any of the current TRG classification
system requires embedding the whole of the tumour bed and can only be performed
after surgery. It would be desirable as well as be of clinical interest to have a prognostic
TRG classification that does not depend on embedding of the whole tumour bed and
could be applied while the patient is still under pre-operative treatment e.g. could be
assessed in endoscopic biopsies. The current thesis will address these challenges.
1.10 Circumferential resection margins in oesophageal cancer
Local OeC recurrence after attempted curative surgery often results in only palliative
options being available for treatment. A R0 resection indicates that longitudinal and
circumferential margins are clear of any macroscopic or microscopic tumour (200).
While an R1 resection indicates evidence of microscopic residual tumour and R2
resection implies evidence of macroscopic tumour, therefore an incomplete resection.
Depending on the pathological definition used, a positive (e.g. R1) resection margin
can either mean that there is viable tumour directly at the margin (definition used by
College of American Pathologists) or there are tumour cells with 1mm of the resection
margin (definition used by the Royal College of Pathologists UK). There are currently
conflicting results as to whether one of these definitions is better than the other with
respect to predicting patient’s prognosis (201-203). Multiple studies have shown the
prognostic importance in achieving an R0 resection (84, 112, 204, 205). Recently, a
meta-analysis using data from 30 European centres including 2060 patients identified
the presence of tumour at the tumour margin to be an independent prognostic marker
for survival (p<0.001) (205). However this included patients who had undergone a
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variety of treatments including those who had surgery alone and patients who
underwent various regimes of chemo(radio) neoadjuvant therapies.
The presence of a ‘positive’ circumferential resection margin has been associated with
a poor prognosis in OeC patients who undergo surgery alone (201, 203, 204, 206,
207). However in cohorts including patients who have undergone neoadjuvant
treatment there have been conflicting results with some showing circumferential
resection margin remains a prognostic marker (208-212), while other studies have
shown in this setting following neoadjuvant treatment the circumferential resection
margin is not a prognostic marker (213-216).
1.11 Tumour infiltrating immune cells in oesophageal cancer
The immune reaction towards the tumour cells has been proposed as the seventh
hallmark of cancer (217). There is growing evidence that the interaction between
malignant cancer cells and the host’s immune cells has an important role in tumour
progression (217-220). The concept of immunosurveillance and immunoediting of the
primary malignancy has led to the use of immune targeted therapy (immunotherapy)
being used in lymphoma (221, 222). Intratumoural immune cells are thought to have
different functions with regards to being pro-tumour or anti-tumour in nature (218, 219,
223). Also different subsets of the same immune cell type, such as macrophages, have
been shown to exhibit different effects on tumour cells (224, 225). There have been a
number of studies recently which have identified the level of lymphocyte infiltration of
the tumour as being related to patient prognosis (226-232), and identified macrophage
infiltration of the tumour as a poor prognostic marker (233-241). Neutrophils have also
been shown to have pro-tumour actions with high infiltration levels in the tumour being
related to poor prognosis (235, 242-247).
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In OeC, the evidence suggests that high tumour infiltration by lymphocytes is related to
a good prognosis (248-255). However, studies (248-256) are difficult to compare as
they used different neoadjuvant therapy regimes and various scoring methods. No
study to date has used a technique to quantify the level of lymphocyte infiltration.
Recent studies have shown that the ratio of “anti-tumour” lymphocytes to “pro-tumour”
macrophages may be the most important prognostic marker with regards to immune
cell distributions at the tumour microenvironment (237, 257).
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AIMS OF THE STUDY
This thesis aims to identify new post-operative prognostic markers for patients with
locally advanced resectable oesophageal cancer.
The specific aims are to
1. Investigate the prognostic value of the circumferential resection margin (CRM)
involvement after pre-operative chemotherapy and establish whether the
presence of tumour cells within 1mm has the same prognostic value as the
presence of tumour cells directly at the margin.
2. Determine whether tumour cell density measurements at the luminal surface of
the resection specimens can be used to reliably and reproducibly predict OeC
patients’ prognosis in patients treated by surgery alone as well as in patients
treated with neoadjuvant chemotherapy.
3. Evaluate the prognostic value of the tumour infiltrating immune cells in OeC
patients treated by surgery alone as well as patients treated with neoadjuvant
chemotherapy and to try to establish whether immune cell ratios at the tumour
microenvironment may also allow prognostic stratification.
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HYPOTHESES
The hypotheses for this work are:
1. The presence of tumour cells within 1mm, as well as directly at the circumferential
resection margin (CRM) is related to poor prognosis in oesophageal cancer
patients who have undergone neoadjuvant chemotherapy followed by surgery.
2. The tumour cell density will vary between cases who have had neoadjuvant
chemotherapy and those who have been treated by surgery alone. A high tumour
cell density at the luminal surface is related to a poor prognosis in patients treated
by neoadjuvant chemotherapy followed by surgery.
3. The distribution and proportion of different immune cells in the tumour
microenvironment will vary between those who have undergone neoadjuvant
chemotherapy followed by surgery and those who underwent surgery alone.
Immune cell infiltration of the tumour is related to prognosis in oesophageal cancer
patients.
~ 48 ~
2. THE PROGNOSTIC ROLE OF THE
CIRCUMFERENTIAL RESECTION MARGIN
STATUS IN PATIENTS WITH OESOPHAGEAL
CANCER
Work presented in this chapter has previously been published and the following
sentence is included in order to comply with copyright rules requested by the
respective publishing journal:
This is a pre-copy-editing, author-produced PDF of an article accepted for publication
in the European Journal of Cardiothoracic surgery (258) following peer review. The
definitive publisher-authenticated version of “Prognostic significance of cancer within
1mm of the circumferential resection margin in oesophageal cancer patients following
neo-adjuvant chemotherapy” (562-567.doi: 10.1093/ejcts/ezs331) is available online at:
http://ejcts.oxfordjournals.org.
2.1 Background
Depending on the type of oesophagectomy performed, the resection of an
oesophageal cancer involves mobilisation of the stomach plus in some cases of the
duodenum, then resection of a segment of the oesophagus containing tumour, along
with the tissue that surrounds it such as fat, lymph nodes and pleura. In the UK, an
oesophagectomy is most commonly done as a two stage procedure known as an Ivor
Lewis oesophago-gastrectomy. The oesophageal segment and the proximal stomach
are removed before the remnant stomach is pulled up and an oesophageal to stomach
anastomosis is created in the chest. The resected specimen is either sent intact or after
lymph node dissection for pathological assessment.
Part of the dataset requirements published by the Royal College of Pathologists UK
(RCPath), is the assessment of whether a complete resection of the tumour (e.g. an R0
resection) has been achieved (200). For an R0 resection both longitudinal (proximal
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and distal) resections margins as well as the circumferential (sometimes also called
radial) resection margin must be free of tumour. R1 would indicate that there are
microscopically visible tumour cells present; R2 is defined as the presence of
macroscopically visible tumour at the resection margin. Several large studies have
demonstrated the importance of an R0 resection for patient survival following surgery
for an oesophageal carcinoma (84, 112, 204, 205). There is evidence that involvement
of either the proximal or distal resection margin increases the risk of local recurrence
(94, 259). However, the prognostic importance consequence of an involved
circumferential margin remains controversial (214, 260, 261).The circumferential
resection margin (CRM) is usually assessed pathologically by slicing the fixed
oesophagectomy specimen perpendicular to its longitudinal axis (Figure 5a & 5b).
~ 50 ~
Figure 5a & 5b: Fresh oesophagectomy specimen and cross-sections after fixation.
(5a) Photographs showing the fresh (unfixed) resection specimen as it arrives in the pathology
department. (5b) photographs of cross-sections cut after fixation of the specimen. The
oesophageal lumen and wall can be identified as well as surrounding tissue resected along with
the oesophagus.
Figure 6 shows a diagrammatic representation of the assessment of the distance of
clearance from the CRM, a surgically created boundary. A circumferential resection
margin (CRM) is defined as ‘positive’ by the RCPath if viable tumour cells are found
within 1mm of the resection margin (200). The College of American Pathologists (CAP)
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defines a positive CRM as evidence of viable tumour cells directly at the resection
margin (202).
Figure 6: Cross-sectional view through an oesophagectomy specimen.
The circumferential resection margin is outlined in blue and represents the outermost margin of
the specimen. Centrally located is the oesophageal lumen. The orange area represents the wall
of the oesophagus including its layers the mucosa, submucosa and muscularis propria.
Surrounding tissues (adventitia, fat) is represented in pink. Tumour area is represented in
yellow. The CRM status is determined by measuring the minimal distance of viable tumour cells
from the margin.
The prognostic significance of CRM involvement using the RCPath definition was first
suggested by Sagar et al in a small series of OeC cancer patients treated by surgery
alone. This initial and subsequent study by the same authors demonstrated that the
presence of cancer cells within 1mm of the CRM (RCPath CRM-positive) was
associated with a poorer prognosis (206, 207). They went on to identify a positive CRM
to be an independent prognostic marker for overall survival and also associated with an
increased risk of local recurrence (206). Further studies examining the relationship
between CRM status and prognosis in patients with OeC are summarised in Table 3.
CRM has been identified as a prognostic factor in oesophageal cancer patients treated
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with surgery alone in multiple studies (201, 204, 206, 207, 210, 262). The studies
assessing the prognostic value of the CRM status after neoadjuvant chemotherapy
have often also included patients who also had surgery alone (211-213, 215, 216, 260,
263). At the time of this study, there was one study published which had examined a
homogenous cohort of neoadjuvant chemotherapy followed by surgery patients (209)
and one study where patients were treated by chemoradiotherapy followed by surgery
(208). Both studies found that CRM status was a prognostic marker after neoadjuvant
therapy. However, there are other studies with mixed treatment cohorts (Table 3) which
have shown no prognostic value of the CRM status in univariate analysis (213, 214,
262, 264, 265). Since the initial publication of this work a further study using a
homogenous cohort of OeC patients who had undergone neoadjuvant
chemoradiotherapy (n=104) has been published (261). This showed that a positive
CRM did have prognostic value through univariate analysis, however was not an
independent prognostic marker (p=0.124).
The reported median frequency of CRM positivity in oesophageal cancer is 42%
ranging from 9% to 71% (201, 204, 206-216, 260-264, 266-268). This wide range could
be related to the use of different OeC treatment regimens. Thus, 8 studies investigated
surgery alone patient cohorts, 1 study investigated neoadjuvant chemotherapy only
patients, 3 studies investigated neoadjuvant chemoradiotherapy cohorts only and 9
studies involved cohorts with mixed pre-operative treatment regimens (Table 3). There
were also differences between the studies in terms of the different tumour histological
subtypes; the 71% CRM positive study involved squamous cell carcinomas (260) while
the study reporting a 21% CRM positivity rate investigated mostly adenocarcinomas
(84%) (261). However the variation in CRM positivity rates may also be related to the
fact that different definitions (RCPath versus CAP) have been used to identify a
positive CRM (208, 211-213, 215, 216, 260, 263, 266).
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Table 3: Summary of the literature investigating the prognostic relevance of the












































































































































































































CRM = circumferential resection margin, N= number of patients. Pros= prospective and Retro=
retrospective study. *= studies investigating patients treated with pre-operative
chemoradiotherapy.
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Studies which examined the prognostic value of the two definitions of a positive CRM
have contrasting results (201, 213, 216, 260, 268). The studies by Pultrum et al (201)
and O’Farnell et al (213) supported the clinical relevance of the RCPath definition,
while Verhage et al (268), Deeter et al (216) and Okada et al (260) concluded that the
CAP definition of a positive CRM was a better prognosticator. However, two of these
studies compared patients treated by surgery alone (201, 268) and three studies
investigated mixed cohorts composed of patients who may or may not have had
neoadjuvant treatment (213, 216, 260). At the time of this study, there were no data
available comparing the prognostic value of tumour cells present at the CRM with that
of tumour cells present within 1 mm but not at the CRM, in a cohort of oesophageal
cancer patients treated with chemotherapy followed by radical resection.
This retrospective study aimed to establish whether the prognostic value of tumour
cells present directly at the resection margin is different to that where tumour cells are
seen within 1mm of the resection margin by using a large cohort of neoadjuvant
chemotherapy treated oesophageal cancer patients from two large UK centres
It was hypothesised that although the presence of a positive CRM may have prognostic
value in neoadjuvant chemotherapy treated oesophageal cancer it is not an
independent prognostic marker as shown in surgery alone studies previously.
2.2 Methods
2.2.1 Patients selection
This study was carried out using a cohort created from databases of
oesophagectomies carried out within the Leeds teaching hospitals NHS trust (LTHT)
and South Manchester NHS trust. A total of 465 patients who had undergone an Ivor-
Lewis oesophagectomy with 2-field lymphadenectomy were assessed for eligibility for
inclusion. The patient inclusion and exclusion criteria are set out in Figure 7. Patients
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with evidence of metastatic disease were excluded from the study. Patients with a
complete pathological response were excluded for the final cohort (n=9) as they had no
residual tumour cells remain to assess for CRM status. Although they could have been
placed in the CRM –ve group these patients are likely to have the best prognosis with
longest survival so could have been the reason for previous findings of CRM being an
independent prognostic marker (209, 211). Through discussions between the research
group it was decided for this study these patients would be excluded from the final
cohort.
Figure 7: Circumferential resection margin study flow chart.
The flow chart shows how the final cohort was created including exclusion criteria and number
of patients excluded at each step.
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In total 232 patients who received two cycles of 5-Fluorouracil/ Cisplatin chemotherapy
according to OE02 trial regimen (99) followed by surgery, were included in the study.
184 patients were treated in Leeds between 2001 and 2009 and 48 patients were
treated in Manchester between 1995 and 2008. The two hospital cohorts were
compared to ensure they were comparable in terms of clinicopathological features and
survival rates, for details see Table 4.








Number (%) Number (%) Number (%) p value
Gender
Male 177 (76.3) 139 (75.5) 38 (79.2)
0.600
Female 55 (23.7) 45 (24.5) 10 (20.8)
Histology
Adenocarcinoma 183 (78.9) 141 (76.6) 42 (87.5)
0.111Squamous 45 (19.4) 40 (21.7) 5 (10.4)
Adenosquamous 4 (1.7) 3 (1.6) 1 (2.1)
ypT (TNM7)
T1a 7 (3.0) 4 (2.2) 3 (6.3)
0.073
T1b 15 (6.5) 14 (7.6) 1 (2.1)
T2 39 (16.8) 26 (14.1) 13 (27.1)
T3 162 (68.9) 131 (71.2) 31 (64.6)
T4a/b 9 (3.9) 9 (4.9) 0 (0.0)
ypN (TNM7)
N0 70 (30.2) 52 (28.3) 18 (37.5)
0.473
N1 60 (25.9) 50 (27.2) 10 (20.8)
N2 49 (21.1) 40 (21.7) 9 (18.8)
N3 53 (22.8) 42 (22.8) 11 (22.9)
Mortality
Alive 136 (58.6) 106 (57.6) 30 (62.5)
0.541
Dead 96 (41.4) 78 (42.4) 18 (37.5)
Cancer specific survival
Alive or other death 158 (68.1) 126 (68.5) 32 (66.7)
0.999Cancer death 64 (27.6) 48 (26.1) 16 (33.3)
Unknown 10 (4.3) 10 (5.4) 0 (0.0)
*South Man= South Manchester cohort
The majority of cases in the cohort were males (76%) and had ypT3 (70%) tumours.
The combined cohort included patients with both adenocarcinomas (n=183) and
squamous cell carcinomas (n=45), as well 4 patients who had adenosquamous
cancers.
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There was no significant difference in age or lymph node status between
adenocarcinomas (n=183) and squamous cell carcinoma (n=45) (Table 5).











Median 62 62 61 0.34
Range 35-78 35-78 41-75
Total number of lymph nodes
Median 30 29 34 0.57
Range 3-82 3-82 3-70
Number positive lymph nodes
Median 2 2 1 0.52




squamous cell carcinoma. P values found using Kruskal Wallis testing.
2.2.2 Circumferential resection margin subgroups
Specialist gastrointestinal pathologists in Leeds (Heike Grabsch, HG) and Manchester
(Gavin Udall and Susan Pritchard) reviewed all histopathology reports. If the distance
of cancer cells from the CRM was not provided in the report, the original Haematoxylin
and Eosin (H&E) stained slides were reviewed and the distance of cancer cells from
the CRM was measured in mm.
The CRM status was classified into three groups;
 Group A: cancer cells at the CRM (equal to a distance of 0 mm from the
margin)
 Group B: cancer cells within 1 mm but not directly at the CRM
 Group C: no cancer cells within 1 mm of the CRM.
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2.2.3 Data collection and follow up
The following clinicopathological data were used for analyses: age at diagnosis,
gender, ypT and ypN categories according to TNM 7th ed.(139), tumour morphology
according to WHO classification (269), total number of lymph nodes examined, total
number of positive lymph nodes and nearest distance of viable cancer cells to the
circumferential resection margin. Follow-up and mortality data were retrieved from
Cancer Registry Information Service database and hospital patient records. Patients
were followed up until the end of the study period or death with routine outpatient clinic
reviews. LTHT data was collected by Mr Paul Jose (research fellow LTHT) and
Manchester data Mr Ahmed Mirza (South Manchester research fellow), before being
combined and analysed by the author of this thesis.
2.2.4 Statistical analyses
After the two hospital centres databases were combined statistical analyses were
performed using Statistical Package for the Social Sciences (SPSS) 17.0 (Chicago,
Illinois). The Kruskal-Wallis test was used to establish the relationship between CRM
status, tumour morphology, ypT and ypN. The relationship of CRM status and cancer
specific survival was determined by the Kaplan-Meier method (270) and differences
between groups were tested by the log-rank test. Follow up time was calculated from
the day of surgery to patient death or end of study period.
A Cox’s proportional hazard model was used for univariate and multivariate analysis.
Variables tested in univariate analyses were patient age, gender, histological tumour
type, ypT category, ypN category, number of lymph nodes retrieved, number of
involved lymph nodes and CRM. Only variables that were significant in univariate
survival analysis were included in multivariate analysis. A p value of less than 0.05 was
considered to be significant.
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2.3 Results
2.3.1 CRM status and clinicopathological features
Thirty-eight (17%) specimens were classified as Group A (cancer cells at CRM), 89
(38%) as Group B (cancer cells within 1 mm but not at CRM) and 105 (45%) as Group
C (no cancer cells within 1 mm of CRM). The median follow up of all patients was 1.5
years (range: 0.1 to 9.0 years) and the median survival of patients alive at the end of
the study period was 2.5 years (range: 0.2 to 9.0 years). The relationship between
clinicopathological features and CRM groups is shown in Table 6.
There was no relationship between any of the investigated clinicopathological features
comparing Group A with Group B (RCPath CRM vs CAP CRM). However, a significant
difference was found in depth of tumour invasion (ypT) and lymph node status (ypN)
when patients in Group A and Group B were combined and compared to those in
Group C. Group A and Group B patients had more frequently a higher ypT category
and higher ypN category compared to Group C patients (p<0.001).










N (%) N (%) N (%) p value
1
N (%) p value
2
Age (years)




Range 35-78 41-76 41-78 35-78
Number of lymph nodes retrieved




Range 3-82 9-64 3-82 3-77
Number of positive lymph nodes




Range 0-63 0-63 0-28 0-16
Gender




Female 55 (24) 6 (16) 25 (28) 24 (23)
ypT category
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T1b 15 (6) 0 (0) 1 (1) 14 (13)
T2 39 (17) 1 (3) 5 (6) 33 (31)
T3 162 (70) 33 (86) 79 (89) 50 (48)
T4 9 (4) 4 (11) 4 (4) 1 (1)
ypN category




N1 60 (26) 8 (21) 22 (25) 30 (29)
N2 49 (21) 8 (21) 23 (26) 18 (17)









45 (19) 8 (21) 22 (25) 15 (14)
Adenosq
5
4 (2) 0 (0) 2 (2) 2 (2)
Group A: Tumour cells at the circumferential margin; Group B: Tumour cells within 1 mm but not
at margin and Group C: No tumour cells within 1 mm of the margin.
1
Kruskal-Wallis test comparing Group A with Group B,
2







2.3.2 CRM status and cancer specific survival
There was no difference in cancer specific survival between Group A (at the margin)
and Group B (tumour within 1mm) patients (p= 0.945). However, patients from both
groups had significantly poorer survival compared to Group C patients (p= 0.008,
Figure 8). Univariate survival showed ypT and ypN were significantly related to patient
prognosis and were therefore included in multivariate analysis (Table 7). Multivariate
survival analysis showed that CRM status was not an independent prognostic factor
(Table 7). Only the lymph node status (ypN category) remained a significant prognostic
factor on multivariate analysis (p= 0.003). Although the survival difference between
Group B vs Group C was shown to be slightly more significant than between Group A
vs Group C, this is likely to be as a result of Group A only having 38 patients compared
to Group B (n=89).
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Figure 8: Kaplan Meier cancer specific survival plot stratifying patients by CRM group
Kaplan Meier plot comparing the cancer specific survival probability of Group A (tumour cells at
CRM), Group B (tumour cells within 1mm but not at CRM) and Group C (no tumour cells within
1mm). There is a significant difference in survival between patients in Group C compared to
both Group A and Group B (Log rank test p= 0.008; Hazard Ratio= 0.45; 95% confidence
intervals 0.27 to 0.75).
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Table 7: Relationship between clinicopathological variables, CRM status and cancer
specific survival
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age 1.01 0.97-1.03 0.744 - - -
Gender 1.47 0.78 to 2.75 0.232 - - -
Morphology 0.48 0.23 to 1.01 0.053 - - -
ypT 1.94 1.27 to 2.98 0.002 1.49 0.96 to 2.32 0.078
ypN 1.99 1.57 to 2.54 <0.001 1.53 1.45 to 2.05 0.004
CRM status
Group A vs. C 2.20 1.06 to 4.54 0.034 0.745 0.33 to 1.70 0.484
Group B vs. C 2.23 1.30 to 3.85 0.004 1.30 0.73 to 2.34 0.375
Number of lymph
nodes
0.99 0.97 to 1.01 0.205 - - -
Number of
positive nodes
1.10 1.07 to 1.12 <0.001 1.06 1.02 to 1.10 0.004
HR= Hazard Ratio, CI= confidence interval
In the subgroup of patients with adenocarcinoma (n=183), Kaplan Meier survival
analysis showed a significant difference in survival between patients in CRM groups
A+B compared to group C (p=0.01). There was no significant difference in survival
between patients in group A and group B (p=0.861, Figure 9a).
In the subgroup of patients with squamous cell carcinoma (n=45), Kaplan Meier
survival analysis showed no significant difference in survival between patients in CRM
groups A+B compared to group C (p= 0.354) and no significant difference in survival
between patients in group A and group B (p=0.643, Figure 9b).
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A B
Figure 9: Kaplan Meier survival plots for adenocarcinomas and squamous cell carcinomas stratified by CRM groups.
A. Kaplan Meier plot for patients with adenocarcinoma (n= 183). There is a significant difference in survival between patients in Group C compared to
both Group A and Group B (Log rank test p= 0.01; HR 0.61; 95% CI 0.43 to 0.87). There was no significant difference in cancer specific survival
between Group A and Group B (p= 0.861).
B. Kaplan Meier plot for patients with squamous cell carcinoma (n=45). There is no significant difference in survival between patients in Group C
compared to both Group A and Group B (Log rank test P= 0.354; Hazard Ratio= 0.617; 95% confidence intervals 0.22 to 1.74). There was no significant
difference in cancer specific survival between Group A and Group B (p=0.643)
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Subgroup analysis looking specifically at the patients with ypT3 only disease was done as
well as looking just at patients with no evidence of nodal disease (ypN0). Using only ypT3
patients (n=162) showed similar numbers of patients in group A (n=33) and B (n=79).
However in this subgroup of patients there were only 50 patients (31%) who were CRM –ve
so placed in group C. Although patients in group A and B had worse survival than patients in
Group C this was not shown to be statistically significant (p=0.219). There was also no
significant difference in survival between patients in groups A and B (p=0.894) (Figure 10).
Figure 10: Kaplan Meier cancer specific survival for the ypT3 patients by CRM group
Although patients in group A and B had visible evidence of poorer survival probability this was not
shown to be significantly different to the Group C patients when only ypT3 patients were included
(p=0.219)
The ypN0 patients were also looked at individually (n=70) there were 5 (7%) patients who
had tumour at the CRM margin (Group A) and 18 patients (26%) had tumour withing 1mm
but not at the margin (Group B). Log rank testing shows that there is no significant difference
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in survival between patients in group A and B than patients in Group C (p=0.701). There was
also no significant difference in survival between patients in groups A and B (p=0.593).
However in patients with evidence of nodal disease (ypN1-3) there was also no significant
difference in survival between patients in groups A and B compared to group C (p=0.049).
2.4 Discussion
Circumferential resection margin (CRM) status has been recognised as an important
prognostic factor for patients with rectal cancer (271-279). In rectal cancer, a 1 mm cut-off is
currently used to define a positive CRM (271). Initial studies in oesophageal cancer patients
treated by surgery alone adopted the 1 mm cut-off and showed that the presence of cancer
cells within 1 mm of the CRM was related to patient survival in univariate (207) and
multivariate analysis (206). A number of subsequent studies using the within 1mm definition
confirmed this finding in univariate analysis (201, 204, 208, 266) and multivariate analysis
(209-212). However, other studies were unable to show that CRM status is an independent
prognostic factor (213, 262, 265), or failed to identify CRM status as being significantly
related to prognosis at all (214, 264).
The ongoing controversy regarding the prognostic value of the CRM in oesophageal cancer
patients may be related to the fact that the investigated patient cohorts received different
treatment regimens. Eight published studies involved a cohort of surgery alone (201, 204,
206, 207, 210, 262, 264, 268), nine studies involved a mixture of patients treated with
neoadjuvant chemotherapy or surgery alone (211-213, 215, 216, 263, 265, 266), three
studies included patients treated with pre-operative chemoradiation (208, 214, 260). Prior to
our own study, one previous study had investigated a cohort of neoadjuvant chemotherapy
patients (209). Evidence shows that patients who have undergone neoadjuvant
chemotherapy have lower rates of R1 resections (84, 280). Furthermore, while most authors
have used the presence of cancer cells within 1 mm as the primary definition of a positive
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CRM (204, 206, 207, 212, 264), some have used the presence of cancer cells directly at the
margin to define a positive CRM (216, 268) which along with heterogeneous patient
treatment groups may explain the wide range of reported CRM positivity rates: median 42%,
range 9% to 71% (201, 204, 206-216, 260-264, 266-268).
The current study was the first to compare the prognostic value of the RCPath definition
(within 1mm) and the CAP definition (at the margin) of a positive CRM in a cohort of
oesophageal cancer patients treated with neoadjuvant chemotherapy followed by surgery. In
the current study, 54% of specimens were classified as CRM positive using the RCPath
definition of tumour cells within 1 mm of the CRM and 17% had a positive CRM using the
CAP definition.
In the current study, patients treated with neoadjuvant chemotherapy and no viable cancer
cells within 1 mm of the CRM had a significantly better survival than those where cancer
cells were present within 1 mm of the CRM. There was no difference in the survival
probability of patients with cancer cells at the margin compared to those with cancer within 1
mm of the CRM. Thus, the results do not support the recently advocated view that the CAP
CRM definition (i.e. cancer cells at the margin) is more accurate for prognostic stratification
of patients (216, 260, 268). The same results were obtained when the analyses were
restricted to patients with adenocarcinomas. Grouping patients by CRM status had no
significant relationship to survival in patients with squamous cell carcinomas which is most
likely to be due to the small overall number of patients in this subgroup (n=45). This part of
the study is in contrast to previous studies examining squamous cell carcinoma of the
oesophagus (208, 260). Studies including only patients with oesophageal adenocarcinoma
have contrasting results regarding the prognostic value of CRM, with some showing it is a
prognostic marker (209, 210) and other saying it does not have a prognostic value (214,
268). However, it is difficult to compare studies given the heterogeneity of the treatments
patients received and the different definitions of a CRM margin used.
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In the current patient cohort, the prognostic value of the CRM status was no longer apparent
in multivariate analysis where only lymph node status (ypN) proved to be an independent
prognostic factor. This finding is in contrast to a number of CRM studies which have shown
CRM to be an independent prognostic marker (206, 210-212, 263), including the only other
study in patients treated with pre-operative chemotherapy (209). However, the current study
cohort included more than double the number of patients and included squamous cell
carcinomas as well as adenocarcinomas, giving a very different cohort group than that used
in the previous neoadjuvant chemotherapy study (209). There were also differences in
variables included in the multivariate analysis as here only variables significant on univariate
analysis were included in the multivariate study. It’s difficult to compare this current study to
others which included a mixed patient treatments in the study cohort (212, 263) or the
studies which involved patients who had only undergone surgery alone (206, 210). Although
there is no widely accepted evidence to confirm neoadjuvant therapy reduces CRM rates, it
has been shown to reduce the number of overall R1 resections in OeC through downstaging
of the tumour itself (94, 281).
This work has some limitations. This was a retrospective analysis using data from two
different centres. However as the ypT category, ypN category, cancer mortality and survival
did not differ between the two centres, it was felt that the datasets from the two hospitals
could be combined (Table 4). The study had a relatively short follow-up period, and thus
analyses with longer follow up might show different results. Due to the retrospective nature
of the current study, neither time to recurrence or pattern of tumour recurrence or primary
tumour regression data were available, so we were unable to investigate the relationship
between CRM status and these variables.
In conclusion, this work demonstrated that oesophageal cancer patients treated by pre-
operative chemotherapy with cancer cells at the CRM or within 1 mm of the CRM of the
resected specimen have a significantly worse survival than patients with no cancer cells
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within 1 mm of the margin. This work therefore supports the use of the ‘cancer within 1 mm
of the CRM’ rule e.g. the RCPath definition (200), to define a positive CRM.
Furthermore, our results suggest that post-operative lymph node status is the most important
independent factor in determining prognosis in oesophageal cancer patients treated with
neoadjuvant chemotherapy, more important than the circumferential resection margin status.
However, there is currently still uncertainty whether a better outcome can be achieved with a
three field or a two field lymphadenectomy(282). It is possible that also the new TNM7
classification including more ypN categories (2 previously in TNM6 now 4 in TNM7) has had
an influence on better stratification of patient prognosis (147, 283).
Since the original publication of this work, a meta-analysis of all data published on CRM
status in OeC has been carried out. This analysis pooled 14 studies (including the work
from this study) and included 2433 patients who had undergone a potential curative
oesophagectomy for oesophageal cancer (203). It showed that CRM involvement was less
frequent in patients from neoadjuvant chemotherapy studies compared to surgery alone
studies using either the RCPath definition (40.1% vs. 34.3) or the CAP CRM definition
(22.2% vs. 11.2%). A significantly poorer survival was found in patients who had tumour
within 1mm compared to those with no microscopic evidence of tumour within 1mm
(p<0.001), in keeping with the findings in this study. Patients with tumour involvement at the
CRM (CAP definition) were shown to be a higher risk group with larger OR values in both 3
and 5 year survival. However as patients with tumour within 1mm but not at the margin
(Group B in this study) also had a significantly worse survival compared to patient with no
tumour involvement within 1mm, the meta-analysis in agreement with this study concluded
the RCPath definition for CRM involvement was more comprehensive (203).
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3. THE OE02 THESIS COHORT’S
CLINICOPATHOLOGICAL CHARACTERISTICS AND
SURVIVAL
3.1 Background- OE02 MRC trial
The MRC OE02 trial investigated the potential benefit of neoadjuvant 2 drug chemotherapy
in the management of OeC patients with resectable disease and it’s results changed practice
in the UK (99). Prior to the OE02 trial, the majority of UK patients with resectable disease
had a surgical resection and 3 year overall survival between 20-30% (284-286) and 5 year
survival being reported as ranging between 0.5-7% (287, 288).
The OE02 trial was an intention-to-treat trial which recruited 802 patients in the UK and the
Netherlands during 1992 to 1998. Patients were randomised to either the surgery alone or
neoadjuvant chemotherapy (two cycles of Cisplatin and 5-Fluorouracil) followed by surgery
treatment groups. Included patients had squamous cell carcinoma, adenocarcinoma and
undifferentiated tumours found anywhere along the oesophagus but below the cricoid.
Patients with distant metastases (including cervical lymph node involvement) were excluded.
402 patients were randomised to the surgery alone group (S), of which 386 went on to have
surgery, and 400 patients were allocated to the pre-operative chemotherapy group (CS) of
which 344 actually completed at least 1 or 2 cycles and subsequently underwent surgery
(99). The primary outcome measure used was patient survival from time of randomisation.
This was the largest ever trial carried out to compare these two treatment groups and 93% of
patients were followed for five years, with 83% of patients followed up for at least 10 years.
The chemotherapy cycles and consequent toxic side effects may have contributed to the
higher rate of deaths before surgery in the CS group compared to the S group (3% vs. 1%).
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Tumours resected in the CS group were significantly smaller (p=0.001) and with less lymph
node involvement than tumours from the S group.
The initial survival data published in 2002 showed a difference in the two groups median
overall survival rates with patients in the CS group surviving a median of 16.8 months
compared to patients in the S group whose median survival was 13.3 months. On statistical
analysis it was demonstrated that CS group had a significantly better overall survival
(p=0.04) and disease free survival (p=0.0014) than those who had underwent surgery alone
(99). Longer term survival figures published subsequently in 2009 confirmed the survival
benefit of neoadjuvant chemotherapy (94).
Although the primary outcome analysis from OE02 has been published, no data has been
published looking at possible prognostic markers for patients in both treatment arms. Using
material from resection specimens from this trial gives an opportunity to analyse potential
new prognostic markers from a unique trial that changed practice and thus will most likely be
the last trial where patients with oesophageal cancer are randomised to surgery alone.
Although the trial was obviously powered to show a clinical difference and thus may not have
enough power to demonstrate a biomarker difference, using material from patients from a
randomised control trial is clearly preferable to the use of local hospital material due to
inherent bias.
3.2 Methods
3.2.1 OE02 material local collection
OE02 trial material and pathology data were requested by Dr H Grabsch affiliated with Leeds
Institute of Cancer and Pathology (LICAP), University of Leeds. The material for translational
research was funded by a project grant from Cancer Research UK. H&E stained slides were
reviewed to confirm the histopathological data, fill in missing data and establish the tumour
regression grade by histopathologist Dr N West (NW) and Dr H.I Grabsch (HG). Tumour
regression grading was not recorded at the time of the initial OE02 trial. All tissue slides
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were scanned and stored on a networked server for viewing as well as analysis. Tissue
blocks where used to create tissue microarray slides for immunohistochemistry
investigations discussed later on.
3.2.2 Patients
Although 802 cases were included in the original OE02 trial, material from 508 resection
cases was retrieved by the LICAP.
3.2.3 Statistical analysis
Statistical analysis was performed using the computer program Statistical Package for the
Social Sciences (SPSS) 21.0 (Chicago, Illinois). Clinicopathological features between the
508 OE02 trial cases from which material was received and the cases not received from the
OE02 trial were compared. Follow up from randomisation to patient death or end of study
period was used for survival analysis and survival plots were constructed using the Kaplan-
Meier method (270) testing differences between groups by the log-rank test.
Mann-Whitney non-parametric testing was used to compare age, gender, histological
subtype, grade of differentiation, T category, N category, blood vessel invasion, lymphatic
vessel invasion and Mandard tumour regression grading. A Cox’s proportional hazard model
was used for univariate and multivariate analysis. Variables tested in univariate testing were
patient age, gender, histological subtype, grade of differentiation, T category, N category,
blood vessel invasion, lymphatic vessel invasion and Mandard tumour regression grading.
Only variables that were significant in univariate survival analysis were included in
multivariate analysis. A p value of less than 0.05 was considered to be significant.
3.3 Results
3.3.1 Cohort comparison
Table 8 shows a comparison of the 508 case cohort for which material was received by
LICAP and the not received OE02 cases (n=294). Patients treatment arm is determined by
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their actual treatment not by the treatment arm the patient was originally assigned to on
randomisation (therefore eight cases originally assigned to chemotherapy followed by
surgery group that actually only underwent surgery alone were reallocated). Original
histology was taken from initial biopsy results. T and N categories were taken from original
pathology reports if available. The statistical analyses showed that the clinicopathological
features of the received OE02 cases are similar to the cases not received (Table 8).
Table 8: Clinicopathological data for OE02 trial cases for which material was received and



















Male 603 75.2 382 75.2 221 75.2
0.993
Female 199 24.8 126 24.8 73 24.8
Treatment arm
Chemo+ surgery 391 48.8 257 50.6 134 45.6
0.064
Surgery alone 411 51.2 251 49.4 160 54.4
Original Histology
Adenocarcinoma 533 66.5 348 68.5 185 62.9
0.823
Squamous 247 30.8 153 30.1 94 32.0
Other 21 2.6 7 1.4 14 4.8
Unknown 1 0.1 0 0.0 1 0.3
T category (TNM6)
T0 27 3.4 20 3.9 7 2.4
0.638*
T1 53 6.6 40 7.9 13 4.4
T2 242 30.2 179 35.2 63 21.4
T3 334 41.6 254 50.0 80 27.2
T4 0 0.0 0 0.0 0 0.0
No resection 120 15.0 0 0.0 120 40.8
Unknown 26 3.2 15 2.4 11 3.7
N category (TNM6)
N0 261 32.5 205 40.4 56 19.0
0.194*
N1 389 48.5 287 56.5 102 34.7
No resection 120 15.0 0 0.0 120 40.8
Unknown 32 4.0 16 3.1 16 5.4
R1 Resection
Yes 197 24.6 143 28.1 54 18.4
0.293
No 423 52.7 322 63.4 101 34.3
No resection 120 15.0 0 0.0 120 40.8
Unknown 62 7.7 43 8.5 19 6.5
A p value between the variables is calculated using Mann-Whitney test. * These p values were
calculated with the unknown cases excluded as they led to inaccurate representation of the
distributions of N and T category.
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3.3.2 Survival comparison between the cohorts
There was a longer median survival in the thesis OE02 trial cohort compared to the rest of
the OE02 trial cases not received by LICAP (1.6 years vs. 0.8 years median length to last
follow up or death from randomisation). This is to be expected as all patients whose material
was received by Leeds must by definition have undergone surgery so no cases where the
patient did not have surgery or did not survive long enough for surgery were excluded from
my cohort (40.8% of cases not received did not have an attempted curative resection). This
also would have caused the greater proportion of overall deaths in the cases not received
(86.4%) compared to the thesis cohort (78.9%).
Kaplan Meier survival analysis shows similar distribution between the two treatment arms, in
both cancer specific and overall survival using the time from randomisation (Figure 11 and
Figure 12). On log rank (mantel-cox) assessment there is no significant difference in survival
between the two treatment groups of patients in regards both overall and cancer specific
survival in the not received OE02 cohort (n=294 p=0.626 and p=0.510 respectively). In the
same test in the thesis cohort of the 508 cases received there was also no statistically
significant difference between the two treatment arms (overall survival p=0.084 and cancer
specific p=0.149).
The two treatment group’s overall and cancer specific survival was also stratified according
to if they were received or not received by LICAP (Figure 13 and Figure 14). The Kaplan
Meier plots show patients whose trial material was received and hence included in this thesis
had a significantly better survival than those patients who material was not received or did
not undergo surgery for any resection material to be available
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Figure 11: Kaplan-Meier overall survival plots of the OE02 received and not received cohort of patients.
Kaplan Meier survival plots showing the overall survival in both cohorts, with the received LICAP thesis cohort (n=508) to the left (green/pink plots) and the non-received case
cohort (n=294) to the right (orange/blue plots). The log rank comparisons show no significant difference in overall survival between both treatment groups in either cohort
(received cohort p=0.084 and non-received p=0.626)
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Figure 12: Kaplan-Meier cancer specific survival plots of the OE02 received and not received cohort of patients
Kaplan Meier survival plots showing the cancer specific survival in both cohorts, with the received LICAP thesis cohort (n=508) to the left (green/pink plots) and the non-
received case cohort (n=294) to the right (orange/blue plots). The log rank comparisons show no significant difference in cancer specific survival between both treatment
groups in either cohort (received cohort p=0.149 and non-received p=0.510).
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Figure 13: Kaplan Meier overall and cancer specific survival plots for the surgery alone treatment group stratified by whether cases were received or not received
for inclusion in thesis
The two plots show the difference in a.) Overall survival; b.) Cancer specific survival for patients from the surgery alone treatment group divided by whether they were
received by LICAP (n=251) so included in the thesis and those cases not received (n=160). For both overall and cancer specific survival there is a significantly better survival
shown in cases from the received cohort (p<0.001).
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Figure 14: Kaplan Meier overall and cancer specific survival plots for the chemotherapy + surgery treatment group stratified by whether cases were received or
not received for inclusion in thesis
The two plots show the difference in a.) Overall survival; b.) Cancer specific survival for patients from the chemotherapy + surgery treatment group divided by whether they
were received by LICAP (n=257) so included in the thesis and those cases not received (n=134). For both overall and cancer specific survival there is a significantly better
survival shown in cases from the received cohort (p<0.001).
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3.3.3 Received cohort added pathological features
Once the case cohort was shown to be representative the material received was
reviewed along with the original pathology reports to firstly check for concordance with
the pathological data but also to establish new pathological data (work done by NW).
The full clinicopathological demographics of the thesis cohort after these reviews is
summarised in Table 9 and also sub-divided by treatment arm. Mann Whitney U test
analysis demonstrates a significant relationship between treatment group and pT
category, pN category, presence of lymphatic or blood vessel involvement and
Mandard grading (Table 9). There was no statistically difference in age, gender, tumour
differentiation or tumour histology between the two treatment arms.
~ 79 ~







Number (%) Number (%) Number (%) p value
Age
Median 62.71 62.4 63.6
0.242
Range 30.0-83.2 36.4-83.1 30.0-80.7
Gender
Male 382 (75.2) 200 (77.8) 182 (72.5)
0.166
Female 126 (24.8) 57 (22.2) 69 (27.5)
Histology
Adenocarcinoma 345 (67.3) 173 (67.3) 172 (68.5)
0.583
Squamous 133 (24.8) 68 (26.5) 65 (25.9)
Other 18 (3.6) 8 (3.1) 10 (4.0)
No residual tumour 11 (4.3) 8 (3.1) 3 (1.2)
Unknown 1 (0.2) 0 (0.0) 1 (0.4)
Differentiation (Predominant)
Poor 215 (42.3) 101 (39.3) 114 (45.4)
0.906
Moderate 222 (43.7) 117 (45.5) 105 (41.8)
Well 44 (8.7) 21 (8.2) 23 (9.2)
Unknown 16 (3.2) 10 (3.9) 6 (2.4)
No residual 11 (2.2) 8 (3.1) 3 (1.2)
T category (TNM6)
T0 (No residual) 11 (2.2) 8 (3.1) 3 (1.2)
0.031
T1 50 (9.8) 27 (10.5) 23 (9.2)
T2 57 (11.2) 33 (12.8) 24 (9.6)
T3 376 (74.0) 184 (71.6) 192 (76.5)
T4 12 (2.4) 4 (1.6) 8 (3.2)
Unknown 2 (0.4) 1 (0.4) 1 (0.4)
N category (TNM6)
N0 209 (41.1) 121 (47.1) 88 (35.1)
0.006
N1 299 (58.9) 136 (52.9) 163 (64.9)
R1 resection status
Yes 140 (27.6) 70 (27.2) 70 (27.9)
No 322 (63.4) 165 (64.2) 157 (62.5) 0.810
Unknown 46 (9.1) 22 (8.6) 24 (9.6)
Lymphatic invasion
Yes 161 (31.7) 61 (23.7) 100 (39.3)
0.001
No 307 (60.4) 177 (68.9) 130 (52.5)
Suspicious 37 (7.3) 19 (7.4) 18 (7.2)
Unknown 3 (0.6) 0 (0.0) 3 (1.2)
Blood vessel invasion
Yes 59 (11.6) 16 (6.3) 43 (17.1)
<0.001
No 412 (81.1) 227 (88.3) 185 (73.7)
Suspicious 35 (6.9) 14 (5.4) 21 (8.4)
Unknown 2 (0.4) 0 (0.0) 2 (0.8)
Mandard tumour regression grade**
TRG1 22 (4.3) 15 (5.8) 7 (2.8)
<0.001
TRG2 12 (2.4) 10 (3.9) 2 (0.8)
TRG 3 51 (10) 36 (14.0) 15 (6.0)
TRG 4 170 (33.5) 96 (37.4) 74 (29.5)
TRG 5 251 (49.4) 99 (38.5) 152 (60.6)
Unknown 2 (0.4) 1 (0.4) 1 (0.4)
*chemo+surg= chemotherapy followed by surgery treatment arm patients. **Mandard grading;
TRG 1= complete regression, TRG2= few residual tumour cells, TRG3= predominantly fibrosis,
TRG4= predominantly tumour cells and TRG5= no evidence regression.
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3.3.4 Survival analysis
Cox regression analysis was done to assess whether patient age, gender, histological
subtype, grade of tumour differentiation, T category, N category, lymphatic invasion or
blood vessel involvement were related to patient survival in the OE02 received cohort.
Time from randomisation to last follow up or death was used for survival analysis.
In the surgery alone patient group, age, R1 status, T and N category as well as
lymphatic vessel involvement were related to overall survival. There was no
relationship with prognosis when patients were stratified for gender, histological
subtype or blood vessel involvement (Table 10). Multivariate analysis showed that only
patient age, N category, R1 status and the presence of lymphatic involvement were
independent prognostic markers for overall survival.
Table 10: Cox regression overall survival analysis in the surgery alone group (n=251).
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.02 1.01 to 1.04 0.006 1.02 1.01 to 1.04 0.019
Gender 0.82 0.60 to 1.11 0.199 - - -
Histology 1.03 0.85 to 1.25 0.767 - - -
Differentiation 1.00 1.00 to 1.00 0.573 - - -
pT category 1.47 1.20 to 1.82 <0.001 1.24 0.97 to 1.58 0.070
pN category 2.20 1.62 to 3.00 <0.001 1.85 1.33 to 2.57 0.007
R1 status 0.46 0.34 to 0.63 <0.001 0,58 0.42 to 0.80 0.001
Lymphatic
involvement
1.41 1.15 to 1.72 0.001 1.32 1.06 to 1.64 0.013
Blood vessel
involvement
1.20 0.98 to 1.47 0.074 - - -
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In the chemotherapy followed by surgery treatment group, cox regression analysis for
overall survival showed prognostic value for patient age, ypT category, ypN category,
R1 status lymphatic involvement, blood vessel involvement and Mandard tumour
regression grading. However, on multivariate analysis only age, ypT category, ypN
category, R1 status and blood vessel involvement were identified as independent
prognostic markers (Table 11).
Table 11: Cox regression overall survival analysis in the chemotherapy and surgery
alone group.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.02 1.00 to 1.03 0.013 1.02 1.00 to 1.04 0.0012
Gender 0.85 0.60 to 1.20 0.346 - - -
Histology 0.92 0.77 to 1.09 0.315 - - -
Differentiation 1.00 1.00 to 1.00 0.663 - - -
ypT category 1.64 1.45 to 1.98 <0.001 1.43 1.16 to 1.77 0.001
ypN category 2.01 2.50 to 2.68 <0.001 1.63 1.20 to 2.22 0.002
R1 status 0.45 0.33 to 0.61 <0.001 0.62 0.44 to 0.86 0.004
Lymphatic
involvement
1.34 1.09 to 1.65 0.005 1.16 0.92 to 1.45 0.208
Blood vessel
involvement
1.59 1.24 to 2.03 <0.001 1.40 1.08 to 1.81 0.010
Mandard Grade 1.24 1.08 to 1.42 0.002 1.02 0.87 to 1.20 0.818
Cox regression analysis performed using cancer specific survival as the outcome
measure by treatment arm showed no relationship with age, gender, histological
subtype or grade of tumour differentiation in either treatment group. The ypT category,
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ypN category, R1 status, lymphatic invasion and blood vessel invasion showed
prognostic value in either treatment arm (Table 12 and Table 13). Mandard tumour
regression grade was only assessed in the chemotherapy followed by surgery group
and was found to be related to cancer specific survival. In patients from the surgery
alone group T category, N category, R1 status and lymphatic involvement were
identified as independent prognostic markers to cancer specific survival (Table 12).
Table 12: Cox regression analysis for cancer specific survival in the surgery alone group.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.01 1.00 to 1.03 0.125 - - -
Gender 0.73 0.51 to 1.04 0.084 - - -
Histology 1.02 0.81 to 1.28 0.869 - - -
Differentiation 1.00 1.00 to 1.00 0.702 - - -
pT category 1.85 1.40 to 2.43 <0.001 1.43 1.04 to 1.97 0.027
pN category 2.92 2.01 to 4.23 <0.001 2.15 1.44 to 3.22 <0.001
R1 status 0.40 0.29 to 0.57 <0.001 0.51 0.56 to 0.73 <0.001
Lymphatic
involvement
1.60 1.28 to 2.01 <0.001 1.47 1.14 to 1.88 0.003
Blood vessel
involvement
1.31 1.05 to 1.63 0.017 1.10 0.87 to 1.38 0.441
Table 13 shows Cox univariate and multivariate analysis for cancer specific survival in
the chemotherapy followed by surgery group. Multivariate analysis identified ypT
category, ypN category, R1 status and blood vessel involvement as independent
prognostic marker. Mandard tumour regression grading was not an independent
prognostic marker on multivariate analysis
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Table 13: Cox regression analysis for cancer specific survival in the chemotherapy and
surgery group.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.02 1.00 to 1.03 0.059 - - -
Gender 0.82 0.56 to 1.21 0.318 - - -
Histology 0.83 0.67 to 1.02 0.068 - - -
Differentiation 1.04 0.93 to 1.16 0.537 - - -
ypT category 2.00 1.56 to 2.57 <0.001 1.67 1.28 to 2.17 <0.001
ypN category 2.57 1.83 to 3.60 <0.001 1.92 1.35 to 2.72 <0.001
R1 status 0.38 0.30 to 0.54 <0.001 0.59 0.40 to 0.85 0.005
Lymphatic
involvement
1.37 1.09 to 1.73 0.008 1.18 0.91 to 1.52 0.223
Blood vessel
involvement
1.36 1.16 to 2.59 <0.001 1.50 1.14 to 1.98 0.004
Mandard Grade 1.33 1.13 to 1.55 <0.001 1.08 0.89 to 1.31 0.530
3.4 Discussion
The OE02 trial when its initial results were published in 2002 (99) and the subsequent
follow up results published in 2009 (94) changed practice in the UK to include
neoadjuvant chemotherapy in the gold standard treatment for locally advanced OeC. It
is unlikely there will ever by another trial which includes randomisation of patients to
surgery alone for OeC as the results identified a significant survival benefit in patients
who had neoadjuvant chemotherapy compared to those who underwent surgery alone
(9% benefit in survival) (99). This chapter has shown that the cohort created from
received cases at LICAP from the OE02 trial was comparable to the cohort of patients
not received. The two cohorts have as demonstrated in table 6 have an identical
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gender split (75.2% male: 24.8% female), similar median ages (62.7 in the received
cohort vs 62.9 in the not received cohort) and both cohorts involved predominance of
adenocarcinomas (68.5 in received and 62.9 in non-received cases). Non parametric
tests show no significant difference in any of the clinic-pathological variables in the
cases received and not received from the OE02 cohort. This is an important finding as
it suggests that the cohort used for this thesis work can be taken as representative of
the OE02 trial.
Although the primary outcome analysis from OE02 has been published this is the first
data looking at possible prognostic markers for patients in both treatment arms of this
trial. Patient age, gender, tumour histological type and grade of differentiation were not
shown to have any prognostic value in cancer specific survival for either treatment
group. From the received cases cox regression analysis has shown (y)pT, (y)pN
category and R1 resection status as independent prognostic markers in the OE02
cohort for cancer specific survival regardless of the treatment group. This finding is in
keeping with other recent studies which have examined for clinicopathological variables
associated with poor prognosis in resected OeC with (205, 289-291). An R1 resection
indicates microscopic evidence of tumour cells at the resection margin and as well as
in this cohort has been shown previously to be an independent prognostic marker to
survival (204, 205) and risk factor to early cancer related mortality (289, 290). The
Tumour Node Metastasis (TNM) classification is currently the only established
prognosis prediction tool and is used for most malignant tumours worldwide but has
been criticised recently (1.7 Tumour node metastasis classification for oesophageal
cancer). The accuracy and validity of the TNM classification for patients treated with
neoadjuvant chemo(radio)therapy has been questioned as the classification was based
on evidence from surgery alone treated patients (142-148). The finding in this study
that both T and N category from the TNM (6th edition classification) were independent
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prognostic markers for cancer specific survival for patient not just from the surgery
alone treatment group but also from the neoadjuvant chemotherapy followed by
surgery treatment group, would suggests these concerns are unnecessary. This study
results would support the findings of other recent studies which have all supported the
prognostic importance of T and N category for OeC in both the 6th and 7th editions of
the TNM classification (148, 292, 293).
Blood vessel and lymphatic involvement are not routinely assessed and were not part
of the pathology minimum dataset at the time of the OE02 trial so this data was
collected locally on receipt of resection specimens to LICAP. Using this local review
data blood vessel invasion is shown to be an independent prognostic marker in the
chemotherapy followed by surgery treatment group, while lymphatic invasion has been
shown to be an independent prognostic marker, only in the surgery alone treatment
group (for both overall and cancer specific survival). Both show prognostic value on
univariate analysis in both treatment groups. It’s often difficult to differentiate between
lymphatic and vascular invasion and hence studies often report both together as
“lymph-vascular” invasion (204, 294). The prognostic value of vascular invasion (blood
vessel involvement) has been reported in prostate (295), breast (296) and colorectal
cancers (297). In OeC there has been extensive literature showing the prognostic value
of vascular involvement (175, 204, 294, 298-302) with evidence of blood vessel
invasion at the tumour being associated with a poor prognosis. In this study we have
shown an influence of the presence of vascular invasion on both overall and cancer
survival but only in the chemotherapy followed by surgery treatment group is it was an
independent prognostic marker. This has been shown in previous studies (204, 209,
303, 304), however, other studies have only shown blood vessel invasion to have
prognostic value without being an independent prognostic marker (175, 299-302).
Oesophageal cancer metastasis is more common via haematological routes than
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locoregional recurrence (304, 305) so the presence of blood vessel involvement is
likely to increase this possibility of this route of recurrence. However no recurrence
data was available to assess for any patterns associated with those patients with
evidence of blood vessel involvement. Blood vessel invasion clearly has prognostic
importance but why it is only an independent prognostic marker in the neoadjuvant
chemotherapy treatment group is unclear.
Lymphatic invasion is thought to be directly linked to the lymph node metastasis due to
the creation of small lymphatic capillaries at the tumour microenvironment (306-308). In
oesophageal cancer Osugi et al showed that lymphatic vessel invasion correlated with
lymph node metastasis (p<0.001) in a cohort of squamous cell cancer patients treated
with surgery alone (298). This they hypotheses was the reason that vascular or
lymphatic invasion lead to poor outcomes by being a marker for distal micro-
metastasis. Langer et al showed that lymphatic invasion was also significantly
associated with survival (p<0.001) but also that the absence of lymphatic invasion
correlated with tumour regression (p<0.001) (175). The findings in this cohort support
these previous findings that the presence of lymphatic invasion in the surgery alone
treatment group is an independent prognostic marker for both overall and cancer
specific survival (p=0.013 and 0.003 respectively).
The survival benefit between the two treatment groups identified in the OE02 trial
publications is not shown to be significant in the cohort of cases received by LICAP.
The reasons for this are likely to be related to the 120 cases where no resection
material was available in the non-received cohort (40.8%). In the initial OE02 published
data, 4.5% of patients did not proceed to have any surgery in the trial because they
died before surgery or where found to have unresectable tumour in the work up to
surgery (i.e. disease progression) (99). There were also cases were the resection was
not possible intra-operatively so were unlikely to have resection specimens (10%).
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These cases with no resection material were likely to represent tumours with
aggressive features and made up 14% of the surgery alone patients included in the
original OE02 analysis. This may help to account for the improved survival seen in both
treatment groups for the patients received by LICAP (Figure 13 and Figure 14).
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4. QUANTITATIVE MEASUREMENT OF TUMOUR
REGRESSION BY MEASURING TUMOUR CELL
DENSITY
4.1 Background
Following the results from OE02 trial the “gold” standard treatment for locally advanced
resectable OeC in the UK involves neoadjuvant cytotoxic combination chemotherapy
followed by potential curative surgery (99). In the UK, the decision how a particular
patient with oesophageal cancer is treated is made within a multidisciplinary team
meeting considering results from endoscopy, pathology, imaging and patient’s
individual performance status, age etc. A study in 1999 identified that patients with
oesophageal cancer who respond to chemotherapy have a better survival than patients
who underwent chemotherapy and did not respond (309). This finding was supported
by other studies which all demonstrated that patients with oesophageal cancer who
undergo neoadjuvant therapy, and show a complete pathological response have
significantly better survival rates as high as 60% survival at 5 years (125, 185, 310,
311). Most importantly, patients who do not respond to neoadjuvant chemotherapy can
have a worse outcome than if they had proceeded straight to surgery especially if there
is tumour progression (112). As reported in the OE02 trial, chemotherapy can cause a
variety of chemotoxic side effects such as vomiting, hair loss, severe fatigue, bronchial
pneumonia and chemotherapy itself may lead to death. There was a 3% rate of deaths
before surgery in the chemotherapy + surgery treatment arm (94). Neoadjuvant
chemotherapy is time consuming as it usually requires at least 2 cycles and cycles are
given over 2-4 week with breaks in between, all of which delay the time to potential
curative surgery. Additionally, there might be significant distress and anxiety for the
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patients during the chemotherapy which must be managed carefully throughout the
process. At this moment in time, there is no tool available in clinical routine to identify
the patients who will or will not benefit from neoadjuvant chemotherapy. Currently, the
reaction of the tumour to chemotherapy (progression vs stable disease vs. regression)
during treatment is assessed by radiological imaging. The World Health Organisation
(WHO) introduced guidelines to ensure standardised reporting of the degree of
radiological response to chemo(radio)therapy in 1981 (312). Since 2000, a simplified
version of these guidelines known as the Response Evaluation Criteria in Solid
Tumours (RECIST) has been used worldwide (313). The guidelines were updated and
a new version (RECIST V1.1) was published in 2009 (314). RECIST uses an one-
dimensional measurement (longest tumour diameter) instead of bi-dimensional
measurements as previously recommended in the WHO guidelines (312) in an attempt
to standardise the technique of assessing tumour response after neoadjuvant
chemo(radio)therapy (314, 315). In patients with OeC, CT imaging is currently used to
assess tumour regression using the RECIST criteria despite the multi-modality imaging
used for the initial diagnosis and staging (see 1.8 Radiological prognostic markers in ).
At baseline i.e. before any neoadjuvant treatment commences, tumours are defined as
either measurable (e.g. longest tumour diameter >10mm) or non-measurable (e.g.
longest tumour diameter <10mm), while the criteria used for the assessment of lymph
nodes uses the cut-off of 15mm to determine nodes suitable for assessment (314).
Following neoadjuvant treatment repeat CT imaging is performed using the same one-
dimensional measurements, enabling the primary tumour and lymph nodes to be
classified as;
 Complete response (CR): Disappearance of all measurable primary tumour and
all lymph nodes (previously >15mm) now reduced on their longest diameter
<10mm
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 Partial response (PR): 30% or more decrease in the diameter of the primary
tumour compared to the pre-treatment diameters
 Progressive disease (PD): 20% or more increase in the diameters of target
lesions using the smallest diameters measured
 Stable disease (SD): Neither sufficient shrinkage to qualify for partial response
nor sufficient increase to qualify for progressive disease
Although the assessment of the longest tumour diameter has been shown to be an
acceptable measure of response to chemotherapy (316), there is little evidence to
show that response evaluation according to RECIST criteria can predict OeC patient’s
prognosis where the tumour margins can often be difficult to define after neoadjuvant
chemotherapy (317). Another criticism of the use of the RECIST for evaluation of
response to chemotherapy in OeC patients is related to the fact that at least some of
the OeC might regress unevenly (190). This phenomenon has been referred to as post
treatment ‘centrifuge appearance’ and makes reproducible identification as well as
measurement of the longest diameter of the tumour difficult on CT images (121). This
uneven regression changes may lead to an inaccurate radiological assessment of
response and pathological stage (318-322).
Endoscopic ultrasound (EUS) is currently not accepted as a measurement tool for
tumour response. The use of positron emission tomography (PET) in conjunction with
CT for evaluation of tumour response is currently been considered (314). Several
studies have shown the potential benefit of using PET imaging for assessment of
tumour response during neoadjuvant therapy (316-321). In this context, the MUNCION
(Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy In
oesOphageal and oesophagogastric adeNocarcinoma) trial investigated prospectively
the use of PET imaging to guide duration of neoadjuvant chemotherapy given to OeC
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patients (320). Within that trial, baseline PET imaging was done before and 2 weeks
after patients had commenced chemotherapy. Patients with evidence of response at 2
weeks continued to complete a 12 week course of chemotherapy, while ‘non-
responders’ proceeded straight to surgery. After resection, histopathological response
was assessed using Becker’s tumour regression grading (178), which classified 8
(16%) patients from the PET identified ‘responders’ group as complete pathological
response and 29 (58%) patients as major pathological response. None of the patients
in the PET ‘non-responder’ group showed evidence of a major pathological response
(320). Whilst these results were promising, validation of the results within a randomised
trial is still awaited.
In order to individualise patient treatment, there is a clinical need for a reliable tumour
regression grading system that could be used while the patient is still receiving
treatment as well as after treatment. Such a tool could assist to potentially stop
ineffective treatment therefore allow switching to other treatment/treatment modalities
or indicate continuation of the current treatment.
The use of T-category (depth of invasion into oesophageal wall) of the tumour has
been advocated to assess response/’downstaging’ following neoadjuvant treatment
(280). In this context, the initial radiologically determined T category (cT) using CT or
EUS was compared to the pathologically determined pT category of the resection
specimen (280). However, there is evidence that radiological T staging is not very
accurate (322) and there is growing evidence that the T-category after neoadjuvant
chemotherapy may not reflect pathological response (121, 147, 148, 180, 185). This is
mostly related to the fact that the pT category is determined based on the deepest
location of the primary tumour in the wall disregarding the amount of tumour present in
the respective location or whether the tumour is continuously extending from the
luminal surface to the deepest point or not. Thus, for example, if there are only 10
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viable tumour cells left after neoadjuvant chemotherapy and these are located in the
peri-oesophageal fat, the tumour is staged as ypT3 despite a major histopathological
regression. Schneider et al demonstrated that from 19 OeC patients with a major
pathological response after neoadjuvant chemotherapy only one tumour was actually
“downstaged” with respect to its radiological T category (i.e. lower ypT category than T
category predicted from radiological assessment). Guo et al reported similar findings
and concluded that tumour regression grading (TRG) would better reflect the changes
in the tumour due to neoadjuvant chemotherapy than the T category (121).
However, as outlined in section 1.9 Tumour regression systems used to assess
oesophageal cancer ), various different tumour regression grading systems exist
worldwide with no consensus on which one should be used (177, 178, 323). Most TRG
systems are criticised for being subjective with high levels of both, inter and intra-
observer variability (174, 192, 196, 197).
Current TRG systems such as the Mandard (177), Becker (178) and Chirieac (194)
classifications as well as the TNM classification (324) rely on the assessment of the
resected specimen. A new system which potentially could monitor tumour response
accurately while the patient is receiving chemotherapy could enable changes in patient
management during chemotherapy treatment. This would ultimately lead to a
personalised treatment approach with better patient outcomes and less unnecessary
side effects. The use of endoscopic serial biopsies during neoadjuvant chemotherapy
could be a possible option to evaluate TRG while the patient is still on treatment.
Only 1 previous study to date has attempted to quantify the amount of residual tumour
in OeC. This study involved squamous cell carcinoma patients (n=183) who had
undergone neoadjuvant chemoradiotherapy followed by curative surgery (180). They
calculated tumour percentage from measurements of the residual tumour area and
dividing this by the total area of the estimated previous tumour site. Patients were then
~ 93 ~
stratified into one of four pre-defined groups depending on their tumour percentage.
The results showed that the percentage of viable tumour was an independent
prognostic marker (p=0.005 in multivariate analysis) with patients with low residual
tumour percentage having significantly better prognosis. Although well designed this
study included a selected type of histological type of OeC and can be criticised for the
subjective nature of determining the residual tumour cell percentage. The study also
including no “control” group of patients who had not undergone any neoadjuvant
treatment to compare tumour percentages so cannot determine whether some of the
changes thought to be a result of scarring following neoadjuvant chemoradiotherapy
may have occurred spontaneously. Two previous studies have looked at the stroma to
tumour ratios in OeC, but both excluded patients who had undergone neoadjuvant
chemo(radio)therapy (325, 326). Both studies used clinical estimates of the residual
tumour through visualisation by 2 pathologists before assigning cases to either the high
stroma group (>50% stroma) and low stroma group (<50% stroma). Both techniques do
not improve on the criticism of existing regression grading systems in that they both
involve a degree of subjective assessment. They both also placed patients into “ready-
made” prognostic groups based on previously defined regression groups by Becker
and Mandard (177, 178). Neither technique was able to produce quantified measures
of tumour to stroma ratios allowing a continuous variable to be created and assessed
for prognostic value.
Morphometric pathological measurements of different cell components was initially
described by Chalkley in the 1940s (327, 328) and developed further by Weibel et al
(329, 330). Morphometric measurements can provide a quantitative measurement of
tumour cell density replacing subjective estimates. Quantitative measurement of
tumour cell density (TCD) using morphometric point counting techniques have been
used successfully in the past and most recently in colorectal and prostate cancer
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studies taking advantage of digitised slides (198, 199, 331). Point counting is a
morphometric technique that allows histological components to be measured
objectively either using a microscope or nowadays using virtual (digitalised) slides
(198, 199). This type of measurement will provide continuous data which can be used
to identify the optimal cut off for prognosis prediction as opposed to predefined
estimates such as used by Tong et al (cohort split into thirds) and Mesker et al (cohort
split at 50%) (180, 325). Nowadays morphometric measurements are performed using
digital slides (“virtual slides”). Virtual slides from a networked server have the
advantage that they can easily be viewed by observers from any internet connected
computer, facilitating collaborations and counterscoring by several observers. Also
virtual slides can be annotated without affecting the original slide as annotations are
saved separately.
The aim of this study was to quantify the tumour cell density (TCD) at the luminal
surface of the tumour using a morphometric methodology in Haematoxylin/Eosin (H&E)
stained slides from the resections specimens of patients recruited into the OE02 trial.
Results will be compared between patients who were treated with neoadjuvant
chemotherapy followed by surgery and those who were treated by surgery alone. The
relationship with clinicopathological data including tumour regression grading according
to Mandard and patient survival will be assessed.
4.2 Methods
4.2.1 Patients and material
H&E stained slides from 508 resection specimens from patients recruited into the OE02
trial (3.2.1 OE02 material local collection) were used for this study. Resection
specimens (n=39) without primary tumour at the luminal surface or with no evidence of
tumour in any of the material received were excluded from the measurements and
further analysis. Patients with complete pathological response (n=11) in the resection
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specimen according to the original pathology report were confirmed on local pathology
review before being classified as TCD=0 and included in the analyses. All H&E stained
slides from all resection specimens were scanned at x40 magnification using the
Aperio XT slide scanner (Leica Biosystems, Nussloch, Germany) to create digital slides
from each OE02 case. Images were stored on a secure server with internet access. No
demographic or clinicopathological data was stored along with these files.
4.2.2 Establishing the shape of the measurement area.
A pilot study was performed to test the feasibility of measuring TCD at the luminal
surface of the tumour using either a squared or circle shaped areas. Regardless of the
shape the area the size was set as 9 mm2 following previous work in the department
(198). Both the size of the area and the luminal surface positioning were chosen to
simulate endoscopic biopsies.
This feasibility study was performed in 20 randomly selected cases. The number of
measurement points was 300 +/- 30 points for both approaches as previously
established (198). Scoring categories and calculation of TCD are described below.
4.2.3 Tumour cell density (TCD) measurement
Digital slides were viewed using the Aperio ImageScope® (Leica Biosystems,
Nussloch, Germany) programme blinded to any clinicopathological findings including
treatment arm. The following criteria were used to ensure consistent slide and area
selection:
STEP1: Selection of slide for scoring:
I. All available slides of an individual case were reviewed to identify all slides with
viable primary tumour.
II. Slides which contained viable tumour without tumour at the luminal surface
were excluded.
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III. From the slides with viable tumour at the luminal surface, the slide with the
deepest infiltration of tumour in the wall was chosen for TCD measurement.
IV. In the event that more than one slide had tumour at the luminal surface with the
same depth of invasion, the slide with the highest estimated density of tumour
was selected.
STEP 2: Selection of the ‘measurement area’ within the slide:
I. the area of tumour which appears to have the highest viable tumour cell density
at the luminal surface on ‘eyeballing’ was selected
II. A 9mm2 area was created using the pen-tool of the software and superimposed
onto the virtual slide. The observer positioned the area in a way that the
measurement area had maximal contact with the luminal surface and contained
tumour throughout.
Once this superimposed area was determined, the RandomSpot® (University of Leeds,
Leeds, UK) software (199) was used to generate measurement points throughout the
9mm2 area. The software will create the first measurement point at a random position
and then all further points equidistant to each other (199). This process is known as
‘systematic random sampling’ and has been shown to be an effective and reproducible
technique (199, 329, 332). For this study, we used 300 points per area +/- 10%. The
number of measurement points needed to provide an accurate estimate of the volume
fractions depends on the number of events (333) e.g. the lower the event, the more
measurement points are needed. Studies in the past including our own (198) have
shown that for the accurate measurement of the proportions of tumour and stroma, 300
+/- 10% measurement points per 9mm2 area provide a satisfactory result.
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Every individual measurement point was viewed by the observer at 20x to 40x
magnification and a category was assigned to each measurement point, adapted from
work done previously in the department (198):
0= Non informative (normal tissue or empty area or inconclusive)
1= Tumour
2= Stroma including fibrosis
3= Necrosis
4= Blood or lymphatic vessel
5= Inflammatory cells irrespective of type
6= Tumour lumen (regardless of content)
7= Mucin (not in tumour lumen)
8= Muscle
In situations where the measurement point was found on an area of empty space such
as when there is a tear in the slide material the point was allocated depending on the
surrounding cells. Therefore if the point is found in an area of tumour with tour cells
either side then the area with the tear would be taken as also a tumour point. In the
event where it was different tissue/cells around the indeterminate scoring point, so that
an assumption couldn’t be made, this point would be scored “0” for non informative.
The category of each point was entered individually into the annotation box of the
Aperio Imagescope software and all values per case were saved as XML file and excel
spreadsheet to enable statistical analyses. The categories ‘tumour (category 1)’ and
‘tumour lumen (category 6)’ were combined as ‘tumour’ for analyses and compared to
‘stroma’ for which stroma/fibrosis (category 2), necrosis (category 3), vessels (category
4), inflammatory cells (category 5), Mucin (category 7) and muscle (category 8) were
combined. Non informative points were not included in the analyses.
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The tumour cell density was calculated and expressed as a percentage of the total
number of informative points. The total informative points were taken as the sum of all
points labelled minus the points labelled “0” for a non-informative.
The observer (TS) was trained in categorisation of the points by an experienced
gastrointestinal pathologist (HG) and performed all scoring blinded to any
clinicopathological data. The observer was also not aware of the treatment modality.
4.3 Intra- and inter-observer studies
As this study involved potentially subjective slide selection rule and rules for position of
the measurement area, intra-observer variability of performing these tasks was
evaluated. Furthermore, inter-observer agreement was assessed for the categorisation
of the measurement points.
4.3.1 Slide Selection
To assess intra-observer variability of the initial slide selection, 40 cases were re-
reviewed and the most suitable slide for analysis was re-selected by observer 1 (TS).
This was done after the observer had initially reviewed 200 cases and repeated again
after the observer had completed reviewing all cases (n=508).
4.3.2 Measurement area selection
To assess intra-observer variability of the placement of the measurement area, 40
cases were reassessed and a measurement area created by observer 1 (TS). This test
was again done after observer 1 had reviewed and point counted 200 cases. The
intra-observer agreement was considered satisfactory if the area was positioned with a
>50% overlap of the originally measurement area.
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4.3.3 Tumour cell density measurement
1. To assess for intra-observer variation in assigning the different categories to the
measurement points, observer 1 (TS) re-assigned categories in 20 randomly selected
cases. To investigate whether there is a learning curve of the categorisation capability
of the observer, 20 cases were re-assigned after the first 200 cases had been scored
and then re-assigned for a third time at the end of the study. Kappa agreement was
determined with a kappa greater than 0.75 defined as excellent, 0.45-0.74 defined as
good and <0.40 defined as barely reproducible.
2. To assess for inter-observer variation a trained histopathologist (Gordon Hutchins,
GH) re-categorised 50 randomly selected cases using the original measurement grid
blinded to the categories of the first observer. The same categorisation rules were
applied. TCD values of these 50 cases were compared between observer 1 (TS) and
observer 2 (GH).
The agreement per individual measurement point and end result e.g. TCD were
compared. Bland Altman analysis (334) and Kappa statistics were performed.
4.4. Statistical analyses
Statistical analysis was performed using the computer program Statistical Package for
the Social Sciences (SPSS) 21.0 (Chicago, Illinois).Differences between intra-observer
TCD scores will be assessed and a mean of these differences produced. Intra- and
inter-observer agreement is tested using a kappa agreement measure. A kappa value
equal or greater than 0.70 was deemed satisfactory. Bland Altman plots were
constructed to compare TCD scoring between the 2 observers.
The relationship between clinicopathological features (age, gender, histology type,
grade of differentiation, T category, N category, blood vessel invasion, lymphatic vessel
invasion and Mandard tumour regression grading) and TCD were analysed for the
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whole group and then by individual treatment groups using Kruskal-Wallis or Mann-
Whitney test.
In order to identify the optimal TCD cut off for Kaplan Meier survival plots and see
whether there is a linear relationship between TCD and survival, survival plots from 5,
4, 3 and 2 equally sized groups were created. Kaplan Meier survival plots were visually
evaluated to decide which groups might best be combined and establish the final cut
off point.
Survival data was calculated from time of randomisation to last follow up or death using
the Kaplan-Meier method (270) and differences between groups were tested by the
log-rank test. All survival analyses were done separately by treatment arm.
For cox regression univariate survival analysis the relationship between survival and
age, gender, histology type, tumour differentiation, pT category (TNM6), pN category
(TNM6), evidence of lymphatic invasion, blood vessel invasion, Mandard grading and
TCD (continuous variable) was assessed. For multivariate analysis, only variables with
significant p values in univariate analysis were included in the model. A p-value of less
than 0.05 was considered to be significant.
4.5 Results
4.5.1 Pilot work – shape of the measurement area
This technique was designed to use a standard area for TCD calculations, taken from
the luminal surface hence give results that maybe comparable to TCD calculations
from biopsy tissue. In 9 (60%) cases of this pilot study, the use of a square shaped
area would only allow a corner of the measurement area to be kept in contact with the
luminal surface (see Figure 15). This was at least partly related to the fact that the
Aperio ImageScope® software (Leica Biosystems, Nussloch, Germany) did not allow
the measurement area to be rotated.
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The H&E slide shows an area of oesophageal adenocarcinoma at the luminal surface outlined
in blue. A square area (green box) for potential TCD measurement was placed in the tumour
region, but only the bottom right corner of this area is actually in contact with the luminal surface
(orange line). Green scoring points can be seen equidistantly distributed through the area.
A circular 9mm2 measurement area was tried as an alternative to the square shaped
area in the same 15 cases. In all cases, the contact of the circular area with the luminal
surface was far greater than using the square shaped area (see Figure 16). After this
initial pilot work, a decision was taken, that cases will be measured with a 9mm2
circular area placed at the luminal surface.
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The H&E slide shows an area of oesophageal adenocarcinoma at the luminal surface outlined
in blue. A circle area (blue outline) for potential TCD measurement was placed in the tumour
region with a good large area of contact with the luminal surface. Green scoring points can be
seen equidistantly distributed through the area.
4.5.2 Intra-observer variation of slides selection and measurement
area placement
4.5.2.1 Slide selection
Intra-observer variation of slide selection for measurement was done in 20 cases at two
different time points: (1) after the first 200 cases and (2) at the end of the whole
experiment (508 cases). At time point (1) in 15 of the 20 cases (75%), the same slide
was selected. At time point (2), a further 20 cases were re-assessed and this time in 19
(95%) cases the same slide was selected. This data suggests that there was a learning
curve of the observer. After discussion with the supervisor, it was decided that this
represents an acceptable level of agreement.
4.5.2.2 Measurement area placement
Using the same 40 cases assessed for slide selection intra-observer variability but
excluding the ones where there was an initial disagreement in slide selection (n=6), the
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circular measurement area was re-selected using the same rules as for the initial
placement (see 4.2.3 Tumour cell density (TCD) measurement). The placement of the
‘original’ measurement area and the ‘reselected’ measurement area were reviewed.
The reselection was classified “acceptable” if the measurement area was placed in the
exact same position or within ‘close proximity’ (at least >50% overlap between the two
positons of the measurement areas).
In 29 cases (85%) the measurement area was re-positioned in an acceptable position
of which in 20 cases (59%) the scoring area was in the identical position as the original
position. The 5 cases that did not achieve good intra-observer agreement are
summarised in Table 14. In 2 cases, there was some overlap in the position of the
measurement areas, but the overlap was <50%. In 3 cases, there was no overlap of
the circles at all and in all three cases, the TCD increased between 33% and 58%
compared to the original circle.
Table 14: Tumour point frequencies and TCD % differences in the 5 cases with
disagreement of scoring position.
Cases 1 and 2 had the measurement areas placed in close proximity but overlap was < 50%.
Cases 3, 4 and 5 the measurement areas did not overlap at all.
4.5.3 Intra-observer variation of categorisation of measurement
points
20 cases were randomly selected and re-categorised blinded to the original or previous
categorisation. Results are shown in Table 15. The average difference in TCD















Case 1 138 (48) 105 (37) -9%
Case 2 116 (40) 92 (32) -8%
Case 3 128 (46) 228 (79) +33%
Case 4 50 (17) 216 (75) +58%
Case 5 108 (38) 208 (72) +34%
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200 cases had been scored) was 8.2%; between the 1st rescore and the 2nd rescore
this average difference had reduced to 4.8%. The average difference between the
original score and the 2nd rescore was higher at 13.5%. This reduction in TCD
difference in later scoring suggests an improvement in scoring through the process with
more consistent scoring.
































UGI0006 51.2 41.8 45.6 0.78 0.79 0.79
UGI0041 74.7 71.9 82.3 0.44 0.61 0.55
.UGI0062 30.2 29.2 31.3 0.94 0.90 0.87
UGI0084 57.0 59.5 60.5 0.80 0.86 0.79
UGI0094 73.3 71.5 75.0 0.86 0.84 0.87
UGI0112 21.5 31.0 51.7 0.58 0.47 0.32
UGI0728 38.3 44.9 43.2 0.76 0.85 0.79
UGI0737 40.4 46.0 43.2 0.75 0.71 0.75
UGI0747 30.3 28.9 27.5 0.86 0.85 0.81
UGI0773 54.7 56.4 56.8 0.84 0.84 0.78
UGI0796 56.9 58.3 60.1 0.82 0.87 0.85
UGI0911 55.7 49.3 59.4 0.83 0.78 0.80
UGI0958 43.6 44.6 43.6 0.81 0.81 0.79
UGI0973 75.6 74.6 80.1 0.92 0.83 0.86
UGI1012 27.5 51.6 53.3 0.49 0.67 0.47
UGI1023 30.0 67.6 75.6 0.28 0.67 0.20
UGI1037 41.1 44.3 46.3 0.83 0.89 0.80
UGI1060 19.9 64.1 82.9 0.30 0.47 0.13
UGI1081 17.4 55.1 61.3 0.27 0.54 0.22
TCD= tumour cell density.
The median kappa agreement between the original TCD scoring and the 1st rescore
was 0.8 with a range (0.27 to 0.90 agreement). The median agreement between the 1st
rescore and the 2nd rescore shows even closer agreement with the median kappa
agreement of 0.81 and a range of agreement between 0.47 and 0.90. The median
agreement even between the original and the second rescore remained good 0.79
(range 0.13 to 0.87) despite the improved scoring correlation later in the process.
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4.5.4 Inter-observer variability
4.5.4.1 Point by point agreement analysis
For the inter-observer variability assessment GH reviewed 50 randomly selected cases
and 48 of them were found suitable for rescoring. Two cases were deemed inadequate
to be scored accurately and were excluded from all analyses. In total categorisation of
13877 measurement points were compared between TS and GH. 3 errors due to
incorrect typing of the category were found and excluded from assessment. The
comparisons of the non-informative points, tumour and stroma point agreement
between the two observers is summarised in Table 16.
Table 16: Inter-observer agreement in assigning categories.
GH frequency TS frequency % agreement
0= ‘Non informative’ 326 165 50.6
1+6= ‘Tumour’ 6271 5563 88.7
2+3+4+5+7+8= ‘Stroma’ 7280 5464 75.0
This table also shows that GH identified a total of 6271 tumour points (label 1 or 6) and
in 88.7% TS agreed. Kappa statistic estimate was performed to assess inter-observer
agreement for individual points per case; Kappa agreement = 0.73 (95% CI = 0.728 –
0.737, p<0.0001).
4.5.4.2 Case by case TCD agreement
The TCD comparison between the two observers (TS and GH) showed the median
TCD value in TS scoring was 53.0% TCD (range 16.4 to 98.8%) compared to GH
whose median was lower at 46.0% (range 12.6% to 91.4%). The mean difference in
TCD each case was 6.6% and standard deviation of +/- 7.61 (Appendix 3: Inter-
observer TCD score comparison). Bland Altman plot shows good agreement with most
(81.2%) score differences within 1 Standard deviation of the mean (Figure 17).
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Figure 17: Bland Altman plot comparing the TCD scoring of two observers.
The bland Altman plot demonstrates the distribution of the 48 cases scored by two observers
(TS and GH). Mean is at 6.6% with standard deviation lines either side by 7.61%.
4.6 Patient cohort
Slides or blocks from a total of 508 resection specimens from the OE02 trial were
retrieved retrospectively (see Chapter 3. The OE02 thesis cohort’s clinicopathological
characteristics and survival). After applying the inclusion/exclusion criteria (see 4.2.1
Patients and material) slides from 469 patients were included in the final TCD analysis
(Figure 18). Eleven cases with complete pathological response were classified as 0%
TCD.
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Figure 18: TCD final cohort creation flow chart.
CONSORT diagram illustrating the cases excluded from TCD analysis and the stepwise
creation of the final cohort.
In the final cohort 358 (75.8%) patients were male and 229 (48.8%) were treated with
neoadjuvant chemotherapy followed by resection (Table 17). The median (range) age
was 62.9 years (30-83.1 years). In 11 cases there was no residual tumour in the
resection specimens (per definition TCD =0%).Using the originally collected biopsy
data revealed that 6 cases were squamous cell carcinomas, 4 adenocarcinomas and 1
case with other histology.
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Chemotherapy+ surgery 229 48.8
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* Mandard grading; TRG 1= complete regression, TRG2= only a few residual tumour cells
evident, TRG3= predominantly fibrosis, TRG4= predominantly tumour cells and TRG5= no
evidence of any regression seen. ±TNM staging was performed according to the 6
th
edition of
the UICC TNM staging manual (140)
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Median (range) follow up time from randomisation was 1.49 years (0.02 to 13.21) and
from surgery to last follow up or death 1.39 years (0.0 to 13.18). At the end of the follow
up period 97 patients (20.7%) were still alive, 289 patients (61.6%) had died of cancer,
28 patients (6.0%) had died of complications related to their surgery and 48 patients
(10.2%) had died due to factors unrelated to surgery or cancer. In 7 patients, the cause
of death was unknown. Of the patients who were alive at the end of the study period,
the median (range) follow up time from randomisation was 6.1 years in the
chemotherapy followed by surgery treatment group and 5.8 years in the surgery alone
treatment group.
The clinicopathological variables by treatment arm (surgery alone vs neoadjuvant
chemotherapy plus surgery) are illustrated in Table 18. There was no significant
difference between the treatment arms with respect to age, gender, histology,
differentiation of the tumour and T category using TNM6 (Table 18). However, there
was significant difference in the N category, lymphatic vessel invasion, blood vessel
invasion and Mandard regression grading between the two treatment arms in this
cohort. Patients treated by chemotherapy followed by surgery had a higher percentage
of N0 disease, lower proportion of lymphatic vessel or blood vessel involvement and
more frequent evidence of primary tumour regression (Table 18).
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N (%) N (%) N (%) P value
Age
Median 62.7 62.5 63.5
0.423
Range 30.0-83.1 36.4-83.1 30.0-80.7
Gender
Male 358 (76.3) 182 (79.5) 176 (73.3)
0.118
Female 111 (23.7) 47 (20.5) 67 (26.7)
Histology
Adenocarcinoma 331 (70.6) 163 (71.2) 168 (70.0)
0.895
Squamous 111 (23.7) 51 (22.3) 60 (25.0)
Other 16 (3.4) 7 (3.1) 9 (3.8)
No residual tumour 11 (2.3) 8 (3.5) 3 (1.3)
Grade of differentiation
Poor 204 (43.5) 92 (40.2) 112 (46.7)
0.709
Moderate 209 (44.6) 109 (47.6) 100 (41.7)
Well 41 (8.7) 18 (7.9) 23 (9.6)
Unknown 4 (0.8) 2 (0.8) 2 (0.8)
No residual 11 (2.3) 8 (3.5) 3 (1.3)
(y)pT stage±
T0 (No residual) 11 (2.3) 8 (3.5) 3 (1.3)
0.110
T1 40 (8.5) 19 (8.8) 21 (8.8)
T2 51 (10.9) 29 (12.7) 22 (9.2)
T3 355 (75.7) 169 (73.8) 186 (77.5)
T4 12 (2.6) 4 (1.7) 8 (3.3)
(y)pN category±
N0 181 (38.6) 101 (44.1) 80 (33.3)
0.017
N1 288 (61.4) 128 (55.9) 160 (66.7)
Lymphatic vessel invasion
Yes 160 (34.1) 61 (26.6) 99 (41.3)
0.006
No 270 (57.6) 149 (65.1) 121 (50.4)
Suspicious 37 (7.9) 19 (8.3) 18 (7.5)
Unknown 2 (0.4) 0 (0.0) 2 (0.8)
Blood vessel invasion
Yes 59 (12.6) 16 (7.0) 43 (17.9)
<0.001
No 374 (79.7) 199 (86.9) 175 (72.9)
Suspicious 35 (7.5) 14 (6.1) 21 (8.8)
Unknown 1 (0.2) 0 (0.0) 1 (0.4)
Mandard tumour regression grade*
TRG1 11 (2.3) 8 (3.5) 3 (1.3)
<0.001
TRG2 9 (1.9) 7 (3.1) 2 (0.8)
TRG3 37 (7.9) 26 (11.4) 11 (4.6)
TRG4 167 (35.6) 93 (40.6) 74 (30.8)
TRG5 244 (52.0) 95 (41.5) 149 (62.1)
Unknown 1 (0.2) 0 (0.0) 1 (0.4)
Mandard grading; TRG 1= complete regression, TRG2= only a few residual tumour cells
evident, TRG3= predominantly fibrosis, TRG4= predominantly tumour cells and TRG5= no
evidence of any regression seen. + TNM staging according to the 6
th
edition of the UICC TNM
staging manual.
~ 111 ~
Next, was to establish the relationship between TCD and survival per treatment arm
and determine the potential best cut off value for stratifying patients into groups with
different prognosis.
4.7 Tumour cell density results
4.7.1 TCD % distributions and their relationship to the treatment
groups
A total of 135054 points were categorised of which 132607 were deemed ‘informative’
(dropout rate: 1.8%). The median number of points reviewed per case was 287.0
(range: 270 to 320 points) with a median number of informative points of 282.8 (range:
206 to 303 points). The median number of tumour points per case (Figure 19) was
145.7 points (range: 0 to 273) and the median TCD percentage (Figure 20) was 53.2%
with a range from 0 to 95.5% TCD.
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Figure 19: Histogram of tumour points per case in the whole TCD cohort
Histogram showing that the distribution of the number of tumour points per case follows a
normal distribution
Figure 20: Histogram showing TCD % per case in the whole TCD cohort
Histogram showing that the distribution of the TCD % per case follows a normal distribution
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There was a significant difference in TCD % between the two treatment arms
(p<0.001). The median TCD in the chemotherapy + surgery group was significantly
lower compared to the median TCD in the surgery alone group (median (range) TCD
chemotherapy and surgery arm: 50.0% (0-93.1%), surgery alone arm: 55.6% (0-
95.5%), p<0.001).
4.7.2 Identification of the cut off for prognostic stratification
Equal sized TCD groups were created as set out in the methods (4.2 Methods). The
cut-offs and the respective group sizes are shown in the Table 19 below:
Table 19: TCD range by group classifications and by treatment arm
Chemotherapy and surgery
group (n=229)
Surgery alone group (n=240)
TCD range % No. cases TCD range % No. cases
Complete responders (T0)
0.0 8 0.0 3
5 equally sized groups
1
st
fifth 0.0 to 28.4 44 0.0 to 39.6 47
2
nd
fifth >28.4 to 44.5 44 39.6 to 51.6 47
3
rd
fifth >44.5 to 51.2 45 51.6 to 61.7 48
4
th
fifth >51.2 to 70.8 44 61.7 to 74.8 48
5
th
fifth >70.8 to 100 44 74.8 to 100 47
4 equally sized groups
1
st
quartile 0.0 to 31.6 55 0.0 to 43.6 59
2
nd
quartile >31.6 to 50.7 55 43.6 to 55.6 59
3
rd
quartile >50.7 to 67.4 56 55.6 to 71.1 60
4
th
quartile >67.4 to 100 55 71.1 to 100 59
3 equally sized groups
Low third 0.0 to 37.1 74 0.0 to 47.4 79
Mid- third >37.1 to 61.0 73 47.4 to 65.4 79
High- third >61.0 to 100 74 65.4 to 100 79
2 equally sized groups
Low group 0.0 to 50.7 111 0.0 to 55.6 118
High group >50.7 to 100 110 55.6 to 100 119
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Using this patient stratification, Kaplan Meier survival plots were created for both
overall and cancer specific survival using log rank test for assessing the statistical
significance. None of the groupings showed as significant relationship between TCD




Figure 21(a-d): Univariate overall survival analysis by TCD grouping in the surgery alone
treatment group.
The four plots (a-d) assessing the prognostic value of TCD on overall survival by splitting the
surgery alone treatment arm into 5 (a), 4 (b), 3 (c) or 2 (d) equally sized TCD groups. As the
complete responders group only included 3 patients the curve has not been shown although







Figure 22 (a-d): Univariate cancer specific survival analysis by TCD grouping in the
surgery alone treatment group.
The four plots (a-d) assessing the prognostic value of TCD on cancer specific survival by
splitting the surgery alone treatment arm into 5 (a), 4 (b), 3 (c) or 2 (d) equally sized TCD
groups. As the complete responders group only included 3 patients the curve has not been




For the chemotherapy and surgery treatment group the TCD groupings do not produce
significant differences in overall survival using the 5, 4 or 3 group system. However the
2 group system (cut off of 50.7%) produced a statistically significant differences in




Figure 23 (a-d): Univariate overall survival analysis by TCD grouping in the chemotherapy
and surgery treatment group.
The four plots (a-d) assessing the prognostic value of TCD on overall survival by splitting the
chemotherapy and surgery treatment arm into 5 (a), 4 (b), 3 (c) or 2 (d) equally sized TCD
groups. ypT0 cases are considered separately (n=8). The 2 group classification produced




However in cancer specific survival in the chemotherapy and surgery treatment arm 3
out of 4 of the grouping systems produced significant differences in survival between
the groups and also the complete responders (Figure 24a-d). Unlike for overall survival
log rank p values calculations showed these differences to be statistically significant in
the 5 group classifications system (p=0.030) and 3 group system (p=0.032). Using a 2
group system (high >50.7% vs low <50.7%) showed the clearest differences in group
survival particularly at the 8 year follow up time period (overall p=0.009). When
comparing for differences only in the cases with evidence of residual tumour (i.e.
excluding the complete responders n=8) there is no prognostic significance between
the TCD groupings (5 groups p=0.320; 4 groups p=0.640; 3 groups p=0.521 and 2
groups p=0.264). This was also the case for overall survival when the complete






Figure 24 (a-d): Univariate cancer specific survival analysis by TCD grouping in the
chemotherapy and surgery treatment group.
The four plots (a-d) assessing the prognostic value of TCD on cancer specific survival by
splitting the chemotherapy and surgery treatment arm into 5 (a), 4 (b), 3 (c) or 2 (d) equally





In the 3 group classification in chemotherapy and surgery treatment arm the medium
(>37.1-61%) and high TCD group (>61%) survival probabilities are closely related
throughout. So these two groups were combined to define a low group (TCD up to
37.1%) and a high group (TCD>37.1%). This modified 2 group classification also
produced significant differences in survival for overall and cancer specific survival (p
values 0.036 and 0.012 respectively) (Figure 25). However when just comparing the
low vs high group of patients (excluding ypT0 patients) there was no statistical
difference in survival between just the low and high group (overall survival p=0.678 and
cancer specific survival p=0.257).
~ 124 ~
Figure 25 (a&b): Univariate overall and cancer specific survival analysis using the
modified 2 group TCD classification for patients in the chemotherapy and surgery
treatment group.
The survival plots of the patients from the chemotherapy and surgery treatment group using the




Using this modified classification system (≤37.1% or >37.1% TCD), the patients from 
the chemotherapy and surgery treatment group (n=229) clinicopathological
demographics were compared, results can be found in Table 20. Patients with low TCD
tumours (0-37.1% TCD) were significantly more frequently classified as Mandard TRG
2 or 3 compared to patients with high TCD tumours (>37.1% TCD). 51.8% of patients
with high TCD tumours had a Mandard TRG 5 (no evidence of regression) compared to
34.2% of patients with low TCD tumours.
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Table 20: TCD high and low groups clinicopathological distributions.
The distribution of the clinicopathological features from the chemotherapy followed by surgery



















Median 62.4 63.2 60.8
0.034
Range 42.4- 75.5 36.4- 83.1 36.8- 77.7
Gender
Male 4 (60.0) 56 (75.7) 122 (83.0)
0.196
Female 4 (40.0) 18 (24.3) 25 (17.0)
Histology
Adenocarcinoma 0 (0.0) 49 (66.2) 114 (77.6)
0.073
Squamous 0 (0.0) 22 (29.7) 29 (19.7)
Other 0 (0.0) 3 (4.1) 4 (2.7)
No residual tumour 8 (100.0) 0 (0.0) 0 (0.0)
Differentiation
Poor 0 (0.0) 36 (48.6) 56 (38.1)
0.098
Moderate 0 (0.0) 34 (45.9) 75 (51.0)
Well 0 (0.0) 4 (5.4) 14 (9.5)
Unknown 0 (0.0) 0 (0.0) 1 (0.7)
No residual 8 (100.0) 0 (0.0) 0 (0.0)
T category
T0 (No residual) 8 (100.0) 0 (0.0) 0 (0.0)
0.856
T1 0 (0.0) 6 (8.1) 13 (8.8)
T2 0 (0.0) 11 (14.9) 18 (12.2)
T3 0 (0.0) 54 (73.0) 115 (78.2)
T4 0 (0.0) 3 (4.1) 1 (0.7)
N category
N0 8 (100.0) 35 (47.3) 58 (39.5)
0.266
N1 0 (0.0) 39 (52.7) 89 (60.5)
Lymphatic invasion
Yes 0 (0.0) 15 (20.3) 46 (31.3)
0.115No 8 (100.0) 53 (71.6) 88 (59.9)
Suspicious 0 (0.0) 6 (8.1) 13 (8.8)
Vascular invasion
Yes 0 (0.0) 5 (6.8) 11 (7.5)
0.657No 8 (100.0) 63 (85.1) 128 (87.1)
Suspicious 0 (0.0) 6 (8.1) 8 (5.4)
Mandard grading*
TRG1 8 (100.0) 0 (0.0) 0 (0.0)
<0.001
TRG2 0 (0.0) 5 (6.8) 2 (1.4)
TRG3 0 (0.0) 16 (21.6) 10 (6.8)
TRG4 0 (0.0) 36 (48.6) 57 (38.8)
TRG5 0 (0.0) 17 (23.0) 78 (53.1)
p
1
values- Calculated using Mann-Whitney test
* Mandard grading; TRG 1= complete regression, TRG2= only a few residual tumour cells
evident, TRG3= predominantly fibrosis, TRG4= predominantly tumour cells and TRG5= no
evidence of any regression seen.
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4.7.3 Assessment of the prognostic value of TCD in univariate and
multivariate analysis
The results of cox regression testing for overall survival in the surgery alone group is
outlined in Table 21 below, identifying patient age, T category, N category and
presence of lymphatic invasion as prognostic factors. TCD was not related to overall
survival in the surgery alone patients (p=0.960). On multivariate analysis, patients age
(p=0.005), N category (p<0.001) and evidence of lymphatic vessel invasion (p=0.012)
were identified as independent prognostic markers for overall survival (Table 21).
Table 21: Surgery alone patients overall survival cox regression analysis table.
Univariate analysis Multivariate analysis
HR 95% CI *P value HR 95% CI *P value
Age 1.02 1.01 to 1.04 0.005 1.02 1.01 to 1.04 0.002
Gender 0.84 0.61 to 1.15 0.274 - - -
Histology 1.03 0.84 to 1.26 0.772 - - -
Differentiation 1.00 1.00 to 1.00 0.572 - - -
T category 1.43 1.15 to 1.76 0.001 1.20 0.94 to 1.54 0.151
N category 2.15 1.57 to 2.94 <0.001 1.85 1.33 to 2.59 <0.001
Lymphatic
involvement
1.39 1.13 to 1.70 0.002 1.33 1.07 to 1.66 0.012
Blood vessel
involvement
1.20 0.98 to 1.47 0.083 - - -
TCD% 1.00 0.85 to 1.18 0.960 - - -
The relationship between age, gender, histology, grade of tumour differentiation, pT,
pN categories, lymphatic involvement, blood vessel involvement and TCD to cancer
specific survival was also assessed via cox regression analysis. The ypT category, ypN
category, lymphatic vessel invasion and blood vessel invasion were significant
~ 128 ~
prognostic marker in univariate analysis (Table 22). Multivariate analysis showed pT
category, pN category and lymphatic vessel invasion as independent prognostic
markers (Table 22).
Table 22: Surgery alone patients cancer specific survival cox regression analysis table.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI *P value
Age 1.01 1.00 to 1.03 0.115 - - -
Gender 0.75 0.52 to 1.08 0.124 - - -
Histology 1.12 0.80 to 1.57 0.505 - - -
Differentiation 1.00 1.00 to 1.00 0.705 - - -
T category 1.81 1.36 to 2.41 <0.001 1.41 1.01 to 1.97 0.041
N category 2.91 1.99 to 4.28 <0.001 2.21 1.47 to 3.34 <0.001
Lymphatic
involvement
1.60 1.27 to 2.01 <0.001 1.50 1.16 to 1.93 0.002
Blood vessel
involvement
1.31 1.05 to 1.63 0.017 1.11 0.88 to 1.41 0.363
Overall TCD% 1.00 1.00 to 1.01 0.370 - - -
The same cox regression analysis were performed on the survival data for patients
from the chemotherapy and surgery group (n=229). As this treatment group involved
neoadjuvant chemotherapy patients, the Mandard TRG system was also included in
the model to assess its prognostic value.
Univariate overall survival analysis identified age, ypT category, ypN category,
lymphatic vessel invasion, blood vessel involvement, TCD and Mandard TRG as
prognostic markers (Table 23). On multivariate analysis age, ypT category, ypN
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category and blood vessel involvement were found to be independent prognostic
marker (Table 23).
Table 23: Chemotherapy and surgery treatment group overall survival Cox regression.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI *P value
Age 1.02 1.00 to 1.04 0.016 1.02 1.00 to 1.04 0.013
Gender 0.973 0.68 to 1.40 0.88 - - -
Histology 0.91 0.77 to 1.09 0.313 - - -
Differentiation 1.00 1.00 to 1.00 0.642 - - -
T category 1.59 1.30 to 1.95 <0.001 1.41 1.13 to 1.76 0.002
N category 1.95 1.44 to 2.63 <0.001 1.63 1.18 to 2.24 0.003
Lymphatic
involvement
1.30 1.05 to 1.60 0.015 1.15 0.91 to 1.45 0.240
Blood vessel
involvement
1.54 1.21 to 1.97 0.001 1.42 1.10 to 1.84 0.008
Mandard Grade 1.22 1.05 to 1.40 0.008 0.96 0.79 to 1.16 0.675
Overall TCD% 1.01 1.00 to 1.01 0.047 1.00 1.00 to 1.01 0.530
The relationship between age, gender, histology, grade of tumour differentiation, ypT,
ypN categories, lymphatic involvement, blood vessel involvement and TCD to cancer
specific survival in the chemotherapy and surgery treatment group, was also assessed
via cox regression analysis (Table 24).
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Table 24: Cancer specific Cox regression analysis in chemotherapy and surgery group
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI *P value
Age 1.02 1.00 to 1.04 0.038 1.02 1.00 to 1.04 0.024
Gender 0.97 0.65 to 1.46 0.898 - - -
Histology 0.83 0.68 to 1.03 0.086 - - -
Differentiation 1.05 0.93 to 1.17 0.437 - - -
T category 1.95 1.50 to 2.53 <0.001 1.61 1.22 to 2.14 0.001
N category 2.44 1.72 to 3.47 <0.001 1.96 1.35 to 2.83 <0.001
Lymphatic
involvement
1.30 1.03 to 1.65 0.028 1.11 0.85 to 1.45 0.433
Blood vessel
involvement
1.68 1.29 to 2.19 <0.001 1.53 1.15 to 2.03 0.003
Mandard Grade 1.34 1.13 to 1.59 0.001 1.00 0.80 to 1.26 0.990
TCD% 1.01 1.00 to 1.02 0.009 1.00 1.00 to 1.01 0.443
There was a significant relationship between cancer specific survival and age, ypT
category, ypN category, lymphatic vessel invasion, blood vessel involvement, Mandard
TRG and TCD % (Table 24). Multivariate analysis identified age, ypT category, ypN
category and evidence of blood vessel involvement as independent prognostic markers
for cancer specific survival.
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4.8 Comparison of the prognostic value of tumour cell density
scoring versus Mandard tumour regression grading in
chemotherapy followed by surgery patients
To further assess the value of the TCD measurement as a surrogate of tumour regression,
TCD results were compared to the results from the Mandard tumour regression grading for
patients from the chemotherapy and surgery treatment group (Figure 26). TCD % values
were taken as a continuous variable with the ypT0 cases included (n=8) with their score
given as 0% TCD. Kruskal Wallis test showed that a significant relationship between TCD %
and Mandard grading (p<0.001)
Figure 26: Boxplot showing a linear relationship between TCD % and Mandard tumour
regression grading system
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Univariate analysis showed TCD % to be prognostic in chemotherapy and surgery patients
for overall (HR 1.01; CI 1.00 to 1.01; p=0.047) and cancer specific survival (HR 1.01; CI 1.00
to 1.02; p=0.009). Mandard TRG was also found to be of prognostic value in univariate
analysis for chemotherapy followed by surgery patients for overall (HR 1.22; CI 1.05 to 1.40;
p=0.008) and cancer specific survival (HR 1.34; CI 1.13 to 1.59; p=0.001) (Figure 27).
However neither TCD% nor Mandard TRG was demonstrated to be independent prognostic
markers.
Figure 27: Kaplan Meier survival plot of cancer specific survival in the chemotherapy and
surgery treatment group stratified by Mandard tumour regression grading.
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The Kaplan Meier plot was visually inspected to identify whether some of the groups should
be combined as they seem to have the same survival. Therefore TRG 1 was compared with
TRG2+3 combined and TRG 4+5 combined (Figure 28).
Figure 28: Cancer specific survival in the chemotherapy and surgery treatment group stratified
by a modified Mandard regression grading system.
Using this modified Mandard tumour regression grading system, a significant difference in
cancer specific survival was seen (p=0.008). However as with TCD when the univariate
survival is assessed without the complete responders (i.e. TRG1 cases not included) there is
no significant difference in survival between the patients with TRG2 or 3 compared to
patients with TRG 4 or 5 (p=0.231).
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4.9 Discussion
The OE02 trial and subsequently published meta-analyses showed that neoadjuvant
chemo(radio)therapy improved prognosis in oesophageal cancer patients prognosis (94, 99,
335, 336). Tumour regression has been shown to have prognostic value in oesophageal
cancer patients who have undergone (radio)chemotherapy (121, 129, 174, 178, 335, 337-
340), with cases showing complete regression having the greatest survival benefit (121,
129). Some studies have stated histological response was an independent prognostic
marker for survival (175, 176, 341, 342). At present, response to neoadjuvant chemotherapy
during treatment is measured radiologically on CT imaging using the RECIST criteria, with
variable degree of confidence. However, except for RECIST, which is a radiological
regression system, there is no universally accepted histopathological response evaluation
system established (175, 341).
Pathological review of the resected tumour following neoadjuvant therapy remains the
current gold standard for the assessment of response to therapy (174, 186). Current tumour
regression grading systems use subjective measures to determine either the amount of
regression (177) or the percentage of residual tumour (175, 176, 179, 189) or the size of the
residual tumour foci (190). In the UK, the tumour regression grading (TRG) system
described by Mandard et al is widely used which was originally developed to assess
response in squamous cell cancers after chemoradiotherapy (177) . Mandard TRG has been
criticised as being a subjective method with particular high inter-observer variation for
grading of tumours with reduced number of tumour cells (175, 176, 340). There is also
controversy on how many different categories should be used with Mandard and Dunne
favouring the 5 group classification (177, 189), while others demonstrating a better
prognostic stratification using a 4 group (176, 186, 194), and some investigators more
recently suggesting a 3 grade system being superior (121, 186, 335). Swisher et al proposed
a 3 grade tumour regression grading system consisting of P0 (complete responders), P1 (1-
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50% residual tumour) and P2 (greater than 50% residual tumour) and indicated that the use
of a pathological category should be added into the TNM classification (186).
The work in this study has used quantitative measurements of the tumour cell density to
provide an assessment of the tumour regression. The tumour cell density (TCD) has been
calculated at the luminal surface of oesophageal cancer resection specimens using virtual
H&E stained sections to simulate endoscopic biopsies and been shown to have prognostic
value in the chemotherapy followed by surgery treatment group. The TCD measurement
technique was based on a well-established morphometric method called point counting
which provides in this case a quantitative measure for tumour cell density of tumours (330).
Through the intra-observer variability analysis the technique has been shown to be
reproducible with a new observer learning curve demonstrated with an improvement in intra-
observer scoring noted through the process. Inter-observer analysis has shown a good
agreement between two independent observers (TS and GH) with a Kappa calculated
agreement of 0.732, demonstrating the scoring system used as shown previously can be
followed closely by different observers (198). Kappa coefficient gives a measure of
agreement and a kappa agreement above 0.70 is generally accepted as good. This is
especially considering this agreement was between a qualified histopathologist and a
second observer with no formal histopathological qualifications, who was pre-trained in the
technique and developed further through the scoring process.
This TCD technique has been shown to be significantly related to Mandard grading through
non-parametric testing (p<0.001), with box plot comparisons show that TCD values correlate
well with Mandard grades. Mandard grading is widely used in the UK for reporting of
regression in oesophageal resections. Survival analysis shows both systems to stratify
patients into prognostic groups. However using TCD calculations give the advantage of
producing quantitative measurements therefore reduce subjective bias. As well as this TCD
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calculations can be done on biopsies at the pre-operative category and through serial
biopsies could be used to assess response through neoadjuvant chemotherapy.
The TCD % demonstrated a range from 0-95.5% with a normal distribution across the cohort
as a whole. There was a statistically significant difference in the TCD scoring between the
treatment arms showing that the regression changes induced by chemotherapy did change
the actual tumour density and that this change can be quantified at the luminal surface.
Some studies have shown that amount of residual tumour cells in OeC is significantly
associated with prognosis but no study has gone on to use quantitative scoring of the
residual tumour density as done in this study (180, 325). However here tumour cell density is
measured as a continuous variable in larger group of patients (n=469), originating from a
large multi-centre randomised trial (99).Only one previous study in OeC has looked at the
tumour cell density in surgery alone patients. This study by Mesker et al showed that even
without neoadjuvant therapy OeC can have varying densities in their resection with 35% of
cases having less than 50% tumour to stroma. This work reflects this finding as not all cases
in the surgery alone group had high tumour densities with the median TCD in this group
being 55.6% (range 0.3 to 95%). This has been described before in surgery alone tumours
with abundant stromal tissue leading to lower tumour cell densities (191, 325). In this study
97 (39%) cases in the surgery alone group had a TCD<51% which using established
regression grading systems such as Mandard’s or Becker’s would classify these patients as
“responders” despite never having any neoadjuvant treatment (176, 177). This may suggest
that in the neoadjuvant chemotherapy followed by surgery group, the resection tumour
density may have not necessarily decreased or changed at all as a result of chemotherapy.
This supports assessing the TCD early in the treatment pathway to establish the tumours
original TCD. Responders will then be cases where the TCD shows a significant decrease
from its original (pre-chemotherapy) TCD to its final resection TCD%.
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TCD is shown in this chapter to be a prognostic survival marker, only in chemotherapy
followed by surgery patients and not in surgery alone patients. TCD has been identified as
independent prognostic marker in previous studies in breast (343), colorectal (198, 344) and
also oesophageal cancer (325). This previous tumour regression study involving
oesophageal cancer patients was by Mesker et al examining the “tumour to stroma” ratio as
opposed to tumour cell density used here (325). Mesker’s study (n=93) also differed from
this current one because it only included patients’ who had undergone surgery alone,
measured the overall tumour cells, therefore not at the luminal surface as in this study and
also this initial study used estimations of the tumour amount as opposed to the quantitative
measures carried out in this work (325). Cases were divided into those with low tumour
stroma ratio (<50%) and those with high tumour stroma ratio (>50%). Patients in the high
tumour ratio group had a significantly better median overall survival (42 months) compared
to those in the low tumour stroma group (16 months) which was statistically significant
(p<0.001). This would suggest that patients with less than 50% tumour cells had a poorer
prognosis than those with high tumour cells, which is in opposition to our study. However the
scoring done in Mesker et al was done in areas with the lowest tumour to stroma ratio which
they describe as generally at the deepest point of infiltration (325). Mesker followed up this
initial study with another assessing tumour to stroma in oesophageal cancer biopsy tissue
using patients who had only undergone surgery (196). This demonstrates that tumour
density measure could potentially be done on biopsy material but this time with a quantitative
measurement as done in this study.
Our TRG grouping tests have identified a similar cut-off of 50.7% TCD to split the cohort into
2 equal groups (low vs high TCD) as used by other tumour regression systems (175, 178,
185, 186) (Table 19). Univariate survival analysis shows this cut-off to give groups with
significant differences in cancer specific survival but only when the ypT0 cases are included
separately. However using TCD enables a quantitative measurement to be carried out as
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opposed to estimations used in regression grades such as Mandard, Becker or Chirieac et al
(177-179). Another difference with using this TCD technique is that it enables a
measurement to be carried out at the luminal surface a site that could be biopsied in the pre-
operative phase of treatment, while all other regression techniques are limited to the
assessment of resected cancers. Although not specifically tested for in this work the use of
TCD calculations through serial biopsies could provide an important marker to monitor
oesophageal cancer during chemotherapy and has been shown in previous oesophageal
cancer studies (196).
While TCD was not shown to be an independent prognostic marker in chemotherapy and
surgery, ypT and ypN categories were independently prognostic using TNM6 (140). This
finding is in agreement with a large recent study looking at prognostic markers in
oesophageal cancer (345) . The study of 850 oesophago-gastric cancers concluded that
ypTNM stages were the only independent prognostic factors. The regression grading tested
was the Becker 4 tier regression grading system which was shown to have prognostic value
but not to be independently prognostic. However there remains other studies who have
found tumour regression grading in oesophageal cancer to be an independent prognostic
marker and have suggested that histopathological response should be incorporated into the
TNM classification (185, 186, 196). These contrasting results are likely due to multiple
factors between the studies. Firstly, there are a variety of different regression systems used
across existing studies (discussed in 1.9 Tumour regression systems used to assess
oesophageal cancer ) with regional preferences found (177-179). Different systems have
different cut-offs and involve different number of classification groups making study results
difficult to compare (177-179, 185, 189). However all have the same limitation of requiring
estimations of regression. Also there are differences in the histological type of the
oesophageal cancer cases included in the analysis with some studies only involving
squamous cell carcinomas (176, 177, 195), some involving only adenocarcinomas (175,
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325, 342) and others have a mixed histological cohort (121, 187). Although it has previously
been suggested that survival differs between the two main histological oesophageal cancer
types (127, 129), in this study non-parametric testing showed no significant difference in
TCD scoring between adenocarcinomas and squamous cell carcinomas. This study to date
will be the first to include patients from a randomised control trial in oesophageal cancer with
patients who have had both surgery alone and neoadjuvant chemotherapy followed by
surgery which will be the last time such a cohort will be used following the results of the
OE02 trial (84). This study is also different to all previous studies as it is the first to measure
the TCD specifically at the luminal surface in an attempt to compare this TCD value to
calculations that could be taken from endoscopic biopsies.
Despite having unique features this study did have limitations to acknowledge, firstly,
although the scoring labels were clear and inter observer agreement good there were still
times where the labelling of points could be due to subjective judgement. Except for cases
reviewed as part of the inter-observer analysis all cases were only reviewed by one single
observer (TS). Although a second observer to review each case would have been ideal the
time consuming nature of reviewing 469 cases limited this option. Secondly, all added
pathological variables were done using the material received for each case by a local
histopathologist (NW). As with the 28 cases where no tumour involving material was
received it is likely that even in cases with tumour present not all the cases material was
available. This could have influenced the added information gained locally such as lymphatic
vessel or blood vessel involvement as well as Mandard grading if it was based on
incomplete material. Finally the criteria for selection of appropriate slide could also be
criticised for using the slide with the deepest infiltration and not the slide with the greatest
density as the first selection rule. This was aimed to be associated with where the tumour
would possibly have the highest pT category, but with the possibility of not all the slides
being available this may not have been the case. The reason the slide with the greatest
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density of visible tumour was not used as the first criteria was because this could have
added an element of subjectivity to the slide selection process. The good intra-observer
agreement in terms of slide selection is reassuring. Ideally this work would have included
some TCD values from the relevant biopsies of each case. However as not all this material
was available this was not possible; however this would be a likely follow up study in future.
This study has shown that morphometric point counting technique is an easy, reproducible
technique which enables quantitative measurements of the TCD in oesophageal cancer.
TCD calculation has been shown to correlates to with the internationally recognised
Mandard grade with both on univariate analysis demonstrating prognostic value in
chemotherapy followed by surgery oesophageal cancer. However using TCD has the
advantage of being an objective measurement through a quantitative calculation of residual
tumour present. This TCD method has been shown to demonstrate a difference in tumour
cell density after chemotherapy, a change which can be measured at the luminal surface.
This finding suggests that TCD measurements could be used to assess tumour response
during the pre-operative phase via endoscopic biopsies which would be the next logical
study to be carried out. With particular interest would be if it’s the actually the final TCD
value which is the most important or the difference in TCD value from pre-chemotherapy to
after chemotherapy which holds the most prognostic significance.
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5. TUMOUR INFILTRATING LEUCOCYTES AND
RELATIONSHIP WITH PROGNOSIS IN
OESOPHAGEAL CANCER
5.1 Background- human immunology
The primarily role of the human immune system is to protect the host from diseases
secondary to bacteria, viruses or other pathogens (346). All organisms, even unicellular
ones such as bacteria, are thought to possess some form of immune system. During
evolution, humans have developed a sophisticated immune response system which has two
main branches; innate (non-adaptive) immunity and adaptive immunity (346).
5.1.1 Innate immune system
The innate system is responsible for the first line of immune protection which includes the
physical barriers to disease such as skin and mucosal membranes (346). It is also
responsible for a non-specific generic response to microorganisms or toxins that breach
these barriers. It is triggered by cell injury or damage (such as in inflammation) or when
microbes are detected directly through recognition of abnormal components (347). This
innate system is also responsible for the recruitment of immune cells to the site of
infection/damage through the secretion of cytokines. It is from this initial innate immune
response that leukocytes, macrophages and neutrophils cells arise.
5.1.2 Adaptive immune response
This is a more sophisticated immune response, with specific immune reactions and the
ability to gain immune memory to ensure that repeat interactions with the same pathogen
are resolved more efficiently (346). Unlike the innate system the adaptive system is antigen
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specific and reacts to recognition of a ‘non-self’ antigen. It has two branches which often co-
exist:
a.) Humoral adaptive system: In this system antibodies recognise and bind to antigens
through antigen-antibody complex. These complexes are then taken up and broken
down by B cells. Following which the B cell can divide and multiply to produce millions of
the same antibody into the circulation to identify other specific pathogens which can also
be destroyed (346).
b.) Cell-mediated adaptive immune system: T cell lymphocytes are responsible for the
cellular mediated adaptive immune response. There are two main types: Helper T cells
(CD4) and Cytotoxic T cells (CD8). All T lymphocyte cells have T-cell receptors (TCR)
complexes, CD3 receptors (used when staining the T cell population in general) plus
other specific co-receptors on their surface. For Helper T cells this co-receptor is a CD4
receptor and for Cytotoxic T cells this is a CD8 receptor. However unlike antibodies T
cells cannot recognise and bind directly to antigens. They require antigen presenting
cells (APCs- typically dendritic or B cells) to first bind and digest the antigen, before
presenting peptide chains of the antigen on its surface on what are known as major
histocompatibility complex (MHC) molecules (346). On binding to a MHC lymphocytes
release cytokines and other stimulatory signals which lead to activation of macrophages
and Cytotoxic T cells which can directly attack the pathogen (348). It is thought that
cytotoxic T cells are also able to attack tumour cells in the same way and studies have
identified the adaptive immune response as having a role in tumour pathology (218, 348,
349).
5.1.3 Cancer Immunology
5.1.3.1 Immune cell infiltration in cancer overview
There are two routes via which immune cells affect cancers: via their circulating presence in
the blood and their influence directly at the tumour microenvironment. There is a substantial
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body of work looking at the prognostic effect of different levels of circulating immune cells
detected in the blood and in particular examining neutrophil to lymphocyte ratios (NLR) in the
blood. High NLRs are associated with poor survival in lung (350, 351), breast (352-355),
gastric (356-358), colorectal (359-362), prostate (363, 364) and ovarian cancer (365, 366).
However this study will only be examining the prognostic influence of different level of
immune cells infiltrating the tumour itself.
Epithelial cancers are composed of a mixture of malignant cells and intratumoural
stroma (often referred to as tumour microenvironment) which includes fibroblasts, immune
cells, lymphatic and blood vessels (367, 368). Variations in the composition of the tumour
microenvironment have been linked to differences in patient prognosis in cancers of the
breast (369, 370), lung (371), skin (372), prostate (331), colon and rectum(198, 373, 374).
The immune system is thought to have several roles in preventing the development of
malignant tumours (217, 219, 220). The first role is the recognition and subsequent
elimination of viruses that may induce tumour development (e.g. Human papilloma virus in
oesophageal or cervical cancers). The second role is the removal of pathogens which may
trigger an inflammatory response, therefore creating an environment conducive to tumour
growth and thirdly, the immune system is thought to play a direct role in the removal of
tumour cells through recognition of tumour antigens.
These tumour infiltrating immune cells, such as T lymphocytes make up an important part of
the tumour microenvironment with studies initially in mice showing that T lymphocytes can
prevent tumour development and inhibit tumour progression (218, 223). It has been
suggested that this effect is mainly related to the activity of cytotoxic T cells (CD8+) which
are referred to as the mediators of the anti-tumour response process, with the capability of
direct lyses of tumour cells (348). Subsequent studies in humans suggest that high levels of
CD8 and CD4 T cells at the tumour microenvironment is associated with a better prognosis
in skin melanomas (375), head and neck cancers (376), breast (237), pancreatic (377),
colorectal (231, 378-384), urological(257) and gynaecological malignancies (385, 386).
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As well as the CD4 and CD8 subsets of T cells, Regulator T cells (Treg cells) have
the properties to be involved in the tumour surveillance process. Treg cells play a role in the
adaptive immune response by limiting and supressing the immune response (346). They are
distinguishable from other T cells by their expression of Forkhead Box Protein P3 (Foxp3).
Their role in tumour immunology is unclear with pro-tumour characteristics and anti-tumour
characteristics both shown in tumours of different origins. Treg cells are thought to be key
suppressors of the anti-tumour response through the suppression of cytotoxic T cells (387,
388). Various studies have shown high infiltration of Treg cells at the tumour
microenvironment is associated with poor prognosis in lung (389), breast (390), gastric (391)
and ovarian cancers (392). However studies in colon cancer have shown that high levels of
Treg cells in the tumour microenvironment is associated with an improved survival (393,
394).
While T cells have been associated with tumour control, other immune cells have been
linked with having a “pro-tumour” effect. Macrophages are one of the other major immune
cell components in the tumour microenvironment (395), but unlike the T cells, macrophage
infiltration has generally been associated with poor prognosis in various cancers (217, 218,
396, 397). Tumour associated macrophages (TAMS) are thought to aid tumour growth due
to the action of their secretion of cytokines, growth and angiogenic factors (398, 399). They
are part of the initial host response stimulated by malignant cells. The strongest body of
evidence of the “pro-tumour” activity of macrophages comes from haematological
malignancies such as lymphoma, where multiple studies have shown that high macrophage
levels in the blood are related to poor prognosis (234, 400-402). A similar pro-tumour impact
of TAMS have also been demonstrated in solid tumours such as lung (225, 403), breast
(238, 241), oral squamous cancer (404), renal (405) and colon cancer (406-409). However
there have been contrasting results in colorectal cancer studies with some showing an
improved survival in tumours with high TAMS (410, 411). These conflicting results maybe a
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result of the phenotypic diversity of macrophages with at least two types of macrophage
phenotypes recognised in tumour immunology: M1 and M2. While M1 macrophages have a
pro-inflammatory affect, M2 macrophages are prone to tissue repair remodelling and
immunoregulation (224). Recent studies used immunohistochemistry against CD163 to try to
specifically stain for M2 macrophages which are thought to be the subset of macrophages
responsible for tumour progression (408, 411) and recent clinical studies have looked at
ways to “polarise” macrophages from their pro-tumour to anti-tumour state as a method of
cancer treatment (412-414).
Neutrophils are the most commonly found leukocyte subtype at human tumour
microenvironments (245). Like macrophages, neutrophils appear to have tumour promoting
activity through promoting angiogenesis and facilitating tumour migration (244, 415-417).
While the first paper investigating the impact on cancer survival of high levels of circulating
neutrophils in peripheral blood was published in 1970 (418), the first study looking at
neutrophils at the actual tumour microenvironment was published over 40 years later in 2006
(419). As with macrophages, a high number of tumour infiltrating neutrophils detected by
CD66b immunohistochemistry stain has been related to a poor prognosis in multiple
malignancies including melanomas (420), colorectal (421, 422), renal (247, 419), liver (246),
gastric (423), cervical (243) and lung cancers (424). A meta-analysis study into tumour
infiltrating neutrophils (TINs) in 2014 pooled 3946 patients from 20 studies involving lung,
gastric, hepatobiliary, renal, colorectal, cervical and head and neck cancer (242). 17 studies
measured the neutrophil levels using CD66b immunohistochemistry and 3 used H&E stained
slides. The scoring of the neutrophil infiltration was dichotomized into high and low levels
(242). The overall conclusion was that high levels of TINs are associated with poorer cancer
specific and overall survival (242). No OeC studies were part of this meta-analysis because
at the time no study looking specifically at TINs in oesophageal cancer was published.
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There is evidence that a high neutrophil to lymphocyte ratio measured in the pre-operative
blood is associated with poor prognosis in a number of cancers (354, 357, 362, 363, 425,
426). However whether this systemic ratio established in circulating blood is reflected in the
actual tumour microenvironment remains unclear. It is thought that cancer cells do recruit
circulating inflammatory cells to the local environment after the recognition of tumour
antigens (217, 218). There is little evidence about the prognostic value of the neutrophil to
lymphocyte ratio in the tumour microenvironment. The neutrophil to lymphocyte ratio has
been measured in the microenvironment of non-small cell lung cancer and hepatocellular
cancer previously and a high lymphocyte to neutrophil ratio has been associated with better
disease free and overall survival (246, 424).
5.1.3.2 Oesophageal cancer and immune cell infiltration
The prognostic value of tumour infiltrating T cells (CD3 CD8 or Treg) has been investigated
in various studies to date in oesophageal squamous cell carcinomas (248, 251-253, 255,
256), oesophageal adenocarcinoma (249, 254) and mixed histological oesophageal cancer
cohorts (250) (Table 25). The majority of studies were done using patients who had
undergone no neoadjuvant therapy except for the studies by Zingg et al (248, 249) and
Tsuchikawa et al (256), which all had mixed cohorts. The study by Zingg et al included 24
patients with oesophageal adenocarcinomas who were treated by neoadjuvant
radiochemotherapy (RCT) followed by surgery and looked specifically at Treg infiltration
(249). The amount of positive Treg cells was manually scored and compared between
periphery and the central tumour regions. Levels were higher at the periphery of the tumour
irrespective of patient treatment modality. No association between infiltration and survival
was seen in either of the treatment groups (p=0.156). The other study by Zingg et al (248)
involved a small cohort of squamous cell carcinomas (n=49) of which 42.9% received
neoadjuvant radiochemotherapy. This study used immunohistochemistry to measure CD3,
CD4, CD8 and FoxP3 staining of T cells. Manually counting of immunostained cells at the
peripheral as well as central region of the tumour was performed. Cut-offs were made
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between high and low groups using the median for each stain. In patients who had
undergone neoadjuvant therapy, there was a significantly higher level of CD3 and CD4 in the
tumour periphery. However, there was no relationship between T cell subtype and overall
survival. The study by Tsuchikawa included only 18 patients all of which had been
diagnosed with squamous cell carcinoma of the oesophagus (256). 8 patients underwent
neoadjuvant chemotherapy (44.4%) and in these patients tumour microenvironment there
were significantly higher amounts of CD4 and CD8 stained immune cells. No survival benefit
was shown in the neoadjuvant chemotherapy patients compared to the surgery alone group
(p=0.701). However these previous studies relied on subjective selection of where the
periphery of the tumour boundaries began and where the areas of highest density in each
region were found. The scoring processes relied on manual scoring of
immunohistochemistry staining which was time consuming and with the scorers not blinded
could have been liable to bias. The studies also had two treatment groups with unbalanced
patient groups with regards cancer staging, with the neoadjuvant groups having significantly
higher stages of disease. The survival data also showed that both study cohorts found no
difference in 3 and 5 year survival between patients who underwent neoadjuvant RCT and
those who proceeded to surgery alone. The finding that infiltrating T cells have varying
subtype distribution and positions of their highest infiltration are supported by other studies
(248, 249, 256) however no study has yet to show a “best” point for scoring.
The only previous tumour infiltrating T cell study to involve an automatic scoring system was
carried out by Rauser et al (254). This study involved 118 patients with adenocarcinoma of
the oesophagus, all of which had proceeded straight to surgery. Resection specimens were
stained with CD3 and CD8 for the detection of tumour infiltrating T cells and cytotoxic T cells.
Automated image analysis was used to score the levels of positive staining as a percentage
of the total area of the respective tissue microarray (427). ROC curve analysis was
performed to established high and low cut offs for each immunohistochemistry stain. A
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significant improved overall survival for patients in the high group of CD3 infiltration was
identified (Median survival high CD3 30.6 months vs low 21.4 months; p=0.014). Although
there was no statistically significant difference in survival between the CD8 groups (0.396),
patients in the high CD8 group were noted to have improved survival compared to patients
with low CD8 infiltration (254).










































































































* Same investigatory group;
+
=Histology, SCC= Squamous cell carcinoma; Adeno= Adenocarcinoma
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This method of using tissue microarrays and image analysis has been shown to be effective
in previous similar studies on tumour infiltrating immune cells in gastric (428), colorectal
(383, 394, 429) and endometrial cancer (430). No study to date has looked at the prognostic
impact of T cell subsets infiltration in oesophageal cancer treated with neoadjuvant
chemotherapy using automatic scoring techniques.
Studies in OeC have concluded that tumour associated macrophages (TAMs) in the tumour
microenvironment may play a role in tumour angiogenesis aiding growth and metastasis
(398, 431-434) (Table 26). Three studies all involving squamous cell oesophageal cancer
patients who underwent surgery alone found that high infiltration of macrophages were
associated with poorer survival (398, 432, 434). One showed a significant difference in 5
year survival between patients with a high and low macrophage count (groups determined
by dividing patients by the median) at the tumour microenvironment (24.2% vs 56.9%
respectively ;p<0.005) (398).
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All three studies investigated only patients with oesophageal SCC and all patients were from
Asia. All three studies used manual scoring to assess for macrophage infiltration at high
density regions. Dutta et al is the only TAM study to date which used quantitative
measurements using automated image analysis (431). This UK study included 47 patients
(38.8%) who had undergone neoadjuvant chemotherapy. The cohort was a mix of
adenocarcinomas (81%) and squamous cell carcinomas (19%), TMAs were stained with
CD68 to assess for macrophages and with CD8 for cytotoxic lymphocytes. Morphometric
scoring methods were carried out to get a quantitative value of the CD68 and CD8 cell
infiltration. It was shown that a high level of macrophage infiltration at the tumour
microenvironment was an independent poor prognostic marker (p=0.041). However survival
analyses were only performed on the subgroup of adenocarcinomas (due to small numbers
in the SCC group) and only from the surgery alone treated cases (n=53). The choice of
using the patient who did not undergone chemotherapy for the subgroup analysis was
carried out as the investigators were concerned that neoadjuvant chemotherapy would
influence the clinicopathological characteristics of the study. This also showed that CD68
infiltration to be an independent prognostic marker in patients who underwent surgery alone
(431). Despite the fact it was demonstrated that patients who had undergone chemotherapy
had higher infiltration of both CD8 and CD68 no subgroup survival analysis in these patients
was carried out. Another criticism of this study was that despite doing staining for both
macrophages and CD8 T cells no ratio analysis was carried out.
Sugimura et al compared immune cell infiltration of both macrophages and CD8 T cell in a
patient cohort who had neoadjuvant chemotherapy as well as those who had surgery alone
treatment (433). This demonstrated that a high infiltration of CD68 positive macrophages
was associated with a significantly poorer prognosis but only in patients who had undergone
neoadjuvant chemotherapy. Patients with a high infiltration of CD8 had a significantly better
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cancer specific survival than patients with low CD8 infiltration (p=0.012). Again no ratio
scoring for lymphocyte to macrophages was undertaken.
Two recent studies, one in urological malignancies (257) and one in breast cancer (237)
have shown a significant prognostic value in such a lymphocyte to macrophage ratio,
although as yet no similar ratio has been assessed in OeC.
The evidence with regard tumour infiltrating neutrophils in oesophageal cancer is currently
limited to two studies (Table 27).





























The first by Wang et al involved 90 Chinese squamous cell carcinoma cases, all treated by
surgery alone (435). The study used CD66b as a marker for neutrophils and CD8 to identify
cytotoxic T cells. Stained tissue samples were independently manually counted by two
observers to assess CD66b positive stained cells peripherally and centrally within the
residual tumour. This study concluded that a high number of intratumoural neutrophils was
associated with the presence of lymph node metastasis, advanced tumour stage and higher
recurrence rates (435). A high number of intratumoural neutrophils was also associated with
poor disease free and poor overall survival (p<0.001 for both). Multivariate cox regression
analysis including patient age, gender, tumour location, tumour length, differentiation grade,
TNM classification and immunohistochemistry stains identified neutrophil tumour infiltration
as an independent prognostic marker, alongside TNM classification. This study measured
CD8 positive T cells and calculated the neutrophils to lymphocytes ratio. However, the
neutrophil/lymphocyte ratio was not related to prognosis. This study was followed by a
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further study looking at surgery alone patients from China but this time involving 112
adenocarcinomas of the oesophagus (436). The study concluded that a high infiltration of
neutrophils was associated with a reduced cancer specific survival (p<0.0001). No other
immune cell staining was carried out in this study. No study to date has examined the
difference in neutrophil infiltration in a cohort after being treated with neoadjuvant
chemotherapy and neutrophils to lymphocyte ratios in this microenvironment.
This study involving potentially 508 cases from the OE02 trial aiming to examine the
prognostic role of leucocytes (CD45), B cells (CD20), T cells (CD3) and T cell subsets (CD8
and Foxp3), macrophages (CD68) and neutrophils (CD66b) in oesophageal cancer patients
who had or did not have neoadjuvant chemotherapy. Quantitative scoring was established
using automated image analysis (in house development, A Wright) to determine infiltration
levels for each immune cell type per case. Differences in the infiltration levels of each
immune cell, across the two treatment arms will be assessed as well as the association with
clinicopathological variables. Cut-offs will be established to create prognostic groups before
survival analysis will determine the prognostic value of each immune cells infiltration. The
prognostic value of ratio of T cells to macrophages or neutrophils will also be assessed to




From the OE02 trial (n=802) LICAP received 508 cases resection material for inclusion in
this study (3.2.1 OE02 material local collection). Cores were taken of tumour areas and
normal tissue from each case. Cases with complete pathological response hence no residual
tumour or cases with no evidence of tumour present on any of the material received were
excluded.
~ 153 ~
5.2.2 Tissue microarray (TMA) construction
Tissue microarrays (TMAs) were created and prepared by Mrs L Hewitt, the senior
technician of the upper gastrointestinal group at LICAP under the supervision of HG as
described previously (437, 438). The TMA maps are shown in Appendix 5: Tumour Micro-
Arrays Maps. In total 1112 cores were distributed over 9 TMA maps, which represented the
LICAP received cohort. These cores included tumour cores and normal tissue cores. All the
cores were stained 7 times using the 7 immunohistochemistry (IHC) stains; CD3, CD8,
CD20, CD45, CD66b, CD68 and Foxp3.
5.2.3 Immunohistochemistry technique
The different percentage of the tumour infiltrating immune cells (neutrophils, lymphocytes,
macrophages and subtypes as appropriate) were identified using immunohistochemical
(IHC) staining techniques. The protocol used for immunohistochemistry is provided in detail
in Appendix 4: Detailed immunohistochemistry protocol. In summary, 4 micron sections
were cut from each TMA and dried at least overnight. Sections were dewaxed according to a
standard protocol and antigen retrieval was performed by microwaving in 10 mmol citrate 
buffer (pH, 6.0) for 12 minutes. The Dako REAL™ Detection System (Dakocytomation, 
Glostrup, Denmark, catalogue no. K5001) was used according to the instructions of the
manufacturer. Protocols for the individual antibodies including best dilutions of the primary
antibodies etc. had been established previously and details of immunohistochemistry
staining are shown in Table 28.
Antibodies against CD3, CD8, CD45, CD68 and CD20 were purchased from Dako. Foxp3
and CD66b were purchased from Abcam (Abcam, Cambridge, UK). After incubation with the
primary antibody the secondary antibody was applied. ABC complex and DAB solution were
applied before slides were stained using Haematoxylin. The slides were the dehydrated and
mounted using a DPX medium.
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Clone Dilution Incubation time




















CD66b ab197678 G10F5 1:30 1 hour at room
temperature
Pan B cells CD20 M0755 L26 1:200 1 hour at room
temperature
5.2.4 Immune cell infiltration scoring
Each stained TMA slide was scanned at x40 magnification using the Aperio XT slide
scanner, (Leica Biosystems, Nussloch, Germany) to create digital slides which were stored
on a server with internet access. No demographic or clinicopathological data was stored
along with these files. Each slide was reviewed once uploaded to ensure slides were
correctly labelled and optimally scanned. These virtual TMA slides were then uploaded onto
a different server for automatic image analysis which was performed by AW using in house
developed software (439, 440).
5.2.5 Quality control pre-analysis
Before the percentage of positive pixels (POPP) could be established from each core quality
control checks were done to ensure POPPs were assigned to the correct case, quality
control checks were done. Two observers reviewed each virtual TMA slide to identify any
cases or cores that needed to be excluded from final analyses (TS and HG).
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1. Each virtual slide image was reviewed to check whether TMA map orientation
matched that indicated in the default TMA maps alignment. Any TMA slides not in a
matching orientation were adjusted.
2. Next every core was individually reviewed and checked against the original virtual
slide image to ensure that cores were in the correct position.
3. Once the observer was happy the correct core was in the correct allocated position
the next check was to ensure the core was centred in the snapshot image before
analysis.
5.2.6 Automatic scoring of staining
The quality controlled slides where then automatically analysed using the TMAi® software
(University of Leeds, UK, http://129.11.65.182/TMAi). The software analysis was run by AW.
TMA slides were automatically de-arrayed using an in-house developed computer vision
algorithm, and assigned an unique identification number. Once each core had been
separated it was processed using another in-house developed algorithm, using colour
deconvolution to separate staining channels into Haematoxylin and DAB images, and
analyse independently. Colour deconvolution has been shown to provide a robust method of
assessing immunohistochemistry staining (441, 442) and has been used previously to
quantify components of the tumour microenvironment in ovarian cancer (443). The same
technique has also been used to assess the tumour microenvironment in gastric cancer
(438). The intensity of DAB staining was co-localised with a basic binary mask of foreground
tissue (generated by thresholding of hue, saturation and intensity channels), in order to
obtain the total percentage of positive pixels within the tumour area (Figure 29). The
percentage of positive pixels (POPP) was used as surrogate for the quantity of immune-
positive cells per core.
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Figure 29: Examples of TMAi colour detection.
3 UGI cases: A+B= UGI0062 with CD68 staining; C+D= UGI2018 with CD3 staining; E+F= UGI0197
with CD45 staining. Each case is shown with their original stained image and their "analysis copy"
image where only blue (negative) and red (positive) colours are used to enable a pixel score to be
achieved. The red pixels represent the detected and quantified brown (e.g. immuno-positive cells) and
the blue pixels all other tissue in the core.
Once an individual TMA slide had been completely analysed the TMAi® program then
produced an excel spreadsheet showing the internal departmental case number (UGI
number), the respective cores pixel counts for colours represented and the percentage of
positive pixels (POPP).
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5.2.7 Quality control post analysis
The next stage of quality control was to look at both the original immunostained core and the
core created for image analysis (Figure 29) to check the following features:
1) All cores labelled as “tumour” cores did contain viable tumour. Cores without tumour
and those with a mixture of tumour and normal epithelium were excluded from
analyses
2) All cores used for analyses were free from artefacts like folds, artificial or excessive
staining etc.
3) The staining was only present in immune cells. Cores with staining of non-immune
cells were excluded
4) The image analysis detected the positive cells with the appropriate threshold
These quality control checks were initially done by TS and then double-checked by HG. In
total, 5022 individual tumour cores were reviewed in this final step of quality control.
In situations where there was more than 1 core result for a particular OE02 case the mean
POPP was calculated and taken as the final result.
5.2.8 Manual scoring of CD20 and CD66b
After the pre-analysis and post-analysis quality control checks it became evident that the
automatic POPP results for cores stained with CD66b were in some cases affected by some
light brown background staining. Visually, it was easy to distinguish between the strongly
stained neutrophils and the non-specific background. However, attempts to choose different
thresholds for the automated image analysis were not successful and thus, the automated
analysis would have produced an artificial high value POPP in some cases. Thus, it was
decided to score CD66b manually on the original glass slides by two observers (TS and HG)
It was also noted that in some of the cores there was extremely little CD20 staining only
representing a few cells. As there was some concern that these small amounts might not be
detected if the scanned image was not exactly in focus, and adjustment of the detection
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threshold led to an over detection, a decision was made to score CD20 manually on the
original glass slides by two observers (TS (all) and double checked by HG or DT). The
following method was used for manual scoring for both antibodies;
 Positive= at least one core with evidence of positive staining of immune cells
 Negative= no evidence of staining of immune cells
 Non-informative = cores with technical artefacts which made the core unscorable,
missing cores, cores with no tumour.
5.2.9 Statistical analysis
Statistical analysis was performed using the computer program Statistical Package for the
Social Sciences (SPSS) 21.0 (Chicago, Illinois). The OE02 trial database was provided by
the MRC Clinical Trial Unit at UCL, London, UK. All median ages and percentages (ranges)
are given to one decimal place. Mean values of percentage of positive pixels (POPP) per
stain were compared between the two treatment arms. Mann Whitney or Kruskal Wallis non-
parametric testing was used to assess whether there was a relationship between IHC results
and treatment arm, age, histological type, gender, grade of differentiation, T category
(TNM6), N category (TNM6), lymphatic or blood vessel involvement and Mandard tumour
regression grade. Follow up time was calculated from randomisation to patient death or end
of study period. Survival plots were constructed using the Kaplan-Meier method (270) any
differences between groups were tested by the log-rank test.
Groupings for initial Kaplan Meier plots were created by dividing the cohort into equal sized
groups of 5, 4, 3 and 2. Further modified or simplified groups were created after visual
inspection of these initial plots.
CD3:CD68 ratio was created by dividing the CD3 POPP by the matching POPP for CD68 of
the same case.
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A Cox’s proportional hazard model was used for univariate and multivariate analysis.
Variables tested in univariate testing were each immune cell POPP initially. Only variables
that were significant in univariate survival analysis were included in multivariate analysis
against established prognostic clinico-pathological variables from work done earlier (3.3.4
Survival analysis). A p-value of less than 0.05 was considered to be significant.
5.3 Results
5.3.1 General cohort descriptive results
The clinicopathological variables distribution of patients which were included in the TMA
study is shown in Table 29. All originated from OE02 trial cases received by LICAP. The
median (range) age was 62.6 years (30-83.2 years), 77.9% of patients were male and. 201
(46.9%) were treated with neoadjuvant chemotherapy followed by resection. T0 category
cases (i.e. complete responders) were not included as there was no residual tumour per
definition. This is led to the greater percentage of surgery alone patients in this cohort.
Median (range) follow up time was 1.46 years (0.02 to 13.21 years) with 73 patients alive at
the end of follow up (17%). The median follow up time from randomisation in the patients still
alive at the end of trial period was 5.59 years (range 0.16 to 13.21 years). 283 patients died
due to a cancer related cause (66%).
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* Mandard grading; TRG 1= complete regression (excluded), TRG2= only a few residual tumour cells
evident, TRG3= predominantly fibrosis, TRG4= predominantly tumour cells and TRG5= no evidence
of any regression seen. Median ages and all percentages are given to 1 significant figure, with TNM6
classification used for T and N staging.
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Table 30 summaries the number of OE02 cases included for analyses from each IHC stain,
with median 337 cases per stain (range 307 to 352 cores). The median drop out percentage
for each stain was 20.9% (range: 17.9-23.5%).
Table 30: The number of cores and cases available for analyses per immunohistochemistry
stains










CD45 (pan leucocytes) 558 429 77 (17.9%) 352
CD3 (pan T cells) 558 429 101 (23.5%) 328
CD8 (cytotoxic T cells) 558 429 92 (21.4) 337
Foxp3 (Treg Cells) 558 429 87 (20.3%) 342
CD68 (pan Macrophages) 558 429 92 (21.4) 337
* CD20 and CD66b not shown as separately scored
5.3.2 Immune cell distribution in the cohort
The median and ranges of POPP measured for each stain is shown in Table 31. This
demonstrates that the median POPP per case is below 5% for all types of T cells and
macrophages. As expected, a higher median % is seen for CD45 which stains all leukocytes.
The manual scored stains (CD20 and CD66b) are shown in section 5.3.4 . Figure 30 shows
representative examples of the IHC using a single OE02 case (UGI2018).
Table 31: Median (range) of POPP for the 5 IHC stains quantified by automated image analysis







CD45 (pan leucocytes) 352 429 19.1 1.1-72.4
CD3 (pan T cells) 328 429 4.4 0.5-50.9
CD8 (cytotoxic T cells) 337 429 2.1 0.3-32.5
Foxp3 (Treg Cells) 342 429 2.5 0.3-6.8
CD68 (pan macrophages) 337 429 2.6 0.3-22.4
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Figure 30(a-h): TMA cores stained with CD45, CD3, CD8, Foxp3 and CD68 from a single OE02
case
The cores shown here are from a single OE02case (cohort number ugi-2018) original cores with
brown staining are found to the left and the image analysis output to the right. Although there is
evidence of high T cells staining (CD3 images c & d) only a small proportion seem to be regT cells
(image g & h) or Cytotoxic T cells (image e & f). This case had a low % of positive macrophage cells
(image i & j).
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5.3.3 Differences in POPP stain between treatment groups
The differences in the POPP for each IHC stain were examined by stratifying patients
according to the two treatment groups. Comparison of the IHC stains between the treatment
arms shows no statistical difference for CD3, CD8 and CD45 (Table 32).
Table 32: The relationship between POPP and treatment group
Chemotherapy and surgery Surgery alone










CD45 (pan leucocytes) 159 18.9 1.1-69.4 193 19.9 1.8-72.4 0.319
CD3 (pan T cells) 150 4.4 0.5-36.4 178 4.5 0.7-50.9 0.542
CD8 (cytotoxic T cells) 151 2.1 0.4-20.9 186 2.2 0.3-32.5 0.706
Foxp3 (Treg Cells) 155 2.1 0.3-6.5 187 2.7 0.6-6.8 <0.001
CD68 (pan macrophages) 156 2.3 0.4-16.5 181 3.0 0.4-22.4 0.004
However, there is a significant difference in IHC staining scores between the two treatment
groups for CD68 (macrophages; p=0.004) and Foxp3 (regT cells p<0.001). For both stains,
there was a higher median POPP in the surgery alone group compared to the chemotherapy
followed by surgery group.
Histograms graphs show the different distributions of CD68 (macrophages) and FoxP3
(regulatory T-cells) scores found in each treatment arm (Figure 31 and Figure 32
respectively).
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Figure 31: Histogram of CD68 values in (A) chemotherapy + surgery group and (B) surgery
alone group.
Distribution of the CD68 (macrophage) staining in the two treatment arms along with the stated mean
scores and standard deviation (Std. Dev.). A higher mean macrophage infiltration is seen in the
patients who underwent surgery alone (4.04% vs 3.10%, p=0.004).
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Figure 32: Histogram of Foxp3 values in (A) chemotherapy and surgery group and (B) surgery
alone group.
Foxp3 (Regulatory T cells) staining in the two treatment arms along with the stated mean scores and
standard deviation (Std. Dev.). A higher mean regulator T cell infiltration is seen in the patients who
underwent surgery alone (3% vs 2.22%, p<0.001).
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5.3.4 Staining results of neutrophils and B cells
The results from the manual scoring of TMA cores stained with CD20 and CD66b is shown
below and are divided by treatment arm (Table 33). There was a trend of more positive
CD20 staining in the chemotherapy and surgery treatment group which did not reach
statistical significance (p=0.060). However the number of CD66b positive cases was
significantly higher in the surgery alone group (p=0.034).

















(n=415*) 95 (49.5) 101 (51.5) 86 (39.3) 133 (60.7) 0.060
CD66b
(n=352**)
73 (45.5) 91 (55.5) 105 (55.9) 83 (44.1) 0.034
*14 CD20 cores deemed unsuitable for assessment or missing
** 77 CD66b cores deemed unsuitable or missing
5.3.5 Relationship between staining results and clinicopathological
variables
This initial analysis identified the POPP in the staining of macrophages (CD68), neutrophils
(CD66b) and regulatory T cells (FOXp3) was lower in the chemotherapy before surgery
treatment group compared to the surgery alone (Table 32).
In the surgery alone treatment group (n=228) there was a significant relationship between
CD3 (pan T cells) POPP and tumour histology with adenocarcinomas having higher mean
POPP (p=0.009). CD8 (cytotoxic T cells) POPP was significantly higher in adenocarcinomas
(p=0.001) and in poorly differentiated cancers (p=0.005). High macrophages (CD68) POPP
was more common in adenocarcinomas (p<0.001), poorly differentiated tumours (p=0.003),
positive lymph nodes (p=0.004) and those with lymphatic invasion (p=0.031).
CD20 (B cells) and Foxp3 (regT cells) did not have any significant relationship to any of the
clinicopathological variables tested (Table 34). The only immune cell POPP shown to have
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a significant relationship to T category was CD66b (neutrophils) which had higher values
associated with higher T category (p=0.030).
Table 34: The distribution of percentage of positive pixels in surgery alone treatment group
(n=228) in relation to clinicopathological variables
CD3 CD8 CD20 CD45 CD66b CD68 Foxp3
Age 0.475 0.762 0.074 0.763 0.700 0.496 0.799
Histology 0.009 0.001 0.334 0.022 0.886 <0.001 0.070
Grade of differentiation 0.412 0.005 0.167 0.245 0.515 0.003 0.926
T category 0.433 0.235 0.521 0.605 0.030 0.953 0.804
N category 0.117 0.130 0.224 0.107 0.144 0.004 0.322
Lymphatic invasion 0.475 0.248 0.373 0.965 0.947 0.031 0.336
Blood vessel invasion 0.844 0.699 0.699 0.760 0.638 0.222 0.301
Mandard grade 0.241 0.525 0.198 0.472 0.751 0.275 0.525
In the chemotherapy and surgery treatment group (n=201) the same variables were
investigated (Table 35). There was no relationship between CD68 and any of the
clinicopathological variables. Similar to the surgery alone group patients, high CD3 (pan T
cells) and high CD8 (cytotoxic T cells) was more frequently seen in adenocarcinomas (p=
0.004 and 0.036 respectively).
Table 35: The distribution of percentage of positive pixels in chemotherapy and surgery
treatment group (n=201) in relation to clinicopathological variables
CD3 CD8 CD20 CD45 CD66b CD68 Foxp3
Age 0.687 0.569 0.874 0.735 0.852 0.164 0.131
Histology 0.004 0.036 0.071 0.200 0.250 0.094 0.831
Grade of differentiation 0.157 0.414 0.376 0.105 0.184 0.506 0.147
T category 0.098 0.579 0.186 0.083 0.744 0.718 0.876
N category 0.368 0.256 0.355 0.310 0.387 0.641 0.530
Lymphatic invasion* 0.054 0.336 0.276 0.168 0.107 0.702 0.853
Blood vessel invasion 0.019 0.008 0.470 0.061 0.653 0.086 0.315
Mandard grade 0.739 0.566 0.650 0.497 0.406 0.163 0.054
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High levels of CD3 and high levels of CD8 was also related to the absence of blood vessel
invasion (p=0.019 and 0.008, respectively).
To determine whether the POPP in the tumour microenvironment is related to prognosis in
oesophageal cancer, cox regression analysis was carried out stratified by treatment group.
5.3.6 Immune cell infiltration and relationship with survival in surgery
alone treated patients
In the surgery alone treatment group (n=228), with the exception of CD66b, none of the
other immune cells was related to overall survival in univariate analysis (Table 36). Kaplan
Meier plots show a survival benefit for patient with intratumoural CD66b staining as opposed
to those tumours who had no evidence of intratumoural CD66b positive cells (Figure 33).
Table 36: Cox regression univariate analysis assessing the prognostic value of the immune
cell POPP in the surgery alone treatment group (n= 228).
Univariate analysis Univariate analysis
OVERALL SURVIVAL CANCER SPECIFIC survival
HR 95% CI P value HR 95% CI P value
CD3 0.98 0.96 to 1.01 0.243 0.99 0.96 to 1.02 0.397
CD8 0.97 0.94 to 1.00 0.065 0.97 0.93 to 1.00 0.072
CD45 0.99 0.98 to 1.00 0.073 0.99 0.98 to 1.00 0.097
CD68 1.00 0.95 to 1.05 0.973 1.03 0.97 to 1.09 0.323
FoxP3 1.03 0.91 to 1.16 0.640 1.07 0.94 to 1.22 0.311
CD20 1.10 0.82 to 1.48 0.535 1.01 0.72 to 1.42 0.961
CD66b 1.33 0.97 to 1.83 0.073 1.48 1.04 to 2.10 0.029
HR= hazard ratio, CI= confidence intervals.
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Figure 33: Kaplan Meier analysis of cancer specific survival by CD66b status in patients from
the surgery alone treatment group.
This survival plot for cancer specific survival in the surgery alone treatment arm shows a significant
survival benefit for patients with evidence of neutrophil infiltration (n=105, blue line) compared to
those who had no evidence of neutrophil invasion (n=83, purple line) (p=0.029).
To assess whether the presence of CD66b POPP is an independent prognostic marker, a
cox regression multivariate analysis was performed including patient age, T category, N
category and blood vessel involvement in the model (Table 37). CD66b did not retain a
statistically significant prognostic value in multivariate analyses.
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Table 37: Multivariate Cox regression analysis including markers prognostic in univariate
survival analysis and CD66b POPP
Multivariate analysis
CANCER SPECIFIC SURVIVAL
HR 95% CI P value
Age 1.02 1.00 to 1.04 0.019
T category 1.51 1.00 to 2.28 0.048
N category 1.86 1.22 to 2.84 0.004
Blood vessel invasion 1.08 0.84 to 1.38 0.562
CD66b 1.35 0.95 to 1.91 0.097
CI= confidence interval, HR = hazard ratio
5.3.7 Immune cell infiltration and relationship with survival in
chemotherapy and surgery treated patients
The same analysis was carried out now looking at the chemotherapy and surgery treatment
group. Univariate cox regression analysis showed that higher CD3 staining was related to
better overall survival (p=0.043), but no significant relationship to cancer specific survival
was demonstrated (p=0.053). No other immune cell score was shown to have any statistical
significant relationship with overall or cancer specific survival (Table 38).
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Table 38: Univariate Cox regression analysis assessing for prognostic value in the immune
cell staining for patients from the chemotherapy and surgery treatment group
Univariate analysis Univariate analysis
OVERALL SURVIVAL CANCER SPECIFIC
HR 95% CI P value HR 95% CI P value
CD3 0.96 0.93 to 0.99 0.043 0.96 0.92 to 1.00 0.053
CD8 0.95 0.90 to 1.02 0.139 0.96 0.89 to 1.02 0.202
CD45 0.99 0.98 to 1.00 0.080 0.99 0.96 to 1.00 0.149
CD68 1.02 0.97 to 1.08 0.468 1.04 0.98 to 1.10 0.227
FoxP3 0.93 0.81 to 1.07 0.292 0.91 0.78 to 1.06 0.203
CD20 1.19 0.87 to 1.62 0.276 1.28 0.91 to 1.81 0.151
CD66b 0.95 0.68 to 1.33 0.772 0.99 0.68 to 1.43 0.941
CI= confidence interval, HR = hazard ratio
On multivariate cox regression analysis, CD3 did not demonstrate independent prognostic
value for overall survival (p=0.195). The ypN category of a patient’s OeC was shown to be
an independent prognostic marker in this subgroup (Table 39).
Table 39: Multivariate Cox regression analysis assessing the independent prognostic value of
CD3 in the chemotherapy and surgery patients
Multivariate analysis
OVERALL SURVIVAL
HR 95% CI P value
Age 1.02 1.00 to 1.04 0.111
ypT category 1.31 0.92 to 1.86 0.131
ypN category 1.76 1.19 to 2.61 0.004
Blood vessel invasion 1.34 0.99 to 1.81 0.054
CD3 0.98 0.94 to 1.01 0.195
HR=hazard ratio, CI= confidence interval
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5.3.8 Developing a quantitative T cell group classification for survival
stratification
With CD3 showing evidence of prognostic value in patients from the chemotherapy and
surgery treatment group (Table 38), CD3 scores were divided into equal groups to establish
an optimal cut off. As in the TCD work, CD3 scores were used to divide the cohort into 5, 4,
3 and 2 equal sized groups (Table 40).
Table 40: CD3 percentage ranges when creating equally sized CD3 groups for prognostic
stratification
Chemotherapy and surgery patients (n=150)







fifth 2.0 to 3.4 30
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rd
fifth 3.4 to 5.1 30
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quartile 2.5 to 4.4 38
3
rd





Low third <3.0 50
Mid- third 3.0 to 6.1 50
High- third >6.1 50
2 group system
Low group <4.4 75
High group >4.4 75
Using these groupings Kaplan Meier survival plots were generated using overall survival
data only, as this was where CD3 had shown potential for prognostic influence. Patients with
a higher POPP of CD3 staining have a better overall survival than those with a low POPP.
These survival plots showed significant difference with overall survival using a 3 group
classification (Figure 34 and Figure 35).
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Figure 34 (a-b): Kaplan Meier survival plots for overall survival in the chemotherapy and
surgery treatment group stratified by the 5 and 4 CD3 groupings.
Kaplan Meier survival plots for overall survival in the chemotherapy and surgery treatment group
stratified by 5 groups (34A above) and 4 groups (34B below) of CD3 scoring. Neither classification




Figure 35 (a-b): Kaplan Meier survival plots for overall survival in the chemotherapy followed
by surgery patient group stratified by the 3 and 2 CD3 POPP groupings.
Kaplan Meier survival plots for overall survival in the chemotherapy and surgery treatment group
stratified by 3 groups (35A above) and 2 groups (35B below) of CD3 scoring. Only the 3 group system




Examining the 3 group CD3 plot (Figure 35a), the mid and low CD3 group plots are seen to
run in close proximity. So to assess whether there would be better patient stratification if the
mid and low group were combined and a modified 2 group cut-off was established using a
6% POPP cut-off. This modified 2 group system as opposed to the original 2 group system
(by dividing the cohort simple by the median) is shown in Figure 36 and gives much clearer
prognostic groups. Log rank calculation show the difference in overall survival between
these two modified groups (6% cut-off) is statistically significant (p=0.012).
Figure 36: Modified 2 group CD3 classification Kaplan Meier overall survival.
The graph above shows a Kaplan Meier overall survival if patients are stratified into the modified CD3
classifications groups with a statistically significant difference in survival between the two groups.
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The differences in the clinicopathological features between the two CD3 groups (using the
modified 6% cut off boundary) are shown below in Table 41.
Table 41: Relationship with clinicopathological variables between the modified CD3 two
groups in patients from the chemotherapy and surgery treatment group
Low CD3 group <6%
(n=100)
High CD3 group >6%
(n=50)




Range 36.4- 77.7 41.6- 83.1
Histology
Adenocarcinoma 71 (71.0) 45 (90.0)
0.008Squamous 27 (27.0) 5 (10.0)
Other 2 (2.0) 0 (0.0)
Grade of differentiation
Poor 40 (40.0) 19 (38.0)
0.887
Moderate 50 (50.0) 27 (54.0)
Well 9(9.0) 3 (6.0)
Unknown 1 (1.0) 1 (2.0)
ypT category
T1 5 (5.0) 5 (10.0)
0.654
T2 9 (9.0) 5 (10.9)
T3 86 (86.0) 38 (76.0)
T4 0 (0.0) 2 (0.0)
ypN category
N0 31 (31.0) 21 (42.0)
0.184
N1 69 (69.0) 29 (58.0)
Lymphatic vessel invasion
Yes 35 (35.0) 10 (20.0)
0.378No 60 (60.0) 35 (70.0)
Suspicious 5 (5.0) 5 (10.0)
Blood vessel invasion
Yes 10 (10.0) 2 (4.0)
0.024No 80 (80.0) 47 (94.0)
Suspicious 10 (10.0) 1 (2.0)
Mandard grade
TRG1* 0 (0.0) 0 (0.0)
0.264
TRG2 0 (0.0) 1 (2.0)
TRG3 10 (10.0) 5 (10.0)
TRG4 36 (36.0) 22 (44.0)
TRG5 54 (54.0) 22 (44.0)
* Only cases with residual tumour were included in this immune cell study.
Kruskal Wallis tests identify significant differences in tumour histology (p=0.008) and blood
vessel invasion status (p=0.024) between the two CD3 groups (Table 41). Patient age,
tumour differentiation, lymphatic invasion status, Mandard tumour regression grade, ypT and
ypN categories across the two CD3 groups did not significantly differ.
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5.3.9 T cell to macrophage ratio and its potential prognostic value
Given the initial findings of differing roles in OeC prognosis between lymphocytes and
macrophages an immune cell ratio for T cells (CD3) to macrophages (CD68) levels was
calculated. The CD3 POPP was divided by the CD68 POPP in a total number of 134
(66.7%) cases with matched values in the chemotherapy and surgery treatment group and in
161(70.2%) cases with matched values in the surgery alone group. Table 42 shows the
median and ranges for the CD3:CD68 (T cell: macrophages) ratio. This demonstrates a
median ratio of 1.74 in the chemotherapy and surgery treatment group, suggesting overall
greater infiltration of T cells compared to macrophages. This is compared to the surgery
alone treatment group where although there remains a predominance of CD3 cells the
median is lower 1.34 (range 0.11 to 16.3).





(Chemotherapy surgery treatment group)
134 1.74 0.11 to 24.21
CD3:CD68 ratio
(Surgery alone treatment group)
161 1.34 0.11 to 16.3
Table 43 shows that there was a significant relationship between CD3:CD68 ratio and
differentiation, ypT category, ypN category and lymphatic invasion status. A higher
CD3:CD68 in the chemotherapy and surgery treatment group was more frequent in
moderately differentiated tumours, low ypT, ypN0 category tumours with no evidence of
lymphatic invasion.
No significant relationship between any clinicopathological variables and CD3:CD68 ratio is
seen in the surgery alone treatment group (Table 43).
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Grade of differentiation 0.038 0.065
T category 0.040 0.371
N category 0.037 0.863
Lymphatic invasion 0.028 0.082
Blood vessel invasion 0.222 0.500
Mandard grade 0.135 0.473
The prognostic value of the T lymphocyte to macrophage (CD3:CD68) ratio was then
assessed in a univariate cox regression analysis stratifying by treatment groups. In the
surgery alone treatment group (n=161) CD3:CD68 ratio had no significant prognostic value
in either overall or cancer specific survival (Table 44).
Table 44: Univariate cox regression analysis assessing the prognostic value of the CD3:CD68
ratio in patients from the surgery alone treatment group.
Univariate analysis Univariate analysis
OVERALL SURVIVAL CANCER SPECIFIC SURVIVAL
HR 95% CI P value HR 95% CI P value
CD3:CD68 ratio 0.96 0.88 to 1.04 0.315 0.93 0.83 to 1.03 0.159
HR=hazard ratio, CI= confidence intervals
In the chemotherapy and surgery treatment group univariate cox regression analysis showed
the CD3:CD68 ratio to have a significant prognostic value (p<0.001) for both overall and
cancer specific survival. These results suggest patients having a high ratio (i.e. prevalence
of CD3 over CD68) have improved overall and cancer specific survival (Table 45).
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Table 45: Univariate cox regression analysis assessing the prognostic value of the CD3:CD68
ratio in patients from the chemotherapy and surgery treatment group.
Univariate analysis Univariate analysis
OVERALL SURVIVAL CANCER SPECIFIC SURVIVAL
HR 95% CI P value HR 95% CI P value
CD3:CD68 ratio 0.86 0.79 to 0.95 0.001 0.83 0.75 to 0.92 0.001
HR=hazard ratio, CI= confidence intervals
As CD3:CD68 ratio was identified as having prognostic value for overall and cancer specific
survival this was assessed against other established prognostic markers in this treatment
group. Therefore multivariate analysis was performed to assess the prognostic value of
CD3:CD68 ratio (as a continuous variable) along with patient age, ypT category, ypN
category and blood vessel involvement. This demonstrates that the immune cell ratio
CD3:CD68 retained its prognostic value in multivariate analysis for both overall and cancer
specific survival (p=0.009 and 0.006 respectively). Only CD3:CD68 ratio and ypN category
were shown to be independent prognostic markers for both overall and cancer specific
survival in tumours in this treatment group (Table 46). The ypT category had independent
prognostic value in cancer specific survival analysis only (p=0.046).
Table 46: Multivariate cox regression survival analysis including patient age, ypT, ypN
categories, blood vessel invasion and the CD3:CD68 ratio
Multivariate analysis Multivariate analysis
OVERALL SURVIVAL CANCER SPECIFIC SURVIVAL
HR 95% CI P value HR 95% CI P value
Age 1.01 0.99 to 1.04 0.269 1.01 0.99 to 1.04 0.354
ypT category 1.40 0.94 to 2.07 0.099 1.69 1.01 to 2.81 0.046
ypN category 1.96 1.28 to 3.00 0.002 2.25 1.38 to 3.68 0.001
Blood vessel
invasion
1.31 0.96 to 1.81 0.094 1.31 0.92 to 1.86 0.136
CD3:CD68 ratio 0.88 0.80 to 0.97 0.009 0.85 0.76 to 0.96 0.006
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With the CD3:CD68 (T cells to macrophage) ratio being an independent prognostic marker in
the chemotherapy and surgery treatment, cut-offs were established using quantitative
measures. The chemotherapy and surgery treatment group was divided by each cases
immune cell ratio score into 5, 4, 3 and 2 equal groups to produce evenly sized patient
groups (Table 47).




































Low third <1.14 45
Mid third 1.15-2.47 44
High third >2.47 45
2 group
Low group <1.75 67
High group >1.75 67
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Kaplan Meier survival plots were constructed using these group classifications to determine
the classification which visually as well as statistically differentiated overall and cancer
specific survival in the chemotherapy surgery treatment group (Figure 37 and Figure 38).
These Kaplan Meier plots illustrate that all the classification systems tested did visually
stratify both overall and cancer specific survival in the chemotherapy and surgery treatment
group. All log rank tests identified significant differences in survival with all the classification
systems tested. While the 2 group classification showed the clearest visual survival benefit,
the 3 group classification also had a clear survival between the patients in the high ratio





Figure 37(a-d): Kaplan Meier survival plots of overall survival stratified by CD3 to CD68
classification systems (a= 5 groups, b= 4 groups c= 3 groups and d= 2 groups).
The four Kaplan Meier survival plots starting with the 5 group classification (top) to the 2 group
classification (bottom). The plots show all 4 systems have significant differences in survival using log
rank testing. Each plot demonstrates patients with a high ratio of T cells to macrophages have a







Figure 38(a-d): Kaplan Meier survival plots of cancer specific survival stratified by CD3 to
CD68 classification systems (a= 5 groups, b= 4 groups c= 3 groups and d= 2 groups).
The four Kaplan Meier survival plots starting with the 5 group classification top and the 2 group
classification bottom show all 4 systems have significant differences in survival. Patients with a high




A modification 2 group system was tested by combining the low and mid group patients
(ratio <2.5) which could be used against the high group (ratio>2.5). Kaplan Meier survival
plots for overall and cancer specific survival (Figure 39) show a significant difference
between these two modified groups (p<0.001 for both overall and cancer specific survival).
There is a significant improved survival in the high CD3:CD68 patients with 11 patients still
alive at the end of follow up (25%) compared to 8 from the low CD3:CD68 group (8.9%).
Cancer related deaths are also reduced in the high CD3:CD68 group (56.8%) compared to
the low CD3:CD68 group (76.7%).
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Figure 39: Kaplan Meier survival plots for overall and cancer specific survival in the
chemotherapy and surgery treatment group stratified by a modified 2 group CD3:CD68 ratio
system
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However, as there seemed to be good prognostic value through most variations of the 3 and
2 group classifications a simple ratio cut-off of 2 was tested. This would essentially divide
patient into those who had double the amount of CD3 to CD68 against those who had less
(named the simplified 2 group classification, Figure 40). This was hypothesised could
possibly be calculated even without access to automated scoring technology. The Kaplan
Meier plot for this simplified 2 group classification not only shows a clear survival difference
between these two groups, but this cut off like the previous classification systems shows a
statistical difference on log rank comparisons for both overall and cancer specific survival
(p=0.001 and 0.002 respectively). Therefore for simplicity, this simplified 2 tier classification
would be the favoured method of determining T cell to macrophage ratios where automated
scoring access may not be available (Figure 40).
Overall survival rates between the two groups show that at the end of follow up from
randomisation, patients in the low CD3:CD68 ratio group (ratio<2) only 6.7% of patients
were still alive (5 out of 75 patients) compared to 23.7% of patients in the high CD3:CD68
ratio (ratio>2) group (14 out of 59 patients). This difference is still evident when looking at
cancer specific survival, in the low CD3:CD68 group 78.7% of its patients had died related to
their disease (n=59) compared 59.3% of patients from the high CD3:CD68 (ratio>2) group
who died related to their primary cancer (n=35).
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Figure 40: Kaplan Meier survival plots for overall and cancer specific survival stratified using
the simplified CD3:CD68 2 group classification.
This simplified 2 group classification is assessed for its survival stratification value in the Kaplan Meier
plots above for overall (top) and cancer specific survival (bottom). Cases with greater than 2 times the
ratio of CD3 to CD68 have a significantly better survival (p<0.001).
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The differences in the clinicopathological variables between the simplified 2 group
classification (above or below 2) are assessed in Table 48.
Table 48: Relationship between clinicopathological variables and the simplified CD3:CD68









Range 36.4- 83.1 41.6- 76.2
Gender
Male 60 (80.0) 48 (81.4)
0.844
Female 15 (20.0) 11 (18.6)
Histology
Adenocarcinoma 55 (73.3) 50 (84.7)
0.101Squamous 18 (24.0) 9 (15.3)
Other 2 (2.7) 0 (0.0)
Grade of differentiation
Poor 35 (46.7) 18 (30.5)
0.132
Moderate 33 (44.0) 35 (59.3)
Well 6 (8.0) 5 (8.5)
Unknown 1 (1.3) 1 (1.7)
ypT category
T1 2 (2.7) 6 (10.2) 0.182
T2 6 (8.0) 7 (11.9)
T3 67 (89.3) 44 (74.6)
T4 0 (0.0) 2 (3.4)
ypN category
N0 21 (28.0) 26 (44.1)
0.054
N1 54 (72.0) 33 (55.9)
Lymphatic vessel invasion
Yes 29 (38.7) 12 (20.3)
0.218No 42 (56.0) 41 (69.5)
Suspicious 4 (5.3) 6 (10.2)
Vascular invasion
Yes 7 (9.3) 4 (6.8)
0.053No 60 (80.0) 54 (91.5)
Suspicious 8 (10.7) 1 (1.7)
Mandard TRG
TRG1 0 (0.0) 0 (0.0)
0.835
TRG2 1 (1.3) 0 (0.0)
TRG3 8 (10.7) 2 (3.4)
TRG4 26 (34.7) 27 (45.8)
TRG5 40 (50.3) 30 (50.8)
Mann-Whitney non-parametric testing did not identify any statistically significant difference in
clinicopathological variables between these two immune cell ratio groups, suggesting that
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these immune cells changes are independent of other variables such as patient age or ypT
or ypN category.
5.4 Discussion
This work has shown that the amount of infiltration of different immune cells in the tumour
microenvironment varies between the two treatment arms of the OE02 trial. In tumours that
had undergone neoadjuvant chemotherapy, higher levels of leukocytes in general, as well as
specifically T lymphocytes were identified, although not statistically significant. This is in
keeping with previous studies in OeC looking at lymphocyte infiltration after neoadjuvant
chemotherapy (256) and chemoradiotherapy (248, 249). However the most important
prognostic marker established in this work was a ratio score of T lymphocytes to
macrophages, which significantly stratified patients into prognostic groups for overall and
cancer specific survival. To date this is the first such study to look at this ratio in OeC and
follows on from studies in breast (237) and urological malignancies (257). On multivariate
cox regression analysis this lymphocyte to macrophage ratio is identified as an independent
prognostic marker for overall and cancer specific survival.
The role of the immune system in tumour protection and elimination was first hypothesised
over 100 years ago by Peter Ehrlich (444). This hypothesis was followed and supported by
subsequent work (445, 446) which highlighted the importance of the immune system’s
interaction with tumour development. However there were other studies later in the century
which raised doubts over any true immune system role in tumour elimination (447-451). This
doubt over the role of immune cells in cancer remained until the 1980s and 1990s when
studies on immunosuppressed mice showed increased tumour formation occurred in this
genetically modified state (223, 452-457). This work in mice specimens was then taken
forward by Van Der Bruggen et al in multiple studies which identified the presence of tumour
specific antigens in humans which were thought to have possible immune cell target
potential (349, 458-460). This discovery lead to a variety of different studies, from various
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fields of medicine, all of which were brought together in two large systematic reviews of the
literature into the role of immune cells in cancer carried out by Dunn et al (217, 218). These
reviews importantly concluded that the immune systems response to cancer cells plays an
important role not only in tumour regression but can also influenced tumour progression.
This historical path has led to the modern emphasis on the use of immunotherapy
approaches in the treatment of multiple cancer types and a growing interest in research
related to immune immunotherapy is ongoing (461-465). Currently two tumours graded
identically, using recognised established markers such as TNM staging, can have very
different outcomes regardless of getting identical treatment (466). Part of the reason for such
discrepancies is patient factors such as existing co-morbidities or age. However these
individually patient factors cannot be solely the reason as even in matched cohorts such as
the OE02 trial, differences in outcome can still be noted between two tumours of identical
TNM staging (84). The impact of different amounts and varying distribution patterns of
immune cell infiltration at the tumour microenvironment has been demonstrated in studies of
breast (369, 370), lung (371), skin (372), prostate (331) and colorectal cancer (198, 344,
373, 374). In one of Dunn et al reviews they suggested that both the innate and the adaptive
immune system participate in host protection from cancerous cells (217, 218). Dunn
described the tumour immune system interaction as a two way process involving both
immunosurveillance, where the immune cells recognised tumour antigens and
immunoediting, where the immune cells could also influence tumour progression (218).
T lymphocytes are strongly indicated as being crucial in tumour control thought to be as a
result of tumour cells expressing antigens, enabling them to be targeted by the T cell
mediated adaptive immune response (228, 349).T cells were first shown to be associated
with cancer prognosis in a study looking at melanomas, which found tumours with a high
infiltration of specifically CD8 T cells (cytotoxic cells) had a longer survival than those with
low CD8 infiltration (375, 467, 468). This work in melanomas has been followed by
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subsequent studies which confirmed that a high infiltration of T cells (generally or Cytotoxic
specific T cells) correlated with a good prognosis for various tumours including ovarian
(386), lung (226, 227, 229, 469), pancreatic (470, 471) and colorectal cancers (378, 379,
383, 429, 472). A study in 2006 looking at T cells in colorectal cancer suggested that the
density of these immune cells in the tumour microenvironment had such importance that
their infiltration had superior prognostic value than that of the TNM classification (383). A
recent large meta-analysis showed agreement with the findings of this OeC study with
regards to prognostic value of high T cell lymphocytes infiltration in the tumour. The meta-
analysis included 52 studies which looked specifically at tumour infiltrating lymphocytes in
various solid tumours; 10 ovarian, 10 colorectal, 7 lung, 5 hepatocellular, 3 renal and 13 from
other cancers sites (230). The results showed an overall survival benefit for patients with a
high CD3 T cell infiltration (pooled HR 0.58, 95% CI of 0.43–0.78 for death) and/or high
levels of CD8 infiltration on pooling of data (HR 0.71, 95% CI of 0.62–0.82). However no
study included in this meta-analysis involved OeC patient. From collective literature it is
clear that the infiltration of lymphocytes indicates a form of ‘anti-tumour’ immune response
(230), with high levels of T cells likely to correlate with a greater recognition and response
from the host immune system to the tumour (473).
The results of this study support this previous literature; however tumour infiltration of T
lymphocytes prognostic value is only identified in the neoadjuvant chemotherapy and
surgery treatment group. In this group of patients’ tumours with high CD3 staining showed a
statistically significant overall survival benefit compared to those with low level staining.
Using Kaplan Meier plots initially beginning with even sized groups, it was established that
using 6% cut-off produced the optimum cut-off for overall survival stratification. This is the
first study which has assessed the prognostic influence of tumour infiltrating lymphocytes in
OeC using a homogenous cohort of neoadjuvant chemotherapy followed by surgery patients
(as the two OE02 treatment groups were analysed separately). Previous studies in OeC
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have shown in patients who have undergone surgery alone that T lymphocyte infiltration was
associated with a significant improvement in survival (250-252, 254, 255). The reason T cell
infiltration was not found to have prognostic value in surgery alone tumours in this study
does not appear to be due to the quantity of lymphocytes between treatment groups as there
was no statistically significant difference between treatment groups. Other studies have also
not found significant differences in T cell amounts in tumours who have or have not
undergone any neoadjuvant treatment (474, 475). Tsuchikawa et al compared tumour
microenvironments in OeC patients who had or had not undergone neoadjuvant
chemotherapy and found no significant difference in CD8 cells levels in what they defined
the tumour nest (256). However no survival analysis was performed in this study to compare
with. Zingg et al studied the OeC tumour microenvironments in patients who did (18.5%) or
did not receive neoadjuvant chemoradiotherapy (249) and also showed no difference in T
lymphocyte infiltration between tumours from the two treatment groups. In agreement to this
study although CD3 infiltration levels were significantly associated with overall survival it was
not shown to be an independent prognostic marker. So it’s possible that the lymphocytes
seen at the OeC microenvironment in surgery alone although present in similar quantities,
maybe lymphocytes of different qualities to the ones present in the chemotherapy followed
by surgery tumour microenvironment. Previous studies have suggested T cells can remain in
an “inactive” state and it’s only once tumour cells have been affected by the destructive
actions of chemotherapy that these lymphocytes become activated (476). However
comparing existing studies is difficult due to the heterogeneity between all the existing
studies which was commented on in the recent meta-analysis study which did not include
any OeC study (230). Previous OeC studies have also suffered from such heterogeneity in
study designs with all examining tumour infiltrating lymphocytes have used selected
histological cohorts often only squamous cell carcinomas (248, 251-253, 255, 256). Most
have examined the whole tumour using various defined areas for scoring (nest vs periphery
vs stroma), with some identifying 2 scoring regions (248-251) and others scoring at 5
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different areas then taking a median (252, 255, 256). None of these previous studies used
automatic scoring technique which was used in this study to reduce any observer
subjectivity.
Only one previous study has used similar automated scoring technique as the one used in
this study (254). In concordance with this study their cohort of 118 adenocarcinomas who
underwent surgery alone failed to show cytotoxic T cell infiltration (CD8) had any prognostic
influence on overall survival in their cohort. Their results did indicate that CD3 infiltration did
have prognostic value in surgery alone patients which is in disagreement with this thesis.
However the scoring technique used was very different to the one used in this study in that
10 randomly selected areas on the TMA were analysed at 400x magnification to produce an
index of T cells. This index was taken as the number of “immuno-positive” nuclei visualised
divided by the total number of cells. The use of an image analysis system (TMAi) like in this
study, has given rapid and reproducible calculations of the individual immune cell infiltration
by calculated the percentage of positive pixels (POPP) staining per core. Using manual
scoring as a technique involves an often difficult process of reviewing 0.6mm tissue cores
under light microscopy, with each core being reviewed individually under high magnification
and a scoring system used to attempt to quantify the amount of immune cells staining. This
scoring can often involve an estimation of the percentage of staining or actual counting of
immune cells which in the situation of having multiple cells can be a difficult task both of
which can lead to a large degree of observer variability. The selection of perceived high
density scoring areas can also introduce further subjectivity and selection bias despite
observers being kept blind to the treatment per case. This study also has the advantage of
including material from a randomised control trial carried out at multiple centres.
Our work has shown significantly higher Foxp3 in surgery alone treatment group but no
prognostic value in survival analysis. This mirrors the existing evidence in OeC studies
involving neoadjuvant treatment followed by surgery (248, 249, 256) and surgery alone
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(252). As well as this, pooled data from a recent meta-analysis (described previously)
looking at tumour infiltrating lymphocytes in various cancers showed Treg cells infiltration at
the tumour microenvironment had no statistically significant impact on overall or cancer
specific survival (230). Although Treg cells clearly have an important role in the human
immune system, there appears to be no prognostic impact of the amount of these cells
infiltrating oesophageal cancer either after neoadjuvant chemotherapy followed by surgery or
surgery alone.
Tumour infiltration by macrophages has been demonstrated to have a poor prognostic
impact in various tumours (225, 240, 405, 477-479) including oesophageal cancer (398, 431-
434). They are associated with tumour progression through angiogenesis promotion and
lymphatic invasion (224, 239). However in this study macrophages have not been
demonstrated to have any prognostic value in either OE02 treatment group. Previous
literature involving OeC and tumour infiltrating macrophages has tended to involve
squamous cell carcinomas after surgery alone, carried out on Asian populations (398, 432,
434). With the exception of one, all the previous OeC studies in tumour infiltrating
macrophages have attempted to estimate levels using manual counting techniques (398,
432-434). This is in contrast to this study which has used quantitative automated scoring of
the amount of immunohistochemistry staining using an established computer program used
before in similar work (438, 439). Counting areas varied between previous studies with one
study scoring at a single high density area (432), two studies scoring at 3 areas (433, 434)
and one study scoring at 5 areas (398). This and the different magnifications used results in
macrophage scores not being able to be compared across studies. Sugimura et al did
include patients who had neoadjuvant chemotherapy followed by surgery in their study
(433). They identified no difference in macrophage infiltration between patients who had
undergone neoadjuvant chemotherapy and those who had surgery alone (433). They also
did not show the amount of CD68 staining to be a significant prognostic marker in
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concordance with this work set out in this chapter. In this study there was a significant
difference in macrophage infiltration between the treatment groups (represented by higher
POPP of CD68 in the surgery alone case). Higher macrophage levels were associated with
poorly differentiated tumours that were more likely to have positive lymph nodes in the
surgery alone group. However these associations were not seen in the chemotherapy and
surgery group. Whether these higher levels in surgery alone are as a result of chemotherapy
reducing “pro-tumour” macrophage numbers is unclear, but a recent study suggested
macrophage infiltration is higher in patients who show no evidence of responding to
chemotherapy leading them to state that macrophages had a role in chemoresistance (433).
The results of studies looking at macrophages in colorectal cancers have gone against the
tide in terms of literature into the prognostic effect, with multiple studies showing
macrophage presence being a good prognostic marker. This anti-tumour effect shown in
these colorectal studies has been suggested as being due to a different phenotypical make
up of their tumour invading macrophages (236, 384, 480). Whether there is also a different
make up in the phenotype of macrophages found in OeC with and without neoadjuvant
therapy has not been tested in this work. Sugimura concluded that tumour infiltrating
macrophages where associated with poor prognosis in OeC not because of the results from
CD68 staining but from CD163 whose levels were significant associated with overall
survival. In recent studies the immunohistochemistry stains CD163 or CD204 have been
utilised to try to specifically stain for M2 macrophages which are thought to be the subset of
macrophages responsible for tumour progression (224). Both of these stains have been
suggested as being more specific at identifying M2 macrophages than using CD68 as was
used in this study (234, 236, 434, 481). However, the ability of both stains to selectively stain
M2 macrophages is still under debate. There is evidence that CD163 is also expressed by
dendritic cells (482) and that CD204 immunohistochemistry stains the same cells as CD68, a
pan-macrophage stain (405). With further work a consideration to include CD163 as subset
stain for macrophages will be considered.
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This current work has created an immune cell ratio using T cell and macrophage infiltration
calculations at the actual tumour microenvironment as opposed to using peripheral blood
levels as a surrogate marker. From the results of the survival analysis it’s clear that it’s not
the individual infiltration levels of ‘anti’ tumour T cells and ‘pro’ tumour macrophages but
instead the ratio of T lymphocytes to macrophages (CD3:CD68) which holds the significant
prognostic value. There have been various studies which have looked at the lymphocyte to
macrophage ratio in blood tests of haematological cancer patients and demonstrated this
has prognostic value (483-485). Following this work in haematological malignancies other
work examining the importance of blood levels of these two immune cells in different solid
tumours such as pancreatic cancer, soft tissue sarcomas, gastric cancer and colorectal
cancers, have all found prognostic value in the ratio from pre-treatment blood tests (486-
489). However, only three previous studies have examined the infiltration ratio of
lymphocytes to macrophages at the tumour itself, two in breast cancer (237, 490) and the
other in urological carcinomas (257).
Using this ratio at the tumour microenvironment has the advantage of being able to be used
post operatively and even potentially used in endoscopic biopsy material during diagnostic
staging or even through neoadjuvant treatment. Using established immunohistochemistry
techniques to stain tissue microarrays and then an automatic image analysis system was
used to provide a quantitative staining score for each core. The ratio is then easily calculated
by dividing the T cell score and the macrophage score which removes any subjectivity to the
scoring technique. The results show that a high T cell to macrophage ratio has strong
prognostic value in oesophageal cancer. Using cox regression analysis including other
recognised prognostic markers such as age, T category, N category and blood vessel
invasion, the T cell to macrophage ratio is shown to be an independent prognostic marker for
both overall and cancer specific survival. This is in agreement with the previously published
studies looking at this ratio in breast and urological malignancies (237, 257, 490). Only ypN
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category (TNM6) was also shown to be an independent prognostic marker alongside this T
cell to macrophage ratio. Furthermore our results have demonstrated a simple cut off can be
used by dividing patients into those with double the CD3 to CD68 staining and those with a
lower ratio will give clear prognostic. This simple measure could be done automatically as
we have done here or even possibly manually in centres where access to automatic scoring
systems may not be possible. This is clearly something that would need to be tested in
future studies.
A limitation to the study was that there were different cohorts for each stain due to variations
core inclusion. This also meant that not all the cores had a matching T lymphocyte and
macrophage POPP scores to create an immune cell ratio. This result from the sectioning of
the TMA blocks. Once each TMA block was created they were then sectioned at different
levels through the block to create the slices for mounting on to slides. This meant that the
quality of each slide varied slightly and some cores as a result were sectioned at different
levels. So where a core may have been acceptable for one stain it may not have been for
other stains which resulted in the drop out described in Table 30. This tissue loss during
sectioning transfer and staining is a recognised limitation of using TMA blocks with a
reported dropout rate ranging from 10-30% (491). In this study across the stains the median
dropout rate was 20.9% in keeping with previous work. However despite these case drop
outs the study still involved a median of 337 cores per stain which is still more than previous
studies looking at tumour infiltrating lymphocytes in oesophageal cancer (248, 249). There
were also 134 cases assessed with a CD3 to CD68 ratio which is similar size to the two
previous similar ratio studies published (237, 257). The use of TMA staining for the
assessment multiple cases has been criticised for the small size of the cores with some
arguing that such a small sample of a tumour tissue cannot reflect the concentration of the
measured cell throughout the whole area (492, 493). Although assessing immune cell
concentrations in the tumour using whole sections would have reduced this doubt, it would
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have been more time and resource consuming especially with over 500 cases to be
assessed. There is also evidence showing that whole section staining can lead to over
interpretation and focal staining patterns (494). The technique of using TMAs has been
validated in large studies in tumours of the breast (494), lung (495), stomach (438) and colon
(496) as well as being used previously in similar OeC studies (254, 431).
Another limitation was in having to manually score the CD20 (B cells) and CD66b
(neutrophils) stained cores due to the computer program not being able to distinguish clearly
between true and negative staining. Previous studies using this stain have used manual
counting techniques to score these stains and in future maybe the first line technique when
trying to assess for B cell and neutrophil infiltration at the tumour. Manual scoring just
identified cases with any evidence of staining no matter how abundant or how few cells
present which may have led to both stains being show as having no prognostic survival
value on cox regression analysis. Previous studies into neutrophils at the tumour
microenvironment have used manual counting of stained neutrophils in each case then
identify the median score before dividing their cohorts into high and low groups (246, 417,
421). However there have been previous studies who have also used this method of scoring
neutrophils as either present or absent (420). Although in this work which looked at
neutrophil infiltration in melanomas the present cases were further divided into abundant
cells and minimal cells which may have helped create enough stratification to enable that
study to find neutrophils were significantly related to poor prognosis .
There has been recent criticism of the use of CD68 staining to represent macrophages in
clinical human studies and it has been suggested that CD68 can be found on non-
macrophage cells including cancer cells (497, 498). CD68 is a glycoprotein is that it is a
specific marker for tumour associated macrophages in mice, however in humans its
expression is more widespread including being present on granulocytes fibroblast and
endothelial cells (498). As well as this non-selective concern, there is also growing evidence
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about the two opposite tendencies of the two macrophage phenotypes M1 and M2. M1
“classical” macrophages exhibiting anti-tumour character while M2 “alternative”
macrophages being the ones shown to have the pro-tumour effects (405, 481). Recent work
using selective stains for M2 macrophages through detection of macrophage scavenger
receptors via CD163 or CD204 proteins has found high levels are associated with a poor
prognosis and hypothesis that it is these M2 cell which are important to assess when
considering prognosis (481).
More recent studies in oesophageal cancer infiltrating immune cells have employed
techniques where the immune cell levels were assessed both at the periphery of the tumour
and more central in immune cell abundant regions which we did not do in this study. The
advantage of measuring from different regions is as studies have shown the immune cell
infiltration varies in different areas of the tumour (255, 256), so the assessment of a single
random biopsy of the tumour may be criticised as not reflective of the immune cell infiltration
of the tumour as a whole. However neither of these prior studies carried out any survival
analysis to determine if the immune cell levels in either of these locations was of any
prognostic value. Ultimately in this study with the random tissue sample taken from the




This work is an attempt to review the prognostic value of established prognostic markers and
identify new prognostic markers for oesophageal cancer treated with neoadjuvant
chemotherapy. In the UK since 2002 neoadjuvant chemotherapy followed by potentially
curative surgery is the gold standard management for resectable cancers following the
results of the OE02 trial. Despite this change in management and continued advances in
endoscopic, radiological and surgical fields the prognosis in oesophageal cancer remains
poor (9). The work in this thesis used resection material from the OE02 trial to examine
some possible new prognostic markers which could have implications in clinical
management. This material originates from an international multi-centre randomised control
trial that changed the majority of practice in the United Kingdom following its results.
Comparison of the original OE02 trial cohort with the cohort used in this thesis shows that
despite the loss of cases which were not received by LICAP at the time of this study (508
cases received from the original 802 trial cases), that the cohort used in this work was
representative of this OE02 original cohort.
For the tumour cell density work the initial hypothesis were confirmed. It has been
demonstrated as a reproducible scoring technique which can be carried out at the luminal
surface of resection material on virtual slides. For the calculation of tumour cell density,
areas of malignant cells in contact with a luminal surface were identified and scoring grids
created using the RandomSpot® (University of Leeds, Leeds, UK) system (199). Using
tumour cell density calculations were made in 480 cases from the OE02 trial a significant
difference in tumour cell density was identified between patients in the surgery alone group
and patients who had undergone chemotherapy before surgery (<0.001). This would indicate
that regression from neoadjuvant chemotherapy could be quantified with the TCD scoring.
TCD scoring is also shown to correlate with the established Mandard tumour regression
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grading system. Through Kaplan Meier survival plots clear survival differences can be seen
between TCD groups created by equal division of the cohort by TCD in 5, 4, 3 or 2 groups.
However it’s by using a combination of the 3 and 2 group cut-offs (modified classification)
that the clearest survival benefits are seen between patient groups. Future work could focus
on assessing the same TCD at the pre-treatment stage of oesophageal cancer i.e. on biopsy
tissue. All cancers of the oesophagus involve biopsies taken which are used for diagnosis
and to guide initial management. This biopsy tissue would be suitable for TCD assessment
which could then be reproduced at the stage following surgery on the resection material as
done in this current work. The comparisons can be made to see whether there are changes
in the absence of chemotherapy which could indicate aggressive disease and comparisons
to see in the majority of cases where neoadjuvant chemotherapy has been given following
the initial biopsy whether the change (expected decrease) in TCD could be more useful
prognostic marker than a single isolated TCD calculation. Also this measure of TCD in
biopsy tissue could also be done through serial biopsies throughout chemotherapy to
monitor response. Such a concept is currently being trialled by using PET imaging to monitor
neoadjuvant treatment (320). There is currently also ongoing work looking at whether an
automated scoring program can be established (199). The RandomSpot® (University of
Leeds, Leeds, UK) program is able to generate spots in an area of interest that is marked
out by an observer. The spots are then reviewed individually and scored again by an
observer but the next stage would be if the computer program its self could score the cases
once the pre-determined area is selected. The program has been designed to recycle clinical
data and the future aims would be to develop an algorithm where the programme has
enough memory and recognition to identify a tumour cell point automatically.
The area of tumour infiltrating immune cells is one of growing interest in the last 10 years
with various solid tumour studies following work in haematological and skin cancers finding
that this local immune response is related to prognosis. Again the initial hypotheses were
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met in that this study has shown that immune cell infiltration varies between treatment
groups. In this current work in surgery alone patients the infiltration levels of immune cells
shows no significant prognostic value. In the chemotherapy followed by surgery treatment
group this work has shown a statistically significant prognostic impact of high T cell
infiltration at the tumour microenvironment. This survival benefit is seen on Kaplan Meier
survival plots when cases were divided by their CD3 staining POPP, with stratification into 2
groups using a 6% cut off shown to be the optimal in terms of overall survival. However CD3
staining levels individually were not an independent prognostic marker unless combined with
CD68 staining to create a T lymphocyte to macrophage ratio. This is the first such work in
oesophageal cancer to report this ratio at the tumour microenvironment following studies in
breast (237) and urological cancer (257). As in these two previous studies the lymphocyte to
macrophage ratio has been found to be an independent prognostic marker for overall and
cancer specific survival for patients who have undergone neoadjuvant chemotherapy
followed by surgery. A ratio of cut off of 2 can divide patients into two prognostic groups with
a clear survival benefit for those with greater double the CD3 to CD68. This promising
finding would need to be reinforced with a further study involving a bigger cohort of patients
who had all undergone neoadjuvant chemotherapy. Recent work has shown that the two
main macrophage phenotypes M1 and M2 macrophages can be selectively stained using
CD163 immunohistochemistry staining to identify M2 macrophages specifically. It’s the M2
macrophages that are thought to exhibit the pro-tumour characteristics which enable tumour
progression and escape. Further work would focus on trying to establish whether a CD3 to
CD163 ratio could give even greater prognostic stratification value. The clinical importance
of this work could be in the use of immune cell scoring to help influence post-operative
management and guide possible adjuvant therapies, however before this would be
considered a much larger trial would need to be conducted. However this initial finding of the
independent prognostic value of a lymphocyte to macrophage intratumoural ratio is
promising.
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Unfortunately as the distance to the CRM was not part of the minimal pathology dataset at
the beginning of the OE02 trial, recruitment CRM distances could not be established so the
CRM work was carried out on a separate cohort to the other thesis work. However using
local hospital and through collaboration with the South Manchester hospital this work was
carried on a large cohort of patients (n=232). The analysis has shown no survival benefit in
the College of American Pathologist (CAP) definition of a CRM positive margin (at the
margin) over that used in the UK by the Royal College of Pathologist (within 1mm of the
margin). While both have prognostic value this study has not identified CRM status as an
independent prognostic marker in neoadjuvant chemotherapy followed by surgery
oesophageal cancer. This work along with other work formed part of a meta-analysis study




Appendix 1: Rules for grid creation and placement
1. To use circle shaped area instead of square (used in colorectal work) as felt this
would enable more luminal surface contact therefore most collaboration with luminal
pre-operative biopsies.
2. Use 9mm2 circles. Therefore to use 3.3856mm diameter (produces a circle
of9.003mm2)
3. Circle to be positioned on a slide with viable tumour (avoid
necrosis/granulation/ulceration) at the surface aiming to have as much contact with the
luminal surface as possible
4. If multiple slides with tumour at the surface to use:
a.) Slide with DEEPEST INFILTRATION
If still no distinction to use
b.) Slide with HIGHEST DENSITY tumour
If still no distinction to use
c.) Slide with LARGEST AREA tumour
5. If using 9mm2 circle leads to over 50% of circle containing normal cells to use
multiple small circles side by side however the total area must remain 9mm2 (i.e. 2x
4.5mm2 or 3x 3mm2 circles).
6. When the circle contains normal areas beyond the tumour (i.e. with no further
tumour beyond the area then instead of scoring these areas as 2 normal stroma, they
should be scored as 0 indeterminate.
NB: Areas with high 0 counts should be re-reviewed
7. In cases where there is no evidence of tumour at the luminal surface these cases
should be identified for further analysis. For their initial spot counting
a.) The maximal layer depth of tumour should be record
b.) A circle should be made centring on the area where there is the highest density of
tumour
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c.) the count should be done as normal using 0 for areas of normal cells outside the
tumour
8. Spot counting should then be carried out in accordance to the colorectal spot




Hence radius= √area ÷π 
Therefore for a 9mm area circle the radius=√9 ÷π 
Radius = 1.69mm and diameter (2r) = 3.386
2. 4.5mm circles:
  Radius =√4.5 ÷π 
Radius = 1.197 and diameter used = 2.394
3. 3mm circles:
  Radius = √3 ÷π 
Radius = 0.977mm and diameter (2r) = 1.954
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Appendix 2: Data for intra-observer variability analysis for Table 6





















































































































































Appendix 3: Inter-observer TCD score comparison
(4.5.4.2 Case by case TCD agreement)
UGI number TS score GH score Difference in TCD
UGI-1024 41.84% 60.28% -18.44%
UGI-1107 25.87% 44.04% -18.17%
UGI-0019 34.39% 35.69% -1.30%
UGI-0358 28.22% 27.82% 0.41%
UGI-1287 29.33% 28.87% 0.46%
UGI-0128 45.26% 44.24% 1.01%
UGI-0677 34.12% 32.66% 1.46%
UGI-1064 41.32% 39.86% 1.46%
UGI-0062 30.24% 28.37% 1.87%
UGI-0693 47.18% 45.04% 2.15%
UGI-0944 41.37% 39.13% 2.24%
UGI-0913 21.25% 18.25% 3.01%
UGI-0739 38.60% 35.21% 3.39%
UGI-0973 75.52% 72.03% 3.50%
UGI-1162 56.99% 53.50% 3.50%
UGI-0935 16.37% 12.59% 3.78%
UGI-0078 56.10% 51.75% 4.35%
UGI-0297 69.34% 64.69% 4.65%
UGI-2035 40.43% 35.74% 4.69%
UGI-1203 66.33% 61.02% 5.31%
UGI-0066 96.83% 91.37% 5.46%
UGI-0098 37.23% 31.58% 5.66%
UGI-0713 31.71% 25.35% 6.36%
UGI-0084 57.04% 50.52% 6.53%
UGI-0278 56.69% 49.82% 6.87%
UGI-0783 72.89% 65.57% 7.33%
UGI-0215 47.67% 40.29% 7.38%
UGI-0003 85.12% 77.62% 7.50%
UGI-1947 67.02% 59.51% 7.51%
UGI-0275 75.96% 68.34% 7.62%
UGI-0631 60.46% 52.48% 7.98%
UGI-2056 32.09% 24.05% 8.04%
UGI-1946 73.68% 65.61% 8.07%
UGI-0181 72.14% 62.77% 9.38%
UGI-0447 48.78% 38.91% 9.87%
UGI-0149 28.52% 18.50% 10.02%
UGI-0626 47.10% 37.05% 10.05%
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UGI number TS score GH score Difference in TCD
UGI-2018 61.32% 51.22% 10.10%
UGI-0068 72.73% 62.06% 10.67%
UGI-0124 57.29% 44.79% 12.50%
UGI-0476 63.54% 50.00% 13.54%
UGI-1144 69.44% 53.13% 16.32%
UGI-0339 71.18% 53.85% 17.33%
UGI-0089 64.62% 47.00% 17.62%
UGI-0570 80.84% 63.07% 17.77%
UGI-0405 70.38% 52.14% 18.24%
UGI-1186 49.83% 29.97% 19.86%
UGI-0480 41.46% 20.70% 20.76%
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Appendix 4: Detailed immunohistochemistry protocol
List of contents
1. Principle / purpose of procedure
2. Personnel / training requirements
3. Specimen requirements
4. Equipment
5. Health and safety
6. Reagents
7. Quality control
8. Procedure or methodology
Title: Immunohistochemistry




Date of implementation June 2009
Review interval 12 month review period
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1. Principle / purpose of procedure
Immunohistochemistry is a technique that allows the localization of proteins in tissue
sections by the use of labelled antibodies. The avidin biotin complex (ABC) method is a
standard immunohistochemistry method that involves three layers. The first layer is the
primary antibody which binds specifically to the antigen in the tissue. The second layer
is a biotinylated secondary antibody and the third layer is a complex of avidin-biotin
peroxidase. The peroxidase is then developed by dab to produce a brown product.
2. Personnel or training requirements
1. Qualified biomedical scientist, clinical scientist, research technician
2. New staff to read the sop and go through the procedure step by step with a trained
member of staff and to be supervised until fully competent.
3. Specimen requirements
1. 5 micrometre tissue sections on superfrost plus glass slides that have been







Nordic houseware microwavable pressure cooker
Plastic slide holder
5. Health and safety
All staff must follow safe practice for dealing with biological material as stated in the
Leeds teaching hospitals NHS trust infection control policy including safe handling and
disposal of sharps, exposure to blood, spillage and waste.
All human derived products should be treated as potential biohazard.
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See departmental assessments for reagents.
6. Reagents
Xylene
Ethanol (100%, 96%, 70%)
Distilled water
Biotin solution (0.04g biotin – sigma b4501 in 200 ml tbs ph 7.4)
Egg block solution (2 egg whites in 200 ml distilled water)
Hydrogen peroxide solution (20 ml h2o2 – sigma 216763 in 180 ml distilled water)
0.01 m tbs working solution ph 7.6 (500ml tris stock, 87 g NaCl, adjust to pH 7.6 and
top up to 10 l with distilled water)
0.2 m Tris stock solution (24.2 g Tris in 1 l distilled water)
Tbs/triton x solution (500µl triton x in 1.25 l tbs buffer)
Zymed antibody diluent - invitrogen 00-3218
Dako real detection system peroxidase/dab+, rabbit/mouse – dako k5001
Bleach
0.5 % lithium carbonate
Mayer’s haematoxylin (1 g haematoxylin – merck 115938, 0.2 g sodium iodate – merck
106525, 50 g aluminium potassium sulphate – merck 101047, 50 g chloral hydrate –
merck 102425, 1 g citric acid – merck 100244. Dissolve in 1 l distilled water while
heating. Add 10 drops 25% ammonia – merck 105422. Leave for 1 day then ready to
use).
Dpx
Biotinylated tyramine stock solution (ez-link- sulfo-nhs-lc-biotin – pierce 21335,
tyramine – sigma t2879, dimethylformamide- sigma 200-679-5, 0.1 m Borat buffer pH
8.0 - merck 106303, 0.01 m tbs ph7.6). Dissolve 100 mg ez-link- sulfo-nhs-lc-biotin in 1
ml dimethylformamide. Dissolve 32 mg tyramine in 50 ml 0.1 m borat buffer. Mix the
two solutions together and adjust to pH 8.0. Store in the fridge at 4 oc for 24 hours and
then aliquot and store at -20oc.
Biotinylated tyramine working solution (dilute stock tyramine 1:50 with 0.01 m tbs, add
1 l h2o2/ml shortly before use for activation).
Vector stain elite abc kit – vector laboratories pk-6100
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Secondary biotinylated antibody - vector laboratories
7. Quality control
When establishing a staining protocol for a new antibody, a dilution curve of the
primary antibody needs to be performed to establish the optimal staining pattern.
One positive and one negative multi-tissue control slide is included for each set of test
conditions in each staining run. For the negative control the primary antibody is omitted
from the procedure. The negative control is included to evaluate non-specific staining
and the positive control is indicative of the correct antigen target and staining intensity.
8. Procedure or methodology
8.1 dako real detection system
8.2 tyramine amplification method
8.1
Dewaxing and rehydration
1. Place paraffin slides in slide holder and immerse slides into xylene for 15 minutes
(x3).
2. Immerse slides into ethanol for 5 minutes (x3).
3. Immerse slides into distilled water for 10 minutes.
Antigen retrieval
4. Place 200 ml of distilled water into the microwavable pressure cooker.
5. Place slides in slide holder into a small plastic container and fill with the appropriate
buffer until slides are completely covered.
6. Place the container in the pressure cooker and lock the lid.
7. Place pressure cooker in the microwave and set at full power.
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8. Once the pressure cooker has reached full pressure the yellow pressure gauge will
rise. Cook at full pressure for 5 minutes.
9. Release the pressure by carefully removing the red rubber weight.
10. Cool with running water for 10 minutes.
11. Wash in distilled water.
Blocking of endogenous peroxidase
12. Immerse slides into hydrogen peroxide solution for 15 minutes at room
temperature.
Blocking of endogenous biotin
13. Immerse slides in egg block solution for 60 minutes at room temperature.
14. Wash slides thoroughly in running water.
15. Wash in distilled water.
16. Immerse slides in biotin solution for 15 minutes at room temperature.
17. Wash slides in tbs/triton x for 5 minutes (x3).
Incubation with primary antibody
18. Dilute primary antibody with zymed and apply 100 l to each slide. Use zymed on
the negative control. Cover slides with a coverslip and incubate flat in a humidified
chamber for 1 hour at 37oc or overnight at 4oc.
19. Rinse off coverslips using squirting bottle containing tbs/triton x and wash with
tbs/triton x for 5 minutes (x3).
Incubation with secondary antibody
20. Apply 4 drops of dako real link, biotinylated secondary antibody, bottle a. Cover
slides with a coverslip and incubate flat in a humidified chamber for 30 minutes at 37oc.
21. Rinse off coverslips using squirting bottle containing tbs/triton x and wash with
tbs/triton x for 5 minutes (x3).
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Incubation with ABC complex
22. Apply 4 drops of Dako real streptavidin peroxidase, bottle b. Cover slides with a
coverslip and incubate flat in a humidified chamber for 30 minutes at 37oc.
23. Rinse off coverslips using squirting bottle containing TBS/triton x and wash with
TBS/triton x for 5 minutes (x3).
Incubation with chromogen
24. Dilute dab+ chromogen, bottle c 1:50 in hrp substrate buffer, bottle d. Apply 100 l
to each slide, cover with a coverslip and incubate flat on the dab tray. Watch the
reaction developing under the wet microscope to establish optimal incubation time;
should be less than 15 minutes.
25. Rinse off coverslips into bleach using squirting bottle containing TBS/triton x and
wash with TBS/triton x for 5 minutes (x3).
NB: dab should be discarded into bleach and left overnight before discarded down the
sink.
Counterstain
26. Immerse slides in Mayer’s haematoxylin for 30 seconds (Mayer’s haemtoxylin
needs to be filtered daily before use).
Wash in running tap water until water runs clear.
Immerse slides in 0.5% lithium carbonate for 1 minute.
Check slides under the microscope and if not blue enough put the slides back into
haematoxylin for 1 minute and repeat the process until satisfied.
Dehydration and mounting
Immerse slides into ethanol for 5 minutes (x3).
Immerse slides into xylene for 15 minutes (x3).
Mount slides using dip straight xylene.
8.2 alternative tyramine amplification protocol
Steps 1-19 as above
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Incubation with secondary antibody
20. Dilute vector secondary biotinylated antibody 1:200 with TBS and apply 100 l to
each slide. The secondary antibody has to be single-species and appropriate for the
primary antibody. Cover slides with a coverslip and incubate flat in a humidified
chamber for 30 minutes at 37oc.
21. Rinse off coverslips using squirting bottle containing TBS/triton x and wash with
TBS/triton x for 5 minutes (x3).
First incubation with ABC complex
22. Dilute vectastain elite ABC kit 1:50 in TBS and apply 100 l to each slide. Make this
ABC complex solution 30 minutes before use. Prepare double the volume needed as
the slides are incubated for a second time with the ABC complex. Apply 100µl to each
slide. Cover slides with a coverslip and incubate flat in a humidified chamber for 30
minutes at 37oc. 23. Rinse off coverslips using squirting bottle containing TBS/triton x
and wash with TBS/triton x for 5 minutes (x3).
Incubation with tyramine solution
24. Defrost the appropriate amount of tyramine stock and dilute 1:50 in 10mm tbs. Just
before use add 1 l h2o2/ml for activation. Apply 100 l to each slide, cover with a
coverslip and incubate flat in a humidified chamber for 15 minutes at 37oc.
25. Rinse off coverslips using squirting bottle containing TBS/triton x and wash with
TBS/triton x for 5 minutes (x3).
Second incubation with ABC complex
26. Use the ABC complex prepared earlier. Apply 100 l to each slide, cover with a
coverslip and incubate flat in a humidified chamber for 30 minutes at 37oc.
27. Rinse off coverslips using squirting bottle containing TBS/triton x and wash with









Appendix 5: Tumour Micro-Arrays Maps
There were in total 9 unique tissue micro-array (TMA) maps each containing a mix of











 Tu or T- labelled a tumour
 N or No= Labelled a normal core
 W= labelled a control core used in the periphery of all maps
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Appendix 6: Data safeguards
All patient specimens or material were anonymous.
No patient initials or DOB were included in data.
All data was stored on a university secured and backed up network drive.
No information was moved out of this file and stored in other drives.
Logbook was kept in locked draw on university property to reduce the chances of data
being lost.
No patient details where ever documented in loose files or logbook entries.
~ 231 ~
Appendix 7: Ethical approval document
Ethical approval granted 23rd November 2007 by the South East Research Ethics
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